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Abstract 
Understanding the fundamental molecular mechanisms that control the proliferation-
differentiation cellular switch and maintenance of the differentiated state is needed to fully 
harness the therapeutic potential for highly detrimental diseases such as cancer and 
neurodegenerative disorders. Intracellular free Ca2+ plays an essential role in the 
differentiation process and, more specifically, the ubiquitous Ca2+ signalling pathway; store-
operated Ca2+ entry (SOCE) is altered with differentiation. The SH-SY5Y neuroblastoma 
cancer cell line was utilised in this study to investigate the role of SOCE in phenotype-specific 
differentiation responses using morphological, biochemical and functional single cell, Ca2+ 
imaging techniques. 
 
Neuroblastoma is a paediatric malignancy of the sympathetic nervous system that is 
comprised of immature neural crest cells. Retinoic acid is used to treat neuroblastoma 
patients however many respond poorly, leading to aggressive disease progression. The SH-
SY5Y neuroblastoma-derived cell line consists of three morphologically distinct phenotypes; 
immature neuroblastic N-type cells, non-neuronal S-type cells and putative intermediate I-
type cells, which exhibit variable tumourgenicity and can be induced to differentiate using 9-
cis-retinoic acid (9cRA).  
 
The 9cRA-induced differentiation response of N-type and S-type populations involved 
morphological changes accompanied by an uncoupling of SOCE from Ca2+ store release that 
could be observed from the first day of 9cRA treatment. SOCE down-regulation was 
attributed to changes in expression and localisation of the CRAC channel protein Orai1 and 
the Ca2+ sensing protein STIM1. The extent of SOCE uncoupling was influenced in N-type and 
I-type cells but not S-type cells by the predominant background cell environment. 
Conditioned media from proliferating and differentiating N-type and S-type populations was 
also able to influence cell phenotype and the associated SOCE responses. 
 
This study describes how the 9cRA-induced differentiation response occurred in a multi-step 
manner in N-type populations and in gradual manner in S-type populations and raises the 
possibility that SOCE proteins could potentially be utilised as drug targets in neuroblastoma 
treatment or neurodegenerative disease therapy. 
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Chapter 1: Introduction 
Mapping the subcellular and molecular changes that accompany cell differentiation is 
a valuable strategy for the resolution of many global health issues. Understanding the 
mechanisms that drive and maintain the differentiated state of neuronal cells is of 
particular importance to fully harness the therapeutic potential for highly detrimental 
diseases such as neurodegenerative disorders (Berridge 2010) and cancer (Chen 2013). 
The ability to encourage differentiation of stem cells towards a fully neuronal 
phenotype is the considered the holy grail of neurobiology. Our laboratory has utilised 
immature neuroblastic cells as a model for the investigation of neuronal differentiation 
and related alterations in Ca2+ signalling pathways associated with Ca2+ entry into the 
cell (Brown 2005; Riddoch 2007; N. Bell 2013). This model can also be used to study 
cancer cell differentiation as uncontrolled proliferation of immature neuroblasts 
manifests as neuroblastoma (Bourdeaut 2008). Manipulation of the Ca2+ signalling 
pathways involved in cancer cell differentiation and defining the associated 
mechanisms that drive a specific cell population towards a differentiated state could 
also have significant implications for the development of novel anti-cancer drug 
targets.  
 
1.1. Neuroblastoma is resilient 
Neuroblastoma is a neural crest-derived paediatric malignancy with which primary 
tumours arise in the sympathetic nervous system, often forming in the adrenal glands. 
Neuroblastoma represents around ~6% of childhood cancers (Siegel 2013), with 
highest prevalence occurring in infants under 1 year old which is likely attributed to 
tumourigenesis taking place during embryonic development (Cancer Research UK 
2014). As with the majority of cancers, age and stage at diagnosis, as well as 
biochemical factors, significantly influence neuroblastoma prognosis. Patients often 
present with metastatic disease whereby prognosis worsens and recurrence is more 
likely. Advanced cases are particularly difficult to treat successfully, despite the use of 
aggressive multimodal therapies. The retinoid 13-cis-retinoic acid (13cRA) is 
administered alongside standard chemotherapeutic agents in order to initiate 
differentiation of immature neuroblastic cells thereby rendering the tumour benign 
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and preventing further proliferation and invasion of advanced and residual disease 
(Barletta 1997). Despite the implementation of retinoid therapy, survival remains fairly 
poor for these patients (Matthay 2009; Navalkele 2011). Elucidating the mechanistic 
contributors to the molecular switch from cellular proliferation to differentiation and 
for maintenance of this differentiated state in cancerous cells is therefore crucial for 
the advancement of increasingly efficacious therapies to ultimately improve patient 
survival. 
 
1.2. Tumour heterogeneity influences treatment success 
Heterogeneity exists within neoplastic tissue, the composition of which may include 
numerous cell phenotypes that exhibit a range of proliferative, motile and invasive 
capabilities (Fidler 1978). The variety of tumourigenic characteristics displayed by cells 
within a tumour poses a complex and challenging problem in terms of treatment 
specificity and efficacy towards all neoplastic cells of the disease but could significantly 
impact the success of a treatment. Since specific cell phenotypes may be more adept 
at surviving aggressive therapeutic insult or acquire resistance to chemotherapeutic 
agents, tumour advancement and metastasis would, presumably, be more likely to 
occur when treatment is only effective against a specific subset of cancerous cells. This 
complexity is increased further when taking into account the host environment, given 
that the aggressive nature of cancerous cells and their potential to establish a tumour 
is also influenced by their microenvironment and local expression of intrinsic factors 
(Raz 1987; Potter 2007). 
 
Neuroblastoma disease outcome is highly variable, progressing aggressively in some 
patients whilst spontaneously regressing or maturating to benign ganglioneuromas in 
others (Pritchard 1994; Nakagawara 1998; Schwab 2003; Hero 2008). This diverse 
variability in disease outcome may be attributed to the heterogeneity of 
neuroblastoma cells and their range of characteristics associated with tumourgenicity 
and treatment resistance (Bernal 1983; Ross 2003; Ross 2004; Walton 2004; Coco 
2005). 
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1.3 Neuroblastoma is comprised of three distinct cell phenotypes 
Neuroblastoma tumours consist of several neural crest cell lineages and three distinct 
cell phenotypes are known to reside in neuroblastoma cell lines (Figure 1.3.1), each 
with a particular set of morphological and biochemical characteristics and tumour 
forming capacity. Neuroblastic N-type cells are generally the predominant cell type 
(Ciccarone 1989) and are identifiable by their small, rounded cell bodies and the 
presence of short neurite-like processes (Figure 1.3.1). In culture, N-type cells are fast 
growing, adhere weakly to substrate, form cell aggregates (Figure 1.3.1), and express 
typical neuronal cell markers such as neurofilament protein (Ciccarone 1989), the 
neurotransmitter enzyme dopamine β-hydroxylase (Ross 1983; Ciccarone 1989) and 
the microtubule protein β-tubulin III (Whitworth 2012; N. Bell 2013). N-type cells 
differentiate towards a neuronal lineage upon exposure to differentiation-inducing 
compounds such as retinoic acid (RA), developing extended neuritic processes 
(Whitworth 2012; N. Bell 2013). 
 
Substrate-adherent S-type cells are non-neuronal precursors that form flat monolayers 
and can be distinguished by their large, flat cell bodies, abundant cytoplasm with the 
absence of neuritic processes (Figure 1.3.1). In culture, S-type cells are slow growing, 
adhere strongly to substrate and express proteins characteristic to a range of non-
neuronal cell types such as the intermediate filament protein vimentin (Whitworth 
2012; N. Bell 2013) which is indicative of Schwann cells, melanocytes and immature 
glial cells, the extracellular matrix protein fibronectin and the melanocyte marker 
tyrosinase (Ross 1985; Ciccarone 1989). This expression profile implies that S-type cells 
may be the embryonic neural crest precursors for Schwann cells, glial cells and 
melanocytes. Upon RA-induced differentiation, S-type cells become more epithelial-
like with a flattened morphology, more abundant cytoplasm and spread cell margins 
(Whitworth 2012; N. Bell 2013). S-type cells express the neuronal microtubule protein 
β-tubulin III, which is down-regulated following RA-mediated differentiation (N. Bell 
2013). This expression could be indicative of recent transdifferentiation from the N-
phenotype and β-tubulin III down-regulation with S-type differentiation implies 
commitment to a non-neuronal lineage. Since morphological and biochemical 
phenotypic interconversion can occur spontaneously in neuroblastoma cell culture 
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(Biedler 1975; Ross 1983; Ciccarone 1989), understanding this phenotypic plasticity 
may provide reasoning as to why retinoid therapy is not always effective. 
 
Intermediate I-type cells exhibit characteristics of both the N- and S-phenotype, being 
moderately substrate adherent with an intermediate abundance of cytoplasm and can 
possess spindly projections comparable to the neurite-like processes of N-type cells 
(Figure 1.3.1). Given their morphological similarity to the N- and S-type cells, they can 
be difficult to distinguish in culture. I-type cells may represent a multi-potent 
progenitor or stem cell population that gives rise to the neuronal N-type or non-
neuronal S-type lineage (Ciccarone 1989; Ross 1995) (Figure 1.3.2iii). Alternatively, it 
has also been shown that bidirectional transdifferentiation occurs between N-type and 
S-type cells (Ross 1983; Ciccarone 1989) (Figure 1.3.2i), which may take place with the 
I-type as an intermediate cell type (Figure 1.3.2ii). The I-type population may not 
actually signify a specific cell population and instead reflect a transient morphology of 
direct N-type to S-type interconversion associated with the cell phenotype at a 
particular point mid-transition. At present, the true identity of the putative I-type 
population and the common pathway for spontaneous transdifferentiation are 
unclear. Regardless of the I-type identity, persistence of this population following 
treatment would likely instigate tumour progression. 
 
Of the three cell phenotypes, I-type cells are considerably more tumourigenic than N-
type and S-type cells and neuroblastoma tumours with high numbers of I-type cells 
were associated with the poorest outcomes (Walton 2004). N-type cells are considered 
to have a greater malignant potential than S-type cells since they form the bulk of 
most neuroblastoma tumours (Walton 2004), have been shown to cause more 
aggressive tumour growth in vivo and, in response to RA treatment, less apoptosis in 
vitro (Picacentini 1996).  This could be reflective of a differentiation-mediated, up-
regulation of the anti-apoptotic protein Bcl-2, which promotes cell survival through 
inhibition of cytochrome c release from the mitochondria (Zhang 1996), and has 
previously been observed in RA-differentiated SH-SY5Y neuroblastoma cells (Hanada 
1993; Lasorella 1995; N. Bell 2013). Bcl-2 up-regulation in this case also correlated with 
a differentiated phenotype and has been associated with increased chemotherapeutic 
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drug resilience (Lasorella 1995) compared to neuroblastoma-derived cell lines with low 
Bcl-2 expression (Hanada 1993). RA-induced Bcl-2 up-regulation in SH-SY5Y cells can 
also increase resistance to the retinoid analogue fenritinide, which can inhibit 
proliferation and trigger apoptosis in neuroblastoma cells (Armstrong 2012). 
Potentially, targeting Bcl-2 to reduce expression or action via the p53 pathway may 
prevent chemotherapeutic sensitivity and increase response. 
 
Neuroblastoma tumours can spontaneously regress or mature into benign 
ganglioneuromas (Pritchard 1994; Nakagawara 1998; Schwab 2003; Hero 2008) 
consisting predominantly of differentiating S-type and N-type cells (Ambros 1996; 
Nishihira 2000; Liu 2005; Bourdeaut 2008). Tumours consisting of predominantly S-
type cells often display a differentiating phenotype and therefore have a more 
favourable prognosis, whilst predominantly N-type tumours are more likely to be 
actively proliferating and aggressive, therefore have a poor prognosis(Mora 2001; Liu 
2005). Given the ability of N-type and S-type cells to transdifferentiate, the 
relationship between N-type and S-type cells may impact tumour behaviour (Liu 2005). 
It has been suggested that immature neuronal and glial precursor cells are able to 
interact and impact differentiation (Biagiotti 2006; Acosta 2009). The process by which 
transdiffernetiation occurs is unclear and it is evident that further investigation of this 
pathway will improve understanding of therapeutic resistance. 
 
It is therefore crucial to determine the cellular pathways that underlie tumour 
differentiation and the mechanisms associated with proliferation-differentiation 
switch to a benign phenotype to ensure elucidation of novel drug targets and increase 
treatment efficacy and patient survival. 
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Figure 1.3.1. The SH-SY5Y neuroblastoma cell line is comprised of three cell 
phenotypes 
The SH-SY5Y cell line consists of three distinguishable cell phenotypes; N-type, S-type 
and I-type. Immature neuroblastic N-type cells (black arrows) are the predominant cell 
type and possess small rounded cell bodies with short neurite-like processes and can 
grow in aggregates (dashed circle). Substrate-adherent S-type cells (dashed arrow) are 
present in smaller numbers and possess more abundant cytoplasm with a flattened 
morphology but no neuritic processes. I-type cells (dotted arrow) have characteristics 
of both phenotypes, possessing a flattened morphology and abundant cytoplasm like 
that of S-type cells but also exhibit neurite-like process similar to that of N-type cells. 
Scale bar represents 20 μm. 
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Figure 1.3.2. Phenotypic transdifferentiation may occur between N-type and S-type 
cells or involve the putative I-type population 
Models of possible trans-differentiation stages, adapted from Ciccarone et al (1989) 
with images from MRes dissertation (Whitworth 2012). i.) Direct conversion may occur 
between N-type (N) and S-type (S) cells. ii.) Putative I-type (I) cells may act as an 
intermediate for transient transition between the N- and S-phenotype or may 
represent a transitional morphology rather than in individual phenotype. iii) Putative I-
type cells may be a stem cell (SC) population that is capable of self-renewal and/or are 
progenitors for N-type and S-type cells, which subsequently may or may not trans-
differentiate between phenotypes.    
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1.4. S-type sub-populations are identifiable in culture 
Variable S-type cell morphology has been shown to exist between different 
neuroblastoma cell lines (Ciccarone 1989) and previous work in our laboratory has 
identified three distinguishable morphological subsets within the S-type population of 
the SH-SY5Y cell line; outstretched, angular and elongated (Figure 1.4.1) (Whitworth 
2012). Outstretched S-type cells (SO) were the most abundant sub-population (62%) 
and appeared flatter and more spread out with poorly distinguishable cell membranes 
(Whitworth 2012). Angular S-type cells (SA) were present in lower quantities (35%) and 
tended to be smaller with a more compact morphology and less abundant cytoplasm 
than SO cells (Whitworth 2012). Elongated S-type cells (SE) were present in the lowest 
numbers (3%) and had a lengthened appearance (Whitworth 2012). These S-type sub-
populations may represent variable phenotypes of a single cell lineage or may 
encompass three specific cell types, therefore, they pose an intriguing aspect for 
further analysis into the potential variability in biochemical attributes and Ca2+ 
signalling profiles in terms of phenotype and also in relation to their differentiated 
state.  
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Figure 1.4.1. The S-phenotype is comprised of three distinct morphologies 
(A) Five cell phenotypes can be distinguished in the SH-SY5Y cell line and the derived S-
type enriched populations; (B) neuroblastic N-type cells (black arrow), (C-E) substrate-
adherent S-type cells (dashed arrows) and (F) possible intermediate I-type cells (dotted 
arrow). Within the S-phenotype, a further three sub-populations can be identified; (C) 
outstretched cells with abundant cytoplasm and a flatter, more spread out appearance 
(bold, dashed arrow), (D) elongated cells with a lengthened morphology (open 
arrowhead, dashed arrow) and (E) angular cells with a shortened, more compact 
appearance (circle tipped, dashed arrow). Scale bar represents 20 μm. Figure adapted 
from MRes dissertation (Whitworth 2012) 
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1.5. Retinoids can induce differentiation 
Retinoic acid is a derivative of vitamin A that regulates many cellular mechanisms such 
as differentiation, growth and gene transcription as well as the proliferation-
differentiation switch. There are three main isoforms of RA that have been studied in 
the context of neuroblastoma differentiation; all-trans-retinoic acid (ATRA), 13-cis-
retinoic acid (13cRA) and 9-cis-retinoic acid (9cRA)(Lovat 1997), of which the latter is 
the most potent but also the most toxic in vivo (Ponthan 2001). High risk 
neuroblastoma patients can receive 13cRA as part of treatment for advanced or 
minimal residual disease (Matthay 2009) since it is less toxic than other isoforms (Lovat 
1997; Ponthan 2001). Although overall survival is improved with 13cRA administration 
in these patients, response remains relatively poor (Finklestein 1992; Smith 1992; 
Villablanca 1995; Matthay 2009). 
 
The mechanism of action of RA is well documented (Abemayor 1989; Rees 1989; 
Heyman 1992; Allenby 1993; Redfern 1994; Chambon 1996; Minucci 1997; Reynolds 
2003; Schug 2007). RA is transported via cytoplasmic cellular retinoic acid-binding 
proteins (CRABPs) and cellular retinol binding proteins (CRBPs) into the nucleus 
(Abemayor 1989; Redfern 1994) and binds heterodimers of retinoic acid receptor 
(RAR) and retinoid X receptor (RXR) (Redfern 1994; Minucci 1997; Reynolds 2003; 
Shaw 2003; Schug 2007; E. Bell 2013), each of which has an α, β and γ isoform (Rees 
1989; Redfern 1994; Chambon 1996). This complex then associates with retinoic acid 
response elements (RAREs) upstream of promoters that regulate transcription of genes 
involved with cell proliferation and differentiation (Reynolds 2003; Shaw 2003; Schug 
2007; E. Bell 2013). 
 
All three of the discussed isoforms of RA can bind RARs but the 13cRA isoform that is 
used in patients has a very low affinity for RARs (Redfern 1994; Lovat 1997) which may 
contribute to its poor efficacy. Only 9cRA is capable of RXR binding (Heyman 1992; 
Allenby 1993; Minucci 1997), which may influence its efficacy with differentiation 
compared to other isoforms (Lovat 1997; Ponthan 2001). Variability of expression of 
RARs and RXRs (Rees 1989; Mollard 2000) as well as varying affinities of RA may 
contribute to treatment resistance. 
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The effects of RA as a differentiation inducer have been extensively demonstrated in 
neuroblastoma cells (Pahlman 1984; Lovat 1997; Simpson 2001; Mora 2001; Reynolds 
2003; Voigt 2003; Dubey 2004; Brown 2005; Constantinescu 2007; N. Bell 2013). RA-
induced differentiation can alter oncogene expression as has been demonstrated with 
the observation that N-myc and p53 are down-regulated in differentiated 
neuroblastoma cells and may instigate the differentiation process (Abemayor 1989). 
Varying effects of RA have been observed in neuroblastoma cells, with short-term (1-3 
days) treatment enhancing migration and invasion of SH-SY5Y cells and long-term (≥5 
days) treatment inducing differentiation (Joshi 2006), perhaps due to differential 
interactions with RARs and RXRs. Ca2+ signalling changes have also been associated 
with altered oncogene expression in differentiating neuroblastoma cells as well as 
other cancers (Macara 1985; Morgan 1986; Okazaki 1986; Reboulleau 1986; Abemayor 
1989). Additionally, 9cRA-induced differentiation alters methacholine-stimulated Ca2+ 
entry and causes down-regulation of store-operated Ca²⁺ entry (SOCE), possibly to 
maintain the differentiated state (Brown 2005). 
 
Retinoic acid-induced differentiation of neuroblastoma cells is also used as a model to 
investigate neuronal differentiation (da Rocha 2015) and in the context of 
neurodegenerative disorders, such as Parkinson’s Disease (PD) (Constantinescu 2007; 
Cheung 2009) and Alzheimer’s Disease (AD) (Petratos 2008). 
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1.6. Neuroblastoma cells are used to study neurodegenerative disorders 
As previously discussed (Introduction 1.3 and 1.5), the SH-SY5Y neuroblastoma cell line 
consists predominantly of immature neuroblastic cells that can differentiate towards a 
neuronal phenotype. For this reason, both proliferating and differentiated SH-SY5Y 
cells have been widely used for in vitro investigations of neurotoxicity and as a model 
for the exploration of neurodegenerative disorder pathology and treatment (K. 
Nakamura 2000; Misonou 2000; Brill 2003; Jamsa 2004; Zheng 2006; Cheung 2009; 
Korecka 2013). Systems genomic characterisation of SH-SY5Y cells revealed that the 
majority of Parkinson’s Disease (PD)-associated genes and Alzheimer’s Disease (AD)-
associated genes, were intact (Krishna 2014), demonstrating the relevance of this cell 
line in the study of neurodegenerative disorders. 
 
Degeneration of dopaminergic neurons is a hallmark of PD and all-trans-retinoic acid 
(ATRA)-differentiated SH-SY5Y cells have been found to exhibit a predominantly  
dopaminergic-like phenotype (Korecka 2013) making them suitable for the study of 
genetic targets or compounds for PD treatment. The neurotoxin MPP(+)inhibits 
complex I in the mitochondrial electron transport chain causing ATP depletion and 
formation of reactive oxygen species (ROS), which leads to loss of dopaminergic 
neurons and mimics symptoms of PD (K. Nakamura 2000; Korecka 2013). MPP(+) 
treatment of SH-SY5Y cells was also shown to induce oxidative stress and cell death 
(Brill 2003). Similarly, 6-hydroxydopamine (6-OHDA) is a toxin used in experimental 
models of PD as it accumulates intracellularly, causing oxidative stress and cell death, 
thereby mimicking the pathology of PD (Lopes 2010). 6-OHDA induces SH-SY5Y cell 
death, which is enhanced in ATRA-differentiated SH-SY5Y cells (Lopes 2010). 
 
The formation of amyloid β protein (Aβ) plaques and ROS accumulation leading 
oxidative stress are contributing factors in the development of Alzheimer’s Disease 
(AD)(Zheng 2006) and oxidative stress induced by hydrogen peroxide treatment has 
been shown to increase Aβ formation in SH-SY5Y cells (Misonou 2000). It is suspected 
that Aβ accumulation in neurons precedes plaque formation in AD and it has been 
found that Aβ is able to accumulate in the lysosomes of ATRA-differentiated SH-SY5Y 
cells, a process that was enhanced by ROS induced oxidative stress (Zheng 2006). 
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Phosphorylated tau is the main component of neurofibrillary tangles, the formation of 
which is also associated with AD development, and an increase in phosphorylated tau 
has been observed in SH-SY5Y cells differentiated with ATRA and brain-derived 
neurotrophic factor (BDNF) (Jamsa 2004).  
 
Whilst the SH-SY5Y neuroblastoma differentiation model investigated in this study has 
noteworthy applicability for neurodegenerative disorders, the focus of this study is the 
phenotype-specific comparisons which can be drawn from the heterogeneity of the 
cell line with regard to neuroblastoma disease, therefore the context of 
neurodegenerative disorders will not be further discussed in depth. 
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1.7. Ca
2+
 is a fundamental intracellular signalling molecule 
Intracellular free Ca2+ is a ubiquitous signalling molecule that plays a key role in many 
physiological pathways, such as cell differentiation, proliferation and apoptosis 
(Hanada 1993; Lasorella 1995; Berridge 1998; Bootman 2001; Sammels 2010; Smyth 
2010). Ca2+ signal spiking is involved in differentiation, including during neuronal 
development (Berridge 2000). Ca2+ homeostasis is therefore crucial for the 
maintenance of these pathways and correct cell functioning. There are several Ca2+ 
transporting mechanisms that utilise Ca2+ binding proteins to allow Ca2+ entry and 
release, allowing for maintenance of cytosolic Ca2+ concentration at ~10-100 nM at 
rest as well as for induction of spatially and temporally versatile Ca2+ signals where 
cytosolic Ca2+ concentration can rise 10-100-fold (Berridge 1998; Berridge 2000; 
Bootman 2001; Putney 2001). 
 
Ca2+ signals can be generated from extracellular Ca2+ entry or internal Ca2+ stores that 
include the endoplasmic reticulum (ER) or sarcoplasmic reticulum (SR) in muscle cells 
(Berridge 2000; Bootman 2001; Mekahli 2011), lyososomes (Galione 2010) and 
mitochondria (Rizzuto 2012). Ryanodine receptors (RyRs) and inositol 1,4,5-
trisphosphate receptors (IP3Rs) located at the ER/SR membrane can be activated by 
Ca2+ itself  and, in the process of Ca2+-induced Ca2+ release (CICR), raise [Ca2+]i by 
releasing Ca2+ from ER/SR stores (Carafoli 1987; Berridge 2000; Parekh 2005). 
Mechanisms that allow Ca2+ entry into the cell via the plasma membrane (PM) include 
store-operated Ca2+ channels (SOCs), receptor-operated Ca2+ channels (ROCs) and 
voltage-operated Ca2+ channels (VOCs). SOCs are activated by ER Ca2+ store depletion 
and are ubiquitously expressed (Berridge 2000; Bootman 2001). ROCs open upon 
binding extracellular agonists such as glutamate, acetylcholine or ATP and are highly 
prevalent on secretory cells and at nerve terminals (Berridge 2000; Bootman 2001). 
VOCs are stimulated by membrane depolarisation and are present in electrically 
excitable cells such as neuronal and muscle cells (Berridge 2000; Bootman 2001; 
Parekh 2005). All of these channels are localised to the PM and function to allow an 
increase in [Ca2+]i via Ca
2+ entry from the extracellular environment (Carafoli 1987; 
Berridge 2000). Cytosolic Ca2+ sensors, including calmodulin and troponin C, are able to 
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activate downstream effects such as muscle contraction, gene transcription and 
metabolism (Berridge 2000). 
 
The main mechanisms that serve to reduce [Ca2+]i act through either extracellular Ca
2+ 
release via the plasma membrane, which includes the PM Ca2+ ATPase (PMCA) and the 
Na+/Ca2+ exchanger, or through reuptake at the ER/SR membrane by the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (Carafoli 1987; Berridge 2000) and 
mitochondrial sequestration by uniporters at mitochondrial membranes (Berridge 
2000; Bootman 2001). Cytosolic Ca2+ buffers such as parvalbumin and calretinin also 
offer a further route for regulation of the spatial and temporal Ca2+ signalling which 
can be utilised to ensure localisation to precise intracellular regions or organelles 
(Berridge 2000).  
 
Due to its presence in many biological systems, aberrant Ca2+ signalling has been 
implicated in many pathological conditions such as neurodegenerative disorders and 
cancer (Parekh 2005; Berridge 2010; Sammels 2010; Chen 2013; Calì 2014). Ca2+ 
signalling is involved in cell migration, a key feature of cancer cell metastasis, and plays 
a role in mechanisms for cell motility, such as focal adhesion and cytoskeleton 
rearrangement (Prevarskaya 2011; Chen 2013). Ca2+ homeostasis is remodelled in 
cancer to increase cell proliferation and angiogenesis (Chen 2013), both of which are 
required for tumour establishment. Mutations found in familial Alzheimer’s disease 
(FAD) can disrupt Ca2+ homeostasis (Targos 2005). In PD, aggregates of α-synuclein 
protein are thought to affect Ca2+ permeability, increasing Ca2+ influx and inducing 
toxicity (Calì 2014). Similarly, knockdown of the PD-associated mitochondrial protein 
PINK1 has been shown to cause an increase in mitochondrial Ca2+ in neuroblastoma 
cells through inhibition of the Na+/Ca2+ exchanger which led to ROS accumulation and 
vulnerability to cell death (Gandhi 2009). The Ca2+ signalling network therefore poses a 
target under much investigation for its role in cancer and neurodegenerative disorder 
progression. 
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1.8. SOCE is a key pathway for Ca
2+
 entry 
SOCE (Figure 1.9.1) is a ubiquitous Ca2+ entry pathway that has a role in many cellular 
processes such as proliferation, differentiation, apoptosis and motility (Bootman 2001; 
Targos 2005). Initiation of ER Ca2+ store release can be triggered by binding of 
extracellular ligands, such as hormones, growth factors and neurotransmitters to cell 
surface G-protein coupled receptors. This leads to binding of phosphatidylinositol to 
phosphatidylinositol transfer proteins, which in turn activates phospholipase C (PLC) 
mediated conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol 
(DAG) and inositol trisphosphate (InsP3) (Berridge 2000; Bootman 2001). Ca
2+ is then 
released into the cytosol from the ER lumen upon InsP3 binding its receptor on the ER 
membrane (Berridge 2000). InsP3Rs, as well as ryanodine receptors (RyRs), can be 
activated by Ca2+ itself in the process of Ca2+-induced Ca2+ release and also cause ER 
Ca2+ store release (Berridge 2000). ER Ca2+ store depletion triggers the opening of SOCs 
at the PM that allow for Ca2+ entry into the cell, which is transported into the ER via 
the action of the SERCA to replenish the depleted ER Ca2+ store (Berridge 2000; 
Bootman 2001; Putney 2011). This process of SOCE (Figure 1.9.1) is crucial for 
replenishing depleted intracellular Ca2+ stores and for prolonging the Ca2+ response for 
downstream signalling (Putney 1986; Bootman 2001; Parekh 2005; Putney 2011). 
 
The current underlying SOCE; Ca2+ release-activated Ca2+ current (ICRAC), is highly Ca
2+ 
selective, mediated by electrostatic repulsion of monovalent ions by bound Ca2+ 
(Prakriya 2006; Smyth 2010), and single CRAC channel conductance is extremely low 
(Prakriya 2006). CRAC channel kinetics are slow and governed by the rate of transition 
from an inactive to a highly active state (Prakriya 2006). ICRAC is inhibited by Ca
2+ itself 
whereby Ca2+ flux through individual channels feeds back to rapidly inactivate ICRAC 
over milliseconds, without affecting ICRAC of other local channels (Zweifach 1995), and 
intracellular Ca2+ feeds back to slowly inactivate ICRAC over tens of seconds due to Ca
2+ 
store refilling (Zweifach 1995; Prakriya 2006). 
 
SOCE remodelling has been associated with cancer cell proliferation, migration and 
invasion (Targos 2005; Chen 2013) therefore SOCE pathway components could 
potentially be targeted as a means of neuroblastoma therapy. SOCE down-regulation 
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in human prostate cancer cells was shown to protect cells from apoptosis and 
reinstating SOCE activity restored apoptosis (Flourakis 2010). SOCE was associated 
with breast cancer cell migration in vitro and breast cancer invasion in mice and 
inhibiting SOCE reduced tumour invasion in mice (Yang 2009). In breast cancer cells, 
carboxyamido-triazole (CAI) treatment caused an inhibition of Ca²⁺ uptake and 
prevented tumour cell growth and invasion (Sherbert 2001). Targeting the Ca2+ 
signalling pathways involved in differentiation could therefore have implications for 
cancer therapy. SOCE dysfunction has also been associated with neurodegenerative 
diseases such as PD and Huntington’s disease (Majewski 2015). In Alzheimer’s Disease 
(AD), altered ER Ca2+ storage and store release has been observed and affects SOCE 
(Targos 2005). Reduced SOCE has been found in cells with mutated presenilin protein, 
a known cause of early-onset AD (Bojarski 2009).  
 
Ca2+ entry via SOCs is closely associated with intracellular Ca2+ store depletion and 
three proteins have thus far been implicated in the integration of these signalling 
events; STIM, Orai and TRPC1. 
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1.9. STIM 
RNAi screens have identified two mammalian stromal interaction molecule (STIM) 
homologues; STIM1 and STIM2 (Liou 2005; Roos 2005). Structurally, STIM1 and STIM2 
share >60% sequence homology (Williams 2001; Zheng 2008). STIM1 and STIM2 are 
both type 1 transmembrane proteins that are expressed in the ER, with C-terminal 
domains in the cytoplasm and N-terminal domains in the ER lumen (Zheng 2008), and 
both possess an EF-hand domain that is able to bind Ca2+ in the ER lumen (Williams 
2001; Liou 2005; Zhang 2005; Wu 2006; Brandman 2007; Zheng 2008) with binding 
affinity in the normal 250-600 µM range for ER [Ca2+] (Stathopulos 2006; Zheng 2008). 
 
STIM1 is a 77kDa single pass ER membrane spanning protein (Liou 2005; Zhang 2005; 
Wu 2006; Zheng 2008) that is also found at the PM (Zhang 2005; Manji 2000; Soboloff 
2006; Zheng 2008). The level of STIM1 expression has been extensively associated with 
extent of SOCE activity. STIM1 knockdown causes a reduction in SOCE whilst 
overexpression increases SOCE in many cell types including HeLa cells (Liou 2005), 
Jurkat T cells (Roos 2005; Huang 2006),  Drosophila S2 cells (Roos 2005), HEK293 cells 
(Mercer 2006; Abdullaev 2008), endothelial cells (Abdullaev 2008), vascular smooth 
muscle cells (Takahashi 2007; Aubart 2009; Potier 2009), endothelial progenitor cells 
(Kuang 2010; Shin 2010) and SH-SY5Y neuroblastoma cells (Abdullaev 2008; Bell 2011). 
STIM2 has also been found to induce Ca2+ entry in a predominantly constitutive store-
independent manner but also in a calmodulin-regulated, transient store-dependent 
manner and (Parvez 2008). Although STIM2-mediated activation of SOCE has been 
observed, STIM2 has a lower Ca2+ sensitivity than STIM1, being activated at higher ER 
Ca2+ concentrations than STIM1 and found to be a regulator of basal cytosolic and ER 
Ca2+ concentration (Brandman 2007). Knockdown of STIM2 in HeLa cells caused a 
reduction in SOCE (Liou 2005) but has also been shown to have no effect in Jurkat T 
cells (Roos 2005), therefore STIM2 may have a role in SOCE but only under certain 
conditions.  
 
STIM1 phosphorylation at multiple serine residues has been identified (Manji 2000; 
Smyth 2009; Sundivakkam 2012; Pozo-Guisado 2013; Sundivakkam 2013) and shown 
to have a role in STIM1 activation during ER Ca2+ store depletion (Lopez 2012; Pozo-
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guisado 2013) as well as inhibit SOCE (Smyth 2009; Sundivakkam 2013). STIM1 can also 
be glycosylated (Manji 2000; Dziadek 2007), which can affect PM localisation (Williams 
2002). Therefore, as well as expression level, modification of STIM1 affect the role of 
STIM1 in SOCE. Similarly, STIM1 has recently been found to exist as two isoforms; 
STIM1S and STIM1L (Darbellay 2011; Sauc 2015). The shorter STIM1S isoform has been 
extensively studied as the predominant STIM1 isoform whilst the longer STIML isoform 
has only recently been identified (Darbellay 2011) and is able to activate SOCE in cells 
lacking STIM1S (Sauc 2015). STIM1L is able to induce SOCE quicker than STIM1S 
(Darbellay 2011; Horinouchi 2012) which may be utilised by the cell to regulate SOCE 
activity accordingly. 
 
Since STIM1 has a role in SOCE activity, expression of STIM1 was explored in this thesis 
(Chapter 5). The function of STIM1 in SOCE is discussed further in 1.11. 
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1.10. Orai 
There are three human homologues of the calcium release-activated calcium channel 
protein Orai; Orai1, Orai2 and Orai3. Orai1 is a 33kDa tetra-pass PM spanning protein 
that forms the SOC pore (Prakriya 2006; Gwack 2007; Kawasaki 2009; Yuan 2012).  Loss 
of ICRAC attributed to depletion of Orai1 was first identified in SCID patients, where a 
point mutation in Orai1 caused defective SOCE activity in patient T cells and reinstated 
expression of wildtype Orai1 in these cells restored SOCE activity and ICRAC (Feske 
2006). Orai1 has since been shown to have a role in SOCE in many other cell types, as 
knockdown of Orai1 induced a down-regulation of SOCE activity in neuroblastoma cells 
(N. Bell 2013), neural progenitor cells (Hao 2014), acinar cells (Hong 2011), osteoclasts 
(Zhou 2011), endothelial cells (Abdullaev 2008), Jurkat T cells (Gwack 2007) and 
HEK293 cells (Gwack 2007; Kawasaki 2010). Orai1 overexpression was also shown to 
cause an increase in SOCE in HEK293 cells (Fukushima 2012) and restore SOCE in SCID T 
cells and fibroblasts (Gwack 2007) and differentiating neuroblastoma cells (Bell 2011).  
 
Structurally, Orai1, Orai2 and Orai3 have a high degree of conservation (>80%) 
however they possess some regions of dissimilarity, including at the cytosolic N- and C-
termini, which may be involved in channel activation (Takahashi 2007; Shuttleworth 
2012). Indeed, Orai3 has been observed to have a distinct role from that of Orai1 and 
Orai2 (Shuttleworth 2012). For example, co-expression of Orai1 or Orai2 with STIM1 
results in an increase in ICRAC, though to a lesser extent or no effect with Orai2 
expression (Mercer 2006; Lis 2007; Takahashi 2007), whilst co-expression of Orai3 with 
STIM1 does not produce detectable Ca2+ selective currents (Mercer 2006; DeHaven 
2007). Similarly, in cells expressing STIM1, siRNA-induced Orai1 knockdown reduced 
SOCE whilst Orai3 knockdown had no effect on SOCE (Mercer 2006; DeHaven 2007; Lis 
2007). Orai3 overexpression did restore Ca2+ entry in cells with knockdown of Orai1 
and stable STIM1 expression, although the magnitude of response was reduced to that 
observed with Orai1 expression (Mercer 2006; DeHaven 2007; Lis 2007). This suggests 
that, whilst Orai3 has a minimal function in SOCE, Orai3 may play a compensatory role 
in SOCE when the usual means of SOCE are compromised. 
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Since Orai1 co-expression with STIM1 has consistently been shown to increase SOCE 
activity to a greater extent than seen with Orai2 or Orai3 expression (Mercer 2006; 
Peinelt 2006; Soboloff 2006; Takahashi 2007), this suggests that the Orai1 isoform has 
a more prominent role in SOCE. The cytosolic N-terminus of Orai1 is structurally 
different to that of Orai2 and Orai3 and has been shown to contribute to its superior 
role in SOCE over Orai2 and Orai3 (Takahashi 2007). Co-expression of STIM1 with Orai1 
that had the Orai2 N-terminal tail only marginally increased SOCE whilst co-expression 
of STIM1 with Orai2 containing the Orai1 N-terminus dramatically increased SOCE to 
levels observed with Orai1-STIM1 co-expression (Takahashi 2007). These results 
provided evidence for a STIM1-Orai1 association to promote SOCE activity and it has 
since been found that SOCE is in fact, for the most part, governed by STIM1-Orai1 
mediated interactions.  
 
Since Orai1 has a role in SOCE activity, expression of Orai1 was investigated in this 
thesis (Chapter 5). The function of Orai1 in SOCE is discussed further in 1.11. 
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1.11. STIM1 and Orai1 mediate SOCE 
Interaction between STIM1 and Orai1 is known to facilitate SOCE (Figure 1.11.1). 
STIM1 is a Ca2+ sensor that alters the gating of SOCs at the PM to allow Ca2+ entry for 
replenishment of depleted Ca2+ stores (Liou 2005; Roos 2005). The N-terminus of 
STIM1 resides in the ER lumen and contains an EF-hand Ca2+ binding domain (Hodeify 
2015) and sterile α motif (SAM) domain (Zheng 2008). In its Ca2+ bound state when the 
ER Ca2+ store is full, STIM1 monomers are sequestered in the ER (Stathopulos 2009). 
However, in its unbound state when Ca2+ stores are depleted, STIM1 oligomerises 
which induces localisation into puncta at ER/PM junctions (Luik 2008) mediated by its 
sterile alpha motif (SAM) domain (Liou 2005; Park 2009; Yuan 2012). These puncta 
reside in close proximity (~20 nm) to the PM (Wu 2006; Hodeify 2015) so that STIM1 
can then interact with the C-terminus of Orai1, which forms the SOC pore (Kawasaki 
2009; Yuan 2012). Clustering alone does not induce SOCE (Park 2009); STIM1 interacts 
with PM phosphoinositides via the polybasic domain (Lewis 2011) and STIM1 interacts 
with the coiled-coil region of the Orai1 C-terminus via the Orai1-activating region 
(SOAR)/CRAC activating domain (CAD) (Kim 2011) within the STIM1 C-terminal 
ezrin/radixin/moesin (ERM) domain (Kawasaki 2009; Lewis 2011; Yuan 2012). As 
around half Orai1 cycles between intracellular and PM pools, this STIM1 interaction 
traps Orai1 at the PM and sequesters Orai1 into cortical STIM1 clusters (Hodeify 2015), 
inducing a conformational change in Orai1 that allows opening of the SOC and an 
influx of Ca2+ to ensue. It is thought that 8 STIM1s bind to each CRAC channel for 
maximal SOCE activity (Lewis 2011). STIM1 also inactivates SOCE through interaction of 
the CRAC-modulating domain/Ca2+-dependent inactivation (CDM/CDI) region with 
Orai1 (Mullins 2009; Yuan 2012). Upon replenishment of the ER Ca2+ store and 
inactivation of SOCE, STIM1 dissociates from Orai1 and translocates back to the ER 
membrane (Liou 2007).  
 
STIM1 is therefore essential for the gating of Orai1, as has been shown by knockdown 
experiments in which SOCE was significantly down-regulated (Roos 2005; DeHaven 
2009; N. Bell 2013). STIM1 has been observed to redistribute to the PM and co-localise 
with Orai1 upon Ca2+ store depletion in sinoatrial node cells (Liu 2015), Xenopus 
oocytes (Courjaret 2014) and HEK293 cells (Fukushima 2012). Similarly, STIM1 
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association with the ER and redistribution of STIM1 into punctate structures forming 
within 100 nm of the PM following Ca2+ store depletion has been observed in HeLa 
cells whilst a STIM1 mutant lacking an EF-hand binding domain failed to reorganise 
into puncta following Ca2+ store depletion (Liou 2005).  
 
Alterations in STIM1-Orai1 mediated Ca2+ entry is involved in cancer cell proliferation, 
migration and invasion (Chen 2013) therefore this pathway is a potential therapeutic 
target. For example, RNAi of STIM1 and Orai1 expression in highly metastatic breast 
cancer reduced tumour invasion in animal models (Yang 2009). Similarly, Orai1 down-
regulation and dampened SOCE was associated with reduced apoptosis in human 
prostate cancer cells and restoring Orai1 expression and SOCE activity promoted 
apoptosis (Flourakis 2010).  
 
The role of STIM1, Orai1 and SOCE within the phenotype-specific differentiation 
response of neuroblastoma cells was investigated in this thesis. 
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Figure 1.11.1. Store-operated Ca
2+
 entry (SOCE) 
When ER Ca2+ stores are full, the Ca2+ sensing protein STIM1 (orange) at the ER 
membrane binds Ca2+ (black) through the EF-hand domain in the ER lumen. To initiate 
Ca2+ store release, extracellular ligands, such as hormones, growth factors and 
neurotransmitters bind to cell surface G-protein coupled receptors (purple), activating 
phospholipase C (PLC, pink) mediated conversion of phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacylglycerol (DAG) and inositol trisphosphate (InsP3). InsP3 
triggers inositol trisphosphate receptor (IP3R) channels opening (red). Ca
2+ can then 
flow down its concentration gradient from the ER into the cytosol. Store depletion is 
detected by STIM1 monomers which oligomerise in their unbound state (orange). 
STIM1 and store-operated Orai1 channels at the PM membrane (blue) translocate and 
associate at ER/PM junctions, forming puncta. Upon STIM1 binding to Orai1 through 
the CRAC-activating domain (CAD) and interacting with PM phosphoinositides via the 
polybasic domain (PBD), Orai1 channels open and Ca2+ enters the cytosol. Ca2+ is then 
transferred to the ER via the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA, green) 
to replenish the depleted ER Ca2+ stores. TRPC1 (yellow) is a non-selective Ca2+ channel 
that can also be activated by SOCE, in a STIM1-dependent and independent manner, as 
well as by other pathways. Figure adapted from Lewis 2011.  
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1.12. TRPC may function as a SOC 
Transient receptor potential cation 1 (TRPC1) channels are non-selectively permeable 
to Ca2+ and involved in cation transport in a variety of biological processes (Yuan 2003). 
TRPC1 is a 90 kDa protein that has been found to have a role in SOCE and was 
originally thought to be the primary SOC involved in SOCE before the discovery of 
Orai1 (Parekh 2005). For example, knockdown of TRPC1 in mouse acinar cells causes a 
reduction in SOCE (Liou 2007). TRPC1 has been found to function as a SOC via 
interactions with STIM1 (Yuan 2007; Alicia 2008; Jardin 2008) and through STIM1-
mediated insertion of TRPC1 into lipid raft domains (LRDs) (Alicia 2008). LRDs also play 
a role in TRPC1-Orai interactions, as has been shown in human platelets where 
disruption of LRDs reduced SOCE by preventing TRPC1-Orai1 interactions (Jardin 2008). 
However, TRPC1 may also function as a SOC without the requirement of STIM1 
interactions (DeHaven 2009) and can be activated by other non-SOCE pathways 
(Putney 2007).  
 
Up-regulation of TRPC1 expression was associated with reduced SOCE in 
neuroblastoma differentiation (N. Bell 2013), myoblast differentiation (Louis 2008; 
Zanou 2012) and hippocampal neuronal cell differentiation (Wu 2004). However, 
inhibition of TRPC1 was found to suppress proliferation of A549 lung cancer cells 
whereas overexpression of TRPC1 enhanced proliferation (Jiang 2013). Similarly, 
knockdown of TRPC1 in keratinocytes caused a reduction in SOCE and inhibited 
differentiation (Cai 2006). This conflicting evidence supports that TRPC1 has some role 
in SOCE but the TRPC1 function in SOCE activity is unclear.  
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Aims 
The aims of this thesis were to investigate proliferating and 9cRA-induced 
differentiating N-type and S-type cells at the single cell level by combining 
morphological, biochemical (protein expression and localisation) and functional (Ca2+ 
signalling) markers to establish a phenotype-specific ‘signature’ of the differentiation 
process. These aims were met through: 
 
 Confirmatory studies of the cellular changes associated with the differentiation 
response of neuroblastoma cells (Chapter 3 and 4) 
 
 Establishment and optimisation of single cell Ca2+ signalling data collection and 
analysis within the SHSY5Y cell line that was comparable to previous analysis at 
the population level using the Ca2+ add-back technique (Chapter 4) 
 
 Investigations revealing the complexity of phenotype-specific differentiation 
response that underlie those observed at the population level and the effects 
of the predominant phenotype on phenotype-specific Ca2+ signals (Chapter 4) 
 
 Determination of the expression and localisation patterns of two key SOCE 
proteins; STIM1 and Orai1 (Chapter 5) 
 
 Study of the relationship of these changes over the time-course of the 
differentiation response (Chapter 6) 
 
 Investigation into the effects of conditioned media on phenotype-specific 
differentiation profiles (Chapter 4 and 5) 
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Chapter 2: Materials and Methods 
 
2.1. Materials 
SH-SY5Y cells were supplied by Professor R. Ross (Fordham University, NY, USA). All 
chemicals were from Sigma-Aldrich (Dorset,UK) unless stated otherwise. 
 
2.2. Cell culture 
SH-SY5Y cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM)/F12:1 
with GlutaMAXTM (Life Technologies, Paisley, UK) supplemented with Fetal Calf Serum 
(10% v/v), penicillin (100IU.ml-1) and streptomycin (100IU.ml-1) and incubated at 37°C 
in a humidified 5% CO₂ atmosphere. Cells were grown in 75 cm2 flasks (Corning, 
Flintshire, UK) and passaged once a week when approximately 90% confluent and 
were not used beyond passage 25.  
 
For passage, cells were washed with pre-warmed phosphate buffered saline (PBS) and 
incubated in 0.02% ethylenediaminetetracetic acid (EDTA) for 5 minutes at 37°C to 
disrupt cell surface adherence proteins. Flasks were agitated to aid cell detachment 
and cells re-suspended in complete media following three flask surface washes to fully 
detach cells. The cell suspension (10 ml) was centrifuged at 1,000rpm for 5 minutes, 
the supernatant removed and pellet re-suspended in complete media for seeding. 
 
2.3. Establishment of N- and S-type cell populations 
SH-SY5Y cells consist predominantly (66%) of N-type cells but with S-type (26%) and I-
type (8%) cells also present (Whitworth 2012). These cell types possess different 
substrate adherent properties, allowing selection and enrichment for either and N- or 
S-phenotype. Since an N-type enriched population is comparable to the mixed 
population (Bell 2011), the SH-SY5Y cell population is now used by our laboratory for 
N-type population studies. 
 
In order to establish S-type populations, the SH-SY5Y neuroblastoma cell line was S-
enriched through removal of less adherent N-type cells (Whitworth 2012; Bell 2011). 
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This was achieved through washing of SH-SY5Y cells in 10 ml pre-warmed PBS, 
incubating for ~3 minutes in 4 ml PBS then the culture flask was agitated. The flask was 
then washed in 10 ml PBS to remove nay loosely adhered cells and the remaining 
strongly adherent S-type cells were cultured. This process was repeated, when cells 
were ~80% confluent, four times to produce an S-type population (Figure 2.3.1). 
Enrichment of SH-SY5Y cells for S-type cells in this way produces a predominantly (81% 
Figure 2.3.2) S-type population and the enrichment process does not select for a 
particular sub-phenotype (Figure 2.3.3) (Whitworth 2012). Further enrichment did not 
significantly increase the proportion of S-type cells in the population (Whitworth 2012) 
and enrichment to S4 rather than S3 was used as this provided a larger quantity of cells 
to be obtained for seeding therefore S-enrichment to S4 was deemed appropriate for 
use in experiments to represent S-type populations.  
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Figure 2.3.1. S-type populations can be enriched based on substrate adherence 
Figure adapted from MRes dissertation (Whitworth 2012). The SH-SY5Y neuroblastoma 
cell line consists primarily of N-type cells (black arrow). Adherence-based S-type 
enrichment causes S-type cells (dashed arrow) to become more predominant with 
each level of enrichment (S1-S4). Enrichment to S4 was used in experiments to 
represent an S-type population. Scale bars represent 20 µm.  
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Figure 2.3.2. Enrichment for S-type cells produces predominantly S-type populations 
Results from MRes dissertation (Whitworth 2012). SH-SY5Y populations are 
predominantly composed of N-type cells (66%) with S-type cells (26%) and I-type cells 
(8%) also present. At each enrichment stage, S-type cells become more predominant. 
S-enrichment to S1 doubles the S-type population proportion (54%, P=0.0193). 
Enrichment to S2 produces a predominantly S-type population (70%). Enrichment to S3 
significantly increases the S-type population proportion (83%) compared to S1 
enrichment (P=0.0225) however this was not increased with further enrichment to S4 
(P=0.6795) and S5 (P=0.9996). Therefore S-enrichment to S4 was deemed sufficient for 
use in experiments since higher cell quantities could be obtained compared to S3. I 
type cells were consistently present with each enrichment (~8%, P=0.3966). N≥5 for 
each enrichment stage. 
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Figure 2.3.3. S-type enrichment does not affect the proportion of SO, SA or SE cells 
Figure adapted from MRes dissertation results (Whitworth 2012). The proportion of 
each individual S-type sub-population was determined as a percentage of the total S-
type population at each enrichment stage. These proportions remain consistent with 
each S-enrichment; ~62% outstretched (SO), ~35% angular (SA) and ~3% elongated (SE). 
N≥5 for each enrichment stage. 
 
 
 
 
  
32 
 
2.4. Cell counts 
A Neubauer haemocytometer (VWR International, Leicestershire, UK) with chamber 
depth of 0.1 mm was used for counting cells. The haemocytometer was cleaned with 
EtOH and a glass coverslip was fixed in place. Cell suspension was added to the 
chamber and cells in the four corner squares (1 mm2 each) were counted. Cells 
touching the left and upper lines of each grid were counted and those touching the 
right and lower right lines were not counted. To determine cell numbers per ml 
suspension, the average number of cells per square was calculated and multiplied by 
104 as the volume of each square is 0.1 μl and the required number of cells were 
seeded. 
 
2.5. Differentiation 
Cells were seeded onto sterile 10 mm Ø glass coverslips in 35 mm Ø tissue culture 
dishes or 24 well tissue culture plates for fluorimetry and immunofluorescence 
experiments, 20mm Ø glass coverslips in 6 well tissue culture plates for single cell Ca²⁺ 
add-back experiments or 60mm Ø tissue culture dishes for imaging and protein 
harvesting at least 24 hours before treatment to allow sufficient cell adhesion. 9cRA (1 
mg) was dissolved in AnaLar EtOH for a stock of 10 mM which was aliquoted and 
stored at -20°C. A new aliquot was used each week and stocks were replaced each 
month. Cells were treated with 1 μM 9cRA in complete media to induce differentiation 
or 0.01% EtOH was used as a control for proliferating cells. Differentiation and control 
media were replaced every 2 days and cells were used for experiments following 7 
days of treatment.  
 
2.6. CRAC inhibition 
Cells were seeded onto sterile 20mm Ø glass coverslips in 6 well tissue culture plates 
for single cell Ca²⁺ add-back experiments or 60mm Ø tissue culture dishes for imaging 
and protein harvesting at least 24 hours before treatment to allow sufficient cell 
adhesion. The CRAC channel inhibitor N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-
yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide (BTP2) was made up to a stock 
concentration of 20 mM in DMSO. Cells were treated with varying concentrations (0.1 
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µM – 20 µM) of BTP2 in complete media to induce CRAC inhibition, or DMSO was used 
as a control. Cells were used for experiments after 24 hours of treatment. 
 
2.7. Imaging 
An Optik XDS-2 microscope with 20x objective was used to capture phase contrast 
images. An Axiovert 200M microscope (Carl Zeiss Ltd) coupled to a laser scanning 
confocal microscope system (LSM 510, Carl Zeiss Ltd) using a 40x or 63x objective and 
helium-neon (HeNe) laser (633nm) was used for differential interference contrast (DIC) 
images and immunofluorescence images. For DIC images, cells were either live in PBS 
or fixed in paraformaldehyde (PFA, 4% w/v) and attached to slides with FluorSave 
Reagent (Calbiochem,Merck KGaA, Germany) overnight. Slides were kept at 4°C until 
imaging.  
 
Phase contrast and DIC images were used to determine the average neurite length and 
percent differentiation of N-type cells and the diameter of SO and SA cells and the 
length of SE cells (Figure 2.7.1). To calculate the percent differentiation of N-type cells, 
the total number of N-type cells and total number of differentiated cells (possessing 
one or more neurites ≥50 μm in length) were counted. The total number of 
differentiated cells was divided by the total number of cells and multiplied by 100 to 
convert to a percentage. 
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Figure 2.7.1. N-type neurite length and S-type diameter or length were measured to 
determine the extent of morphological differentiation 
Figure adapted from MRes dissertation (Whitworth 2012). Phase contrast (main 
images) and DIC images (insets) were used to for cell counts and cell measurements 
using Metamorph and LSM Image Browser software respectively. The length of (A) 
proliferating and (B) differentiating N-type neurite-like process in SH-SY5Y populations 
were used to characterise the extent of morphological neuronal differentiation. The 
cell diameter of (C) proliferating and (D) differentiating SO and SA cells and the cell 
length of SE cells were measured to characterise the extent of non-neuronal 
morphological differentiation. Scale bars representative of 50μm. 
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2.8. Immunofluorescence of protein localisation 
Cells on glass coverslips were washed with PBS then fixed with PFA (4% w/v) for 10 
minutes at RT, washed with PBS then permeabilised using Triton X-100 (0.1% v/v) for 
10 minutes at RT and then wash with PBS and blocked with bovine serum albumin 
(BSA, 5% w/v) for 30 minutes at 4°C. Coverslips were incubated for 2 hours in at 4°C 
with primary antibody from Table 2.8.1 diluted in BSA. Following incubation with 
unconjugated antibodies, coverslips were washed and incubated for 1 hour at 4°C with 
secondary antibody Table 2.8.1 diluted in BSA. Conjugated fluorophores are 
summarised in Table 2.8.2. Cells were then washed in PBS and incubated with nucleic 
acid specific ethidium homodimer-1 (EthD-1, Table 2.8.1 and 2.8.2) diluted in PBS for 
10 minutes at RT. Control cells were incubated with BSA only, primary antibody only 
and secondary antibody only. Coverslips were washed in PBS then dH2O, fixed with 
FluorSave Reagent (Merck, Darmstadt, Germany) overnight and kept in the dark at 4°C 
until imaging. 
 
For imaging, excitation and emission wavelengths of the fluorophores used in 
experiments are shown in Table 2.8.2. Fluorophores with overlapping emission were 
collected separately using multi-track configuration (as opposed to single-track) to 
prevent cross-talk.  Images were acquired with 12 bit data depth, a frame size of 512 x 
512 and a scan speed of 9. 
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Table 2.8.1. Antibodies used in immunofluorescence and Western blotting 
experiments 
Antibodies used in Western blotting (WB) and immunofluorescence (IF) experiments. 
*denotes secondary antibody.  
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Table 2.8.2. Fluorophores conjugated to secondary antibodies used for 
immunofluorescence experiments 
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2.9. Protein extraction and concentration 
Cells were lysed with buffer containing; 10% (v/v) Triton X-100, 2 mM Tris (pH 7.6), 
1.28 mM sucrose, 1 mM EGTA (pH 8), 1 mM EDTA (pH 8) and 1 protease inhibitor 
cocktail tablet (Roche Diagnostics, Indianapolis, USA) per 10 ml. Cells were scraped 
into the lysis buffer, homogenised using a 20 gauge needle and centrifuged at 12,000 
rpm for 10 minutes at 4°C. Supernatent was aliquot and stored at -20°C.  
 
Bradford assays were used to determine protein concentration in cell samples. Various 
amounts of bovine serum albumin (BSA; 0-40 μg) were used for protein standards. BSA 
standards and protein samples (3 or 5 µ) were made up to 40 µl with dH2O. Protein 
Assay Dye Reagent Concentrate (1 ml; BioRad, Herfordshire, UK) was added to the 
standards and samples which were briefly vortexed and left for 15 minutes at RT. The 
Coomassie Brilliant Blue G-250 dye within the reagent binds to protein causing a shift 
in maximum absorption from 465nm to 595nm, with a corresponding change in colour 
from blue to brown. The absorbance measurements from BSA standards at 595nm 
were plotted to form a standard curve to which a line of best fit was added (Figure 
2.9.1). The absorbance measured from the 0 μg BSA standard was subtracted from 
each reading. The value of the slope (Y) from the line of best fit, was used to calculate 
the concentration of triplicate measurements from protein samples. The average 
absorbance from the protein samples was divided by the number of µl used and 
thereby the slope (Y) of the standard curve. This provided an estimate of protein 
concentration in μg/μl which was used to calculate the volume required to load 
samples onto gels. 
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Figure 2.9.1. Example of BSA standard for Bradford Assay 
Figure from MRes dissertation (Whitworth 2012). The average absorbance of BSA 
standard duplicates were calculated. Values were used to produce a trend line with 
intercept=0. The equation value for the line slope was applied to determine unknown 
sample protein concentrations. 
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2.10. Chloroform/methanol protein precipitation 
The chloroform/methanol method (Wessel 1984) was used to precipitate proteins if 
concentrations were too low for SDS-PAGE as determined by Bradford assay. 20 μg of 
protein sample was made up to 100 μl in dH2O before the addition of methanol (4 
volumes), chloroform (1 volume) and dH2O (3 volumes) were added. Samples were 
vortexed between each addition then spun down at 13,000 rpm for 2 mins. The 
aqueous supernatant above the protein layer was discarded. Methanol (3 volumes) 
was added and samples were inverted gently to allow mixing. The samples were spun 
at 13,000rpm for 2 minutes. The supernatant was discarded and the protein pellets 
allowed to air dry for ~5 minutes. Samples were re-suspended in 12 µl or 20 µl dH2O 
and used for western blotting. 
 
2.11. Western Blotting 
20 μg of protein sample (12 µl or 20 µl in dH2O) was incubated at 95°C with sodium 
dodecyl sulfate (SDS) sample buffer (3 µl or 5 µl respectively; 2% w/v SDS, 5% v/v 2-
Mercaptoethanol, 10% w/v glycerol, pinch bromophenol blue in 60mM Tris (pH 6.8)). 
SDS is an anionic detergent that denatures proteins by disrupting noncovalent bonds 
and coats proteins with a negative charge relative to molecular weight whilst 
Mercaptoethanol reduces disulfide bonds. Heating helps denature the proteins and 
enhances SDS binding. Glycerol increases protein sample viscosity to weigh down 
samples in wells before the current is applied. Bromophenol blue is a small molecule 
dye added to allow visualisation of protein separation in SDS-PAGE which migrates 
through the gel quickly.  
 
Protein samples were centrifuged for ~10 seconds at 12,000 g to remove condensation 
on the underside of the lid before being separated by gel electrophoresis through 
NuPAGE 10% Bis-Tris gels (1.0 mm, 10 well or 15 well, Invitrogen). NuPAGE MOPS SDS 
Running Buffer was used with the addition of NuPAGE Antioxidant (both Life 
Technologies) to the inner chamber to maintain the reduced state of proteins during 
electrophoresis. Gel wells were rinsed with running buffer before sample loading. 
Precision Plus Dual Colour Protein Standards (BioRad) to determine molecular weight.  
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Electrophoresis was carried out at a constant voltage of 200 V for ~1 hour or until dye 
reached the bottom of the gel. The electric field applied to the negatively charged 
proteins causes them to migrate toward the positive electrode at the bottom of the gel 
tank. Proteins are separated based on their molecular weight where small proteins 
move through the porous polyacylamide gel quickly and large proteins move through 
the gel more slowly. 
 
Separated proteins were transferred to a nitrocellulose membrane (Bio-Rad, UK) at 
constant voltage of 50 V for ~2 hours. The transfer cassette (BioRad) was pre-
equilibrated in transfer buffer (25mM Tris, 192mM glycine, 20% v/v methanol) and 
loaded in an orientation so that the gel was closest to the negative electrode and the 
nitrocellulose membrane was closest to the positive electrode. Therefore, when the 
electric field was applied, the negatively charged proteins moved towards the positive 
electrode and were bound to the nitrocellulose membrane. An ice pack was placed in 
the transfer tank to prevent overheating during transfer (Bio-Ice Cooling Unit). 
Transfer tanks were then placed on a magnetic stir plate to ensure buffer was 
continuously stirred throughout transfer. 
 
The membrane was washed in PBS and blocked in a mix of Blotting-Grade Blocker non-
fat dry milk powder (5% w/v) with Triton X-100 (0.02% v/v) in PBS for 1 hour at RT with 
gentle agitation to block unoccupied sites on membranes and prevent non-specific 
binding of antibodies.  
 
2.12. Immunodetection of protein expression 
Nitrocellulose membranes (Methods 2.11) were placed in 50 ml falcon tubes with the 
side that was in contact with the gel facing inwards and incubated with the primary 
antibodies in Table 2.8.1 diluted in incubation buffer (2.5% w/v non-fat dried milk in 
PBS) overnight at 4˚C. Membranes were washed in wash buffer (2.5% w/v non-fat 
dried milk, 0.2% v/v Triton X-100 in PBS) for 3 x 5 minutes at RT to remove unbound 
antibody. Membranes were then incubated with horseradish peroxidase (HRP) 
conjugated secondary antibodies (Table 2.8.1) for 1 hour at RT. The blot was washed in 
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wash buffer for 3 x 10 minutes at RT and, once slightly dry, protein standard bands 
were dotted with secondary anti-rabbit antibody (Table 2.8.1).  
 
For chemiluminescence, blots were placed in a solution of 1.25 mM luminol in 0.1 M 
Tris-HCL (pH 8.5), 0.09 mM p-coumaric acid in dimethyl sulfoxide (DMSO) and 0.09% 
v/v hydrogen peroxide) for 1 minute. Membranes were wrapped in saran wrap, placed 
in a film cassette and exposed to x-ray film (HyperfilmTM, GE Healthcare, Amersham, 
Buckinghamshire, UK) for various times (10 seconds - 30 minutes) depending on the 
primary antibody used. Regions of film that are exposed to light (from HRP) darken. 
Exposed film was placed in Kodak Developer until immunoreactive bands were visible, 
briefly washed in water and then placed in Kodak fix for 2 minutes.  
 
Bands were analysed by densitometry using ImageJ software to measure the intensity 
of each band signal (Figure 2.12.1). The integrated pixel density (sum of pixel values in 
selected area) of each band was measured and the selection area remained constant 
for each set of bands analysed. A background value was also subtracted from each 
band intensity. Values were expressed as a ratio of β-actin in order to determine the 
expression levels of proteins. 
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2.13. Determination of [Ca²⁺]i through Ca
2+
-addback in cell populations 
Cells were washed 3 times with Ca²⁺-containing Krebs buffer; (10 mM HEPES (pH7.4), 
4.2 mM NaHCO₃, 1.2 mM MgSO₄, 1.2 mM KH₂PO₄, 4.7M m KCl, 118 mM NaCl, 10 mM 
glucose, 2 mM CaCl₂, 800 μM sulfinpyrazone) and then loaded with 3 μM of the Ca²⁺- 
sensitive fluorescent dye, fura-2/AM (Calbiochem, Germany), for 45 minutes in the 
dark at RT.  
 
Fura-2/AM is plasma membrane permeable and Ca2+ insensitive until cleavage of its 
acetoxymethyl (AM) esters within the cytosol. Cleaved fura-2 is Ca²⁺-sensitive due to 
exposed carboxylate groups. Fura-2 is polar and therefore unable to diffuse out of the 
cell via the PM. However, it may still be transported either out of the cell or into 
cytoplasmic organelles via organic ion transporters. Sulfinpyrazone is an inhibitor of 
organic anion transporters and is therefore added to the Krebs buffer in order to 
prevent this fura-2 transport from the cytosol that could result in poor loading. 
 
After fura-2 loading, cells were washed 3 times in 2ml Ca²⁺-containing Krebs buffer and 
incubated in 2ml Ca²⁺-containing Krebs buffer for 30 minutes in the dark at RT to allow 
complete fura-2/AM de-esterification. Individual coverslips were washed 3 times in 
2ml Ca²⁺-free Krebs buffer and fixed into a coverslip holder (Perkin Elmer, 
Beaconsfield, UK) which was placed in a Hellma fluorescence UV Quartz 10 mm cuvette 
(Scientific Laboratory Supplies, Nottingham, UK) containing 1.5 ml Ca²⁺-free Krebs 
buffer and a magnetic stirrer. The loaded cuvette was transferred to a fluorimeter 
(PerkinElmer, LS-50B) and an excitation wavelength scan (250-450 nm) was carried out 
prior to each experiment so that coverslips with poor fura-2 loading and/or confluency 
could be discarded (Figure 2.13.1).  
 
For measurements of intracellular Ca2+ store depletion and SOCE, Ca²⁺-addback 
experiments were performed in which fura-2 fluorescence was recorded every 20 
seconds at an excitation wavelength of 340 nm and emission wavelength of 510 nm 
(Figure 2.13.2). The trace was allowed to reach a steady baseline before 200 nm 
thapsigargin (TG; Calbiochem) was added to the cuvette. TG is a SERCA inhibitor that 
causes Ca²⁺ to leak from ER stores into the cytoplasm, increasing [Ca²⁺]i and therefore 
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fura-2 fluorescence. Stock TG was made up in DMSO therefore traces from cells with 
an equivalent volume of vehicle DMSO added in place of TG were used as a control. 
Once the TG or DMSO response returned to baseline, 2 mM CaCl₂ was added to the 
cuvette, which causes Ca²⁺ entry representing SOCE to refill ER Ca²⁺ stores. This leads 
to a rise in [Ca²⁺]i and fura-2 fluorescence due to SOCE.  
 
Upon return to a steady baseline, 50 μM ionomycin (Calbiochem) was added to the 
cuvette. Ionomycin is a Ca²⁺ ionophore that alters Ca²⁺ membrane permeability and 
causes a large Ca²⁺ influx that saturates fura-2, producing maximal fluorescence (Fmax). 
Following this sharp increase in fura-2 fluorescence, 1 mM MnCl₂ was added to the 
cuvette which quenches the fura-2, leading to a sharp decrease in fluorescence and 
generation of the autofluorescence (AF) value, which can be used to calculate the 
minimal fluorescence (Fmin) value. 
 
WinLab software (Perkin Elmer) was used to calculate [Ca²⁺]i for which the Grynkiewicz 
formula is used and assumes a dissociation constant (Kd) of 224 nM and an instrument 
constant (IC) of 3. The individual traces were then calibrated (Figure 2.13.3) using the 
Fmax and Fmin values in order to convert the fluorescence changes into changes in [Ca²⁺]i 
using the following equations: 
 
Fmin = 1 / IC (Fmax - AF) 
[Ca²⁺]i = Kd (F – Fmin) / (Fmax - F) 
 
The area under the curve for TG and Ca²⁺ responses were calculated using WinLab 
software to determine the amount of Ca²⁺ entry into the cytosol as a reflection of Ca²⁺ 
store depletion and SOCE, respectively (Figure 2.13.3). For each dish (4 coverslips), 1 
coverslip was used as a DMSO control and the others were used to determine the TG 
response. Average DMSO control trace values were subtracted from the average of the 
typical response values. All data presented throughout this thesis are basal-subtracted 
(i.e. DMSO response) and are therefore response to stimulus only. Extent of changes in 
SOCE were calculated taking any changes in Ca2+ store release into account and 
assuming a linear relationship. 
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Figure 2.13.1. Wavelength scans were performed before each fluorimetry based 
experiment 
Figure from MRes dissertation (Whitworth 2012). Excitation wavelength scans were 
carried out before each Ca2+-addback experiment to ensure cells were loaded with 
fura-2/AM dye. Correct loading produced a trace with a high peak (>150) and small left 
hand shoulder (blue trace). Poor loading resulted in a small peak (<150) and high left 
hand shoulder (red trace). 
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Figure 2.13.2. Typical Ca
2+
-addback traces from fluorimetry based experiments 
Figure from MRes dissertation (Whitworth 2012). (A) Typical Ca2+-addback trace. 
Addition of 200 nM thapsigargin (TG) causes Ca2+ store depletion and therefore 
increases fura-2 fluorescence intensity. Ca2+-addback (2 mM CaCl2) produces a second, 
larger increase in fura-2 fluorescence intensity due to SOCE. Addition of 50 µM 
ionomycin (I) causes fura-2 saturation and a sharp increase in fura-2 fluorescence 
intensity to its maximal value (Fmax) whilst addition of 1 mM manganese (MnCl2) 
queches fura-2 and causes a sharp decrease in fura-2 fluorescence intensity to minimal 
autofluorescence (AF). The two responses are used to calibrate the trace. (B) Typical 
control Ca2+-addback trace with DMSO added in place of TG which causes no change or 
a slight increase in fura-2 fluorescence intensity. Response to Ca2+-addback is also 
reduced. Arrows represent addition of chemical.  
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Figure 2.13.3. Determining [Ca
2+
]i using calibrated Ca
2+
 addback traces from 
fluorimetry based experiments 
Figure adapted from MRes dissertation (Whitworth 2012). (A) Typical Ca2+-addback 
trace. Addition of 200 nM thapsigargin (TG) causes Ca2+ store depletion and therefore 
increases fura-2 fluorescence intensity. The change in [Ca2+]i representative of Ca
2+ 
store release was determined through calibration of the area under the curve (bound 
by dotted lines and trace peak). Ca2+-addback (2 mM CaCl2) produces a second, larger 
increase in fura-2 fluorescence intensity. The change in [Ca2+]i representative of SOCE 
was determined through calibration of the area under the curve (bound by dashed 
lines and trace peak). (B) Typical control Ca2+-addback trace with DMSO added in place 
of TG which causes no change or a slight increase in fura-2 fluorescence intensity. The 
change in [Ca2+]i was determined through calibration of the area under the curve 
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(bound by dotted lines and trace peak). Response to Ca2+-addback is reduced in DMSO 
controls. The change in [Ca2+]i representative of basal SOCE was determined through 
calibration of the area under the curve (bound by dashed lines and trace peak). Arrows 
represent addition of chemical. 
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2.14. Single cell Ca
2+
-addback experiments 
Cells were loaded with fura-2/AM as described above (Methods 2.13). After loading 
and washing, individual coverslips were fixed into a coverslip holder (custom made), 
producing a chamber in which Ca²⁺-free Krebs buffer was added. Measurements of 
relative changes in [Ca2+]i were recorded using ratiometric imaging through detection 
of fura-2 fluorescence at an excitation wavelength of 340 nm and 380 nm and an 
emission wavelength of 510 nm using an Olympus IX70 fluorescent microscope or a 
Nikon Eclipse TE300 microscope. Images were obtained with a charge-coupled device 
(CCD) camera (MicroMax, Sony Interline Chip, Princeton Instruments, Trenton, NJ) and 
using a 20x objective lens.  
 
MetaFluor software (Universal Imaging, Marlow, UK) was used to record data and 
calculate the ratio between 340 nm and 380 nm fluorescence intensity (FR) as a 
representation of [Ca²⁺]i. Ratiometric measurements take advantage of the dual 
excitability of fura-2, which shifts its absorbance maximum to lower wavelengths in its 
Ca2+ bound form. Alternating excitement at 340 nm and 380 nm ensures a maximal 
difference between the fluorescence emission of fura-2 in its unbound and Ca2+ bound 
state. This normalises for changes in fluorescence intensity that are unrelated to 
changes in [Ca²⁺]i, such as unequal fura-2 distribution, uneven cell thickness or noise 
introduced by the detection equipment (e.g. changes in illumination intensity).  
 
To establish a new system for single cell Ca measurements, the optimum exposure 
times for 340 nm and 380 nm excitation were determined using a range of exposure 
times (Figure 2.14.1). The optimum exposure times were 300 ms for 340 nm excitation 
and 80 ms for 380 nm as these exposure times did not cause photobleaching over the 
time of the experiment (Figure 2.14.1B) but still provided ample maximal difference 
between the responses at the two wavelengths of excitation. 
 
Regions of interest were drawn around ~10 cells before each experiment to track the 
response over the Ca2+-addback experiment (Figure 2.14.2). Following establishment 
of a steady trace baseline, 200 nM TG (Calbiochem) was added to induce ER Ca2+ store 
release and a rise in [Ca²⁺]i represented as a peak in FR (Figure 2.14.3A), or an 
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equivalent volume of DMSO as a control was added (Figure 2.14.3B). Following return 
to a steady baseline, 2 mM CaCl₂ was added to induce SOCE and a rise in [Ca²⁺]i 
represented as second peak in FR (Figure 2.14.2).  
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Figure 2.14.1. Optimum exposure times 
to prevent photobleaching in single cell 
based experiments 
Ratiometric imaging through detection of 
fura-2 fluorescence at an excitation 
wavelength of 340 nm and 380 nm and an 
emission wavelength of 510 nm was 
performed using an Olympus IX70 
fluorescent microscope or a Nikon Eclipse 
TE300 microscope. Measurements of 
changes in fluorescence intensity over 
time were recorded to determine 
optimum exposure times for 340 nm and 
380 nm excitation. A range of exposure 
times were used, upwards from (A) 100 
ms for 340 nm excitation with 40 ms for 
380 nm excitation. Optimum exposure 
times were observed at (B) 300 ms for 340 
nm excitation with 80 ms for 380 nm 
excitation since there was no change in 
fluorescence intensity over the time-
course like that in (A) and increasing 
exposure time further to (C) 400 ms for 
340 nm excitation with 100 ms for 380 nm   
                                                                                excitation caused a slight decrease over 
                                                                                the time-course due to photobleaching. 
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Figure 2.14.2. Typical Ca
2+
-addback experiment using a single cell based approach 
Ca2+ addback experiments were recorded using ratiometric imaging through detection 
of fura-2 fluorescence at an excitation wavelength of 340 nm and 380 nm and an 
emission wavelength of 510 nm using an Olympus IX70 fluorescent microscope. 
Images were obtained with a charge-coupled device (CCD) camera (MicroMax, Sony 
Interline Chip, Princeton Instruments, Trenton, NJ) and using a 20x objective lens. Cells 
were identified morphologically using (A) bright field and (B) fluorescence images. (B) 
Regions of interest were created over each cell in the field of view.  Example includes 
individual N-type cells (#1-23) and cell clumps (#24-26). (C and D) The experiment was 
run to capture fluorescence ratio data values in Excel (time-points and data from 3 
cells depicted) and produce a trace for each region of interest corresponding to a 
specific cell phenotype and differentiation status.  
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Figure 2.14.3. Typical Ca
2+
-addback traces using single cell based experiments 
(A) Addition of 200 nM thapsigargin (TG) causes an increase in fura-2 fluorescence and 
the fluorescence ratio between the two excitation wavelengths, representative of a 
rise in [Ca2+]i due to release of Ca
2+ from intracellular ER stores. Ca2+-addback (2 mM 
CaCl2) causes a second increase in fura-2 fluorescence and the fluorescence ratio 
between the two excitation wavelengths, representative of a rise in [Ca2+]i due to 
SOCE. (B) DMSO addition as a control for TG does not increase fura-2 fluorescence and 
the subsequent Ca2+-add-back response is reduced, is representative of basal Ca2+ 
entry.  
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2.15. Analysis of relative changes in [Ca
2+
]i in single cells 
MetaFluor and MetaMorph software (Universal Imaging) were used to record data and 
calculate the fluorescence ratio (FR) as a representation of [Ca²⁺]i. Regions of interest 
(ROI) were applied to individual cells and the experiments recorded (Methods 2.14) 
were re-ran to produce a trace for every cell or cell aggregate in the field of view 
(Figure 2.14.1). The fluorescence ratio data was recorded in Microsoft Excel for each 
region of interest that could be related to morphological phenotype and 
differentiation status (Figure 2.15.1A). 
 
The peak height (PH), rate of rise (ROR), rate of decline (ROD) and area under the 
curve (AUC) for TG and Ca²⁺ responses were calculated using Excel functions in a 
template spread sheet, custom built under a collaboration with Dr Graham Scholefield, 
so that only three cell values needed to be altered manually for each data set (Figure 
2.15.1A).  
 
The minimum and maximum fluorescence ratio values in the TG and Ca²⁺ range were 
calculated to determine the peak height of each response (Figure 2.15.1). To eliminate 
the possibility of finding a minimum value at the end of the Ca²⁺ response, the function 
finds the minimum within the rising phase of the peak, defined as data preceding the 
maximum value. 
 
The rate of rise (ROR) function determines the row number of the dataset at the 
minimum and maximum values in the TG or Ca²⁺ range and minuses the minimum row 
number from the maximum row number (Figure 2.15.1). This value is multiplied by 20 
to give the time value of the TG or Ca²⁺ response range, since the time lapse between 
measurements is 20 seconds. The peak height is then divided by the time range to 
provide the ROR (Figure 2.15.1). 
 
The rate of decline (ROD) function determines the row number of the dataset at the 
maximum value and the minimum value following the peak in the TG or Ca²⁺ range and 
minuses the maximum row number from the minimum row number (Figure 2.15.1). 
This value is multiplied by 20 to give the time value of the TG or Ca²⁺ response range, 
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since the time lapse between measurements is 20 seconds. The peak height is then 
divided by the time range to provide the total ROD (Figure 2.15.1). Since the ROD for 
the Ca2+ often consisted of two phases, the initial and late ROD was also determined. 
The initial ROD function uses the calculations described above but finds and uses the 
time-point at 300 secs following the peak of the Ca2+ response instead of the minimum 
value to determine the time range (Figure 2.15.1). The late ROD function uses the 
calculations described above but finds and uses the time-point at 300 secs following 
the peak of the Ca2+ response instead of the maximum value and still uses the 
minimum value to determine the time range (Figure 2.15.1). 
 
The AUC function finds the area bound by the graph and within a specified time region 
above the specified minimum value (Figure 2.15.1). This function multiplies the 
minimum value by the time range and minuses this from the maximum to account for 
changes in baseline.  
 
The cell type (N-, S-, or I-type and SO, SA or SE) and differentiation status (proliferating 
or differentiating) were defined morphologically as previously described (Introduction 
1.3 and 1.4) and manually attributed to each ROI dataset (Figure 2.15.1A). Data from 
the Excel spreadsheet described above was then automagically extracted to a custom 
built VBA coded Excel tool, developed in collaboration with Dr Graham Scholefield. The 
tool was able to extract and group data together based on the characteristics 
described above, as well as by experiment date and type, and, by use of data filters, 
could average the grouped data, subtract grouped DMSO control data from 
experimental data and perform Student’s t-tests. 
 
Average DMSO control trace values were subtracted from the average of the typical 
response values. All data presented throughout this thesis are basal-subtracted (i.e. 
DMSO response) and are therefore response to stimulus only. Extent of changes in 
SOCE were calculated taking any changes in Ca2+ store release into account and 
assuming a linear relationship. 
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Figure 2.15.1. Determining relative changes in [Ca
2+
]i using Ca
2+
-addback traces from 
single cell based experiments 
(A) Example of template spread sheet with trace values attributed to each ROI defined 
by morphology (Row 1). Colours correspond to those on the (B) example data set 
depicting spread sheet function calculations for SOCE peak. The time of CaCl2 addition 
is used as the start of the SOCE response (yellow). For each region of interest (ROI) 
data set, the minimum value is subtracted from the maximum value (orange) to find 
peak height (red). The area under the curve (AUC) function finds the area that is bound 
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by the graph within a specified time region (dotted green lines) and above the 
specified minimum value (solid green line). The function also multiplies the minimum 
value (orange) by the time range (dotted green lines) and minuses this from the 
maximum (i.e. subtracts dotted green area from total AUC) to provide the AUC (bound 
by solid green line and trace). The rate of rise (ROR) function determines the row 
number of the dataset at the minimum and maximum values (orange) and minuses the 
minimum row number from the maximum row number. This value is multiplied by 20 
to give the time value of the response range (dotted green lines), since the time lapse 
between measurements is 20 seconds. The peak height (red) is then divided by the 
time range to provide the ROR (grey). The rate of decline (ROD) function determines 
the row number of the dataset at the maximum value and the minimum value (orange) 
following the peak and minuses the maximum row number from the minimum row 
number. This value is multiplied by 20 to give the time value of the response range 
(dotted green lines), since the time lapse between measurements is 20 seconds. The 
peak height is then divided by the time range to provide the total ROD (purple dashed 
line). Since the ROD for SOCE often consisted of two phases, the initial and late ROD 
was also determined. The initial ROD function uses the calculations described above 
but finds the time-point at 300 secs following the peak of the Ca2+ response instead of 
using the minimum value to determine the time range (light blue dotted line). The late 
ROD function uses the calculations described above but finds the time-point at 300 
secs following the peak of the Ca2+ response instead of using the maximum value 
whilst still using the minimum value to determine the time range (dark blue dotted 
line). 
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2.16. RNA extraction and sequencing 
Total RNA extraction was performed by Lauren Harkin using the QIAgen RNeasy mini 
kit (QIAgen, West Sussex, UK) according to the manufacturer’s protocol. This 
procedure allows all RNA molecules >200 nucleotides to be purified, thereby enriching 
for mRNA. Briefly, cells were lysed and homogenised in the presence of a denaturing 
guanidine-isothiocyanate buffer which inactivates RNases to prevent RNA degradation. 
Ethanol (70%, 1 volume) was added to samples to promote binding to RNeasy silica-
membranes. Samples were transferred to an RNeasy spin column in a collection tube. 
Samples were centrifuged at 10,000 rpm for 15 seconds to wash away contaminants. 
Flow-through was discarded and wash buffer was added to the samples, which were 
centrifuged at 10,000 rpm for 15 seconds to wash the spin column membrane. This 
was repeated twice and samples were centrifuged for two minutes a third time to dry 
the spin column membrane and ensure ethanol was not transferred in the RNA 
elution. RNase-free water was added to the spin column membrane and centrifuged at 
10,000 rpm for 1 minute to elute the RNA. Purified RNA was stored at -20°C in RNase-
free water until being sent for sequencing. 
 
2.17. Statistical Analysis 
Data are representative of mean ± S.E.M of N total number of experiment days and n 
total number of cells. Microsoft Excel and GraphPad Prism 3 and 6 were used to 
analyse all data using, for unpaired groups, two-tailed Student’s t-tests or, for groups 
of three or more, one-way analysis of variance (ANOVA). Statistical significance was 
accepted as P ≤ 0.05. The level of significance is indicated in figures as P<0.05*, P<0.01**, 
P<0.001***, P<0.0001****. 
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Chapter 3: The 9-cis-retinoic acid-induced differentiation 
response 
Chapter 3 - Introduction 
Induction of neuroblastoma differentiation by retinoic acid administration alongside 
standard chemotherapy is used to treat patients with end stage or residual 
neuroblastoma (Matthay 2009). There are several isoforms of retinoic acid, of which 
9cRA is the most potent for differentiation induction (Han 1995; Lovat 1997). It has 
previously been shown that 9cRA-induced morphological differentiation of N-type cells 
causes elongation of neurite-like processes (Brown 2005; Cheung 2009; N. Bell 2013) 
and that morphological changes occur in S-type cells (N. Bell 2013) however these 
have yet to be fully defined. The aim of this chapter was to characterise the 
phenotype-specific 9cRA-induced differentiation profile of SH-SY5Y neuroblastoma 
cells morphologically and biochemically. 
 
Chapter 3 - Results 
3.1. 9cRA induces a lineage-specific morphological change in neuroblastoma cells 
Treatment of SH-SY5Y cells (N-type populations) and S-enriched SH-SY5Y cells (S-type 
populations) for 7 days with 1 µM 9cRA induced morphological changes that were 
used to distinguish a differentiating phenotype from a proliferating (EtOH treated) 
phenotype (Figure 3.1.1). Proliferating N-type cells possess small, rounded cell bodies 
with short neurite-like processes and grow over one another, forming aggregates 
(Figure 3.1.1A). With 9cRA treatment, N-type cells differentiate towards a neuronal 
lineage developing extended neuritic processes (Figure 3.1.1A and B). Neurite length 
has been extensively used as a marker of N-type cell differentiation and cells 
possessing one or more neurites over 50 µm in length are generally regarded as 
differentiated (N. Bell 2013; Brown 2005; Simpson 2001). Compared to EtOH treated 
cells, the percentage of differentiated cells increased with 9cRA treatment (6% to 18%, 
respectively, P<0.0001, Figure 3.1.2A). The average neurite length was also 
significantly increased in 9cRA treated cells (28 µm to 36 µm, P=0.0002, Figure 3.1.2B). 
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Proliferating S-type cells have abundant cytoplasm with no neuritic processes and 
develop a more flattened and spread out morphology with differentiation (Figure 
3.1.1C and D). The S-phenotype consists of three sub-populations; outstretched (SO), 
angular (SA) and elongated (SE), which all undergo morphological changes with 
differentiation. Since no standardised morphological marker of differentiation has 
been established for S-type cells, cell diameter for SO and SA cells and cell length for SE 
cells was used to quantify the effect of 9cRA-induced differentiation. Cell 
measurements of all three sub-phenotypes increased with 9cRA treatment (Figure 
3.1.3). The diameter of EtOH treated SO and SA cells (33.60 µm and 16.85 µm, 
respectively, Figure 3.1.3) increased with 9cRA treatment (46.94 µm, P=0.0018 and 
24.00 µm, P=0.212, respectively, Figure 3.1.3). The length of SE cells also increased 
significantly with 9cRA treatment (from 56.76 µm to 86.02 µm, P=0.001, Figure 3.1.3). 
The proportions of cell phenotypes within S-type populations were not significantly 
altered with differentiation (Figure 3.1.4), although it is noteworthy that there was a 
greater than two-fold increase in the proportion of SE cells upon differentiation. 9cRA-
induced differentiation also causes a reduction in the proliferation rates of N-type and 
S-type cells. 
 
I –type cells in EtOH treated populations exhibited morphological characteristics of 
both N-type and S-type cells, with abundant cytoplasm and neurite-like processes 
(Figure 3.1.1A). In 9cRA treated populations, I-type cell processes appeared more 
elongated and cell bodies more spread out (Figure 3.1.1B). 
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Figure 3.1.1. Treatment of N-type and S-type populations with 9cRA induces 
morphological differentiation 
N-type and S-type cell populations were treated for 7 days with 1 µM 9cRA to induce 
differentiation or with an equivalent volume of EtOH as a control to maintain 
proliferation. Inset DIC images show the measurement of changes in cell morphology. 
(A) Proliferating N-type cells possess short neurite-like processes (black arrows and 
inset) and (B) upon differentiation, neurites become elongated (arrows and inset). (C) 
Proliferating S-type cells have abundant cytoplasm and a flattened morphology 
(dashed arrows and inset) and (D) become more flattened and spread out with 
differentiation, with an increased diameter (dashed arrows and inset). I-type cells in 
proliferating populations (A) possess abundant cytoplasm and neurite-like processes 
(dotted arrow) and in differentiating populations (B), I-type processes become 
elongated like that of N-type cells and cell bodies become more spread out like that of 
S-type cells (dotted arrow). Scale bars of main phase contrast images represents 50 µm 
and DIC inset images represent 20 µm.  
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Figure 3.1.2. Treatment of N-type cells with 1 µM 9cRA causes elongation of neurites 
N-type cell populations were treated for 7 days with 1 µM 9cRA to induce 
differentiation or with an equivalent volume of EtOH as a control to maintain 
proliferation. Phase contrast or DIC images were used for neurite measurements using 
Metamorph and LSM Image Browser, respectively. (A) Neurite length was used to 
classify N-type cells as morphologically proliferating or differentiated. Cells possessing 
one or more neurites >50μm in length were classed as differentiated. Percentage of 
differentiated cells was 5.84% in control EtOH treated cells and was significantly higher 
in 9cRA treated cells (17.76%, P<0.0001****) therefore 9cRA treatment for 7 days 
alters N-type morphology to a differentiating phenotype. (B) The neurites of N-type 
cells were significantly shorter in EtOH treated cells (27.57μm) than those of 9cRA 
treated cells (36.29μm, P=0.0002***).  EtOH treated n=6394, 9cRA treated n=2694. 
N=6.   
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Figure 3.1.3. 9cRA-induced differentiation of S-type cells develop increased cell 
dimensions 
Treatment with 1 µM 9cRA for 7 days induces morphological changes in the three S-
type sub-populations compared to EtOH treated cells. Phase contrast or DIC images 
were used for neurite measurements using Metamorph and LSM Image Browser, 
respectively.  (A) The diameter of proliferating (P) outstretched (SO) cells significantly 
increased with 9cRA-induced differentiation (D, 33.60 µm to 46.94 µm, P=0.0018**). 
The diameter of proliferating angular (SA) cells (16.85 µm) cells increased with 
differentiation (24.00 µm, P=0.212). The length of elongated cells (SE) significantly 
increased with differentiation (from 56.76 µm to 86.02 µm, P=0.001***). Proliferating 
SO n=2055, SA n=1144, SE n=126. Differentiating SO n=1492,SA n=563, SE n=146. N=7.  
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Figure 3.1.4. Cell phenotype proportions do not change with differentiation of S-type 
cell populations. 
S-type cell populations were treated for 7 days with 1 µM 9cRA or equivalent volume 
of EtOH as a control to induce morphological. Phase contrast or DIC images were used 
for neurite measurements using Metamorph and LSM Image Browser, respectively.  
Compared to EtOH treated S-type populations, in 9cRA treated S-type populations 
there was no significant difference in the percentage of proliferating N-type (7% and 
9%, respectively, P=0.8101), SO (57% and 59%, respectively, P=0.3030), SA (27% and 
21%, respectively, P=0.0641), SE (3% and 7%, respectively, P=0.1153) or I-type cells (5% 
and 4%, respectively, P=0.1293). EtOH treated n=3274, 9cRA treated n=2138. N=5. 
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3.2 Increases in 9cRA concentration do not increase morphological differentiation of 
N-type neuroblastoma cells 
As the extent of differentiation is variable between studies and between batches of 
cells, it is important to confirm the maximum dose of 9cRA in this study. Therefore, 
dose-response experiments were performed in N-type populations (Figure 3.2.1 and 
3.2.2) to determine the optimal 9cRA concentration for a sufficient morphological 
differentiation response.  
 
Previously in this laboratory, treatment with 1 µM 9cRA over 7 days has been deemed 
an appropriate concentration to induce significant differentiation of neuroblastoma 
cells (Bell et al., 2013). As expected, treatment of N-type populations with 1 µM 9cRA 
for 7 days caused a significant increase in percentage of differentiation compared to 
EtOH treated control cells (from 3% to 14%, P=0.0161, Figure 3.2.2A) and neurite 
length was significantly increased (from 26 µm to 34 µm, P=0.0112, Figure 3.2.1B and 
3.2.2B). There was no further significant increase in the percentage of differentiated 
cells with subsequent increases in 9cRA concentration up to 20 µM (P>0.05, Figure 
3.2.2A). There was, however, a significant increase in average neurite length between 
1 µM and 10 µM 9cRA treatment (34 µm and 39 µm, respectively, P=0.0335, Figure 
3.2.2B). This increase was marginal and treatment at a concentration of 10 µM 9cRA 
appeared to lie close to limit of inhibition, since the percentage differentiation and 
average neurite length appeared to fall slightly with 20 µM 9cRA (Figure 3.2.2A and B). 
Consistent with a possible inhibitory dose of 9cRA, 20 µM 9cRA also appeared to 
reduce cell numbers (Figure 3.2.1F). This provided rationale for continuing to use a 
concentration of 1 µM 9cRA as the differentiating medium. Cells treated with 1µM 
9cRA will therefore be referred to as differentiating cells whilst cells treated with the 
equivalent volume of EtOH as a control will be referred to as proliferating cells. 
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Figure 3.2.1. Treatment of N-type cells with 9cRA induces elongation of neurite-like 
processes 
N-type populations were treated with a range of concentrations of 9cRA for 7 days to 
induce differentiation or equivalent volume of EtOH as a control for proliferation. (A) 
Proliferating N-type cells have short neurite-like processes and (B) upon differentiation 
with 1 µM 9cRA for 7 days, their neurites become elongated. Treatment with a higher 
concentration of 9cRA also caused elongation of neurite-like processes at (C) 2 µM (D) 
5 µM (E) 10 µM (F) 20 µM 9cRA. Scale bar of phase contrast images represents 50 µm.  
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Figure 3.2.2. Treatment of N-type cells with 1 µM 9cRA induces maximal phenotypic 
differentiation 
Cells were treated for 7 days with a range of 9cRA concentrations to induce 
differentiation or EtOH as a control for proliferation. Neurite lengths were measured 
from DIC images using LSM Image Browser. (A) Compared to proliferating cells (0 µM 
9cRA, EtOH treated control), there was a significant increase in the percentage 
differentiation with 1 µM 9cRA treatment (3.30% to 14.17% respectively, P=0.0161*). 
There was no further significant increase in percentage differentiation when treating 
N-type cells with concentrations of 9cRA above 1 µM (P>0.05). (B) Compared to 
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proliferating cells, average neurite length was significantly increased with 1 µM 9cRA 
treatment (25.59 µm to 33.82 µm respectively, P=0.0063**). There was a further 
significant increase in neurite length between 1 µm and 10 µM 9cRA treatment (from 
33.82 µm to 38.71 µm, P=0.0335*). There was no significant difference in neurite 
length between cells treated with 1 µm and 2 µm, 5 µm or 20 µm 9cRA (P>0.05). 0 µm 
n=3844, 1 µm n=2085, 2 µm n=1549, 5 µm n=1557, 10 µm n=1527, 20 µm n=1320. 
N=3.  
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3.3. N-type and S-type populations express a neuronal and a non-neuronal marker 
The neuronal microtubule protein β-tubulin III has been shown to be expressed in N-
type cells whilst the non-neuronal type III intermediate filament protein vimentin has 
been shown to be expressed in S-type cells (Whitworth 2012; N. Bell 2013). These two 
markers were used to distinguish between N-type and S-type populations. 
 
β-tubulin III was expressed by proliferating N-type populations and expression was not 
significantly altered with differentiation (P=0.740, Figure 3.3.1A and B). β-tubulin III 
was also expressed by proliferating S-type populations and expression was not 
significantly altered with differentiation (P=0.838, Figure 3.3.1A and B). Proliferating S-
types exhibited 35% less expression of β-tubulin III compared to N-type cells, but this 
was not significant (P=0.159, Figure 3.3.1A and B).  
 
Vimentin was predominantly expressed by both proliferating S-type populations and 
expression was increased by 85% with differentiation, but this was not significant 
(0.509, Figure 3.3.1A and C). Vimentin expression was minimal in proliferating N-type 
populations and was expression was increased by over ~2 fold with differentiation, 
however this was not significant (P=0.346, Figure 3.3.1A and C). Vimentin expression 
was over ~7 fold greater in differentiating S-type cells compared to proliferating N-type 
populations, but this was not significant (P=0.077, Figure 3.3.1C).  
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Figure 3.3.1. The expression of β-tubulin III and vimentin are not significantly altered 
with differentiation 
Western blots were performed on protein extracts from SH-SY5Y (N-type) and S-
enriched (S-type) cell populations following treatment for 7 days with 1 µM 9cRA (D, 
differentiating) or equivalent volume of EtOH as a control (P, proliferating). Blots were 
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probed with anti-β-tubulin III antibody which detected a band at 50 kDa, anti-vimentin 
antibody which detected a band at 57 kDa and re-probed with anti-β-actin antibody as 
a loading control which detected a band at 42 kDa. Quantitative band measurements 
were performed using densitometry in ImageJ. (A) β-tubulin III was expressed by both 
proliferating and differentiating N-type populations and appeared to be expressed to a 
lesser extent in S-type populations. Vimentin was expressed minimally by proliferating 
N-type populations with an apparent increase in band intensity with differentiation. 
Vimentin appeared to be expressed to a greater extent in S-type populations and band 
intensity similar between proliferating and differentiating S-type populations. (B) β-
tubulin III expression was expressed as a ratio of β-actin. β-tubulin III expression was 
not significantly altered with differentiation of N-type populations (P=0.740, N=5) or S-
type populations (P=0.838, N=3). Although β-tubulin III expression was 39.34% higher 
in proliferating N-type compared to proliferating S-type populations, this was not 
significant (P=0.159). (C) Vimentin expression was expressed as a ratio of β-actin. 
Vimentin expression was >2 fold higher in differentiating N-type compared to 
proliferating N-type populations, but this was not significant (P=0.346, N=6). Vimentin 
expression was 84.85% higher in differentiating S-type populations compared to 
proliferating S-type populations, but this was not significant (P=0.509, N=5). Although 
vimentin expression was >7 fold higher in S-type compared to N-type populations, this 
was not significant (P=0.077).  
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3.4. Bcl-2 expression is a differentiation marker in N-type populations 
The anti-apoptotic protein Bcl-2 is known to be up-regulated with differentiation of 
neuroblastoma cells (Hanada 1993) and has previously been used to determine 
biochemical differentiation in SH-SY5Y cells (Riddoch 2007; N. Bell 2013). Bcl-2 was 
therefore used in this study as a biochemical marker of differentiation.  
 
Bcl-2 was expressed in proliferating N-type populations and significantly up-regulated 
with differentiation (P=0.0003, Figure 3.4.1A and B). Compared to N-type populations, 
Bcl-2 was expressed at significantly lower levels in proliferating S-type populations 
(P=0.017) and expression was non-significantly down-regulated by 34% with S-type 
population differentiation (P=0.121, Figure 3.4.1A and B). This up-regulation of Bcl-2 
expression in differentiating N-type cells may correspond with the neuroblastic cells 
becoming more neuronal-like whilst a down-regulation with S-type population 
differentiation may imply a shift away from the neuronal phenotype towards a 
different cell lineage. 
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Figure 3.4.1. Bcl-2 expression is altered with differentiation of N-type and S-type 
populations.  
Western blots were performed on protein extracts from SH-SY5Y (N-type) and S-
enriched (S-type) cell populations following treatment for 7 days with 1 µM 9cRA (D, 
differentiating) or equivalent volume of EtOH as a control (P, proliferating). Blots were 
probed with anti-Bcl-2 antibody which detected a band at 27 kDa and re-probed with 
anti-β-actin antibody as a loading control which detected a band at 42 kDa. (A) Bcl-2 
was expressed by both proliferating and differentiating N-type populations and to a 
lesser extent in S-type populations. With differentiation, there was an increase in band 
intensity in N-type populations and a decrease in band intensity in S-type populations. 
(B) Quantitative band measurements were performed using densitometry in ImageJ. 
Bcl-2 expression was expressed as a ratio of β-actin. Bcl-2 expression was significantly 
lower in proliferating S-type populations compared to proliferating N-type populations 
(P=0.0166*). There was a significant increase in Bcl-2 expression with differentiation of 
N-type populations (87%, P=0.0003***, N=14). Bcl-2 expression was non-significantly 
down-regulated in S-type populations with differentiation (34%, P=0.121, N=13). 
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3.5. Proliferating and differentiating N- and S-type cells express a stem cell and 
melanocyte marker 
Western blotting and immunofluorescence techniques were used to further 
characterise N-type and S-type cell populations biochemically and potentially identify 
the sub-phenotypes within the S-type population. To characterise the cells, the 
expression of several markers associated with Schwann cells, glial cells and 
melanocytes were investigated, since they are thought to exist within the S-type 
population. The expression of a stem cell marker was also studied given that there is 
heterogeneity in the 9cRA-induced differentiation response (Brown 2005). 
 
The neural crest stem cell marker, CD133 (prominin-1) is a cell surface glycoprotein 
that has been identified as a cancer stem cell marker in a variety of malignancies 
(Collins 2005; Olempska 2007; Ricci-Vitiani 2007; Yin 2007). CD133 was expressed by 
both proliferating and differentiating N-type populations and also by S-type 
populations, though to a generally lesser extent (Figure 3.5.1A and B). This may reflect 
the tumourigenic nature of N-type cells over S-type cells. There were no significant 
changes in expression with 9cRA-induced differentiation of N- or S-type cells, however 
it is noteworthy that there was a 40% decrease in CD133 expression in differentiating 
S-type cells and that this was close to significance (P=0.068, Figure 3.5.1B). CD133 was 
observed throughout the cytoplasm of N- and S-type cells and there were no 
significant differences observed in the distribution between proliferating and 
differentiating N- or S-type cells (Figure 3.5.2).   
 
The micropthalmia-associated transcription factor (MiTF) is a known inducer of 
melanocyte differentiation (Tachibana 1996; Li 2003; Loercher 2005; Levy 2006) and 
was investigated in this study given the unclear identity of S-type cells. MiTF was 
expressed by N-type and, unexpectedly to a lesser extent, S-type populations (Figure 
3.5.1A and C). MiTF was observed throughout the cytoplasm of both proliferating and 
differentiating N- and S-type cells (Figure 3.4.3). Surprisingly, there was no significant 
effect of differentiation on MiTF expression (Figure 3.5.2C) or distribution (Figure 
3.5.3). 
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There was no expression detected of two glial cell markers; the intermediate filament 
protein, GFAP and the neural crest transcription factor, SOX10, observed in either N- or 
S-type populations (data not shown). These proteins are normally expressed in 
precursor glial cells however there is the possibility that N- and S-type cells perhaps 
may be too immature for these proteins to be expressed. 
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Figure 3.5.1. N-type and S-type populations express a stem cell and melanocyte 
marker 
Western blots were performed on protein extracts from SH-SY5Y (N-type) and S-
enriched (S-type) cell populations following treatment for 7 days with 1 µM 9cRA (D, 
differentiating) or equivalent volume of EtOH control (P, proliferating). (A) Blots were 
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probed with anti-CD133 antibody which detected a band at 97 kDa or anti-MiTF 
antibody which detected a band at 52 kDa. Blots were re-probed with anti-β-actin 
antibody as a loading control which detected a band at 42 kDa. The stem cell surface 
glycoprotein, CD133, and the transcription factor, MiTF were expressed by both 
proliferating and differentiating N-type and S-type populations. (B) There was no 
change in expression of CD133 in differentiating N-type populations (P=0.237, N=9) 
and a slight but non-significant decrease by 40% in differentiating S-type populations 
(P=0.068, N=8). There was no difference in expression of CD133 between proliferating 
N-type and S-type populations (P=0.673) but CD133 expression was significantly less in 
differentiating S-type populations compared to differentiating N-type populations 
(P=0.0478*). (C) There was no significant change in the expression of MiTF between 
proliferating and differentiating N-type populations (P=0.244, N=9) or S-type 
populations (P=0.370, N=9). Compared to N-type populations, expression of MiTF was 
significantly down-regulated by 24% in proliferating (P=0.0342*) and differentiating 
(P=0.0175*) S-type populations. 
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Figure 3.5.2. Proliferating and differentiating N- and S-type cells express CD133 
throughout their cytoplasm  
Cells were stained with CD133 antibody (green). Images were captured using laser 
scanning confocal microscopy. (A) Proliferating and (B) differentiating N-type cell 
populations stain positively for CD133 throughout their cytoplasm and neurite-like 
processes (white arrows). (C) Proliferating and (D) differentiating S-type cell 
populations stain positively for CD133 throughout their cytoplasm. There was no 
apparent change in localisation with differentiation of N-type or S-type populations. 
Scale bars represent 20 µm. Images representative of >20 images. N=2. 
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Figure 3.5.3. Proliferating and differentiating N- and S-type cells express MiTF 
throughout their cytoplasm 
Cells were stained with MiTF antibody (red). Images were captured using laser 
scanning confocal microscopy (A) Proliferating and (B) differentiating N-type cell 
populations stain positively for MiTF throughout their cytoplasm and neurite-like 
processes (white arrows). (C) Proliferating and (D) differentiating S-type cell 
populations stain positively for MiTF throughout their cytoplasm. There was no 
apparent change in localisation with differentiation of N-type or S-type populations. 
Scale bars represent 20 µm. Images representative of >20 images. N=2. 
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Chapter 3 - Discussion 
Retinoic acid has been used as a treatment alongside standard chemotherapy in 
neuroblastoma patients with end stage or residual disease (Matthay 2009). However, 
given the heterogeneity of the disease and cell responses, this treatment is not always 
effective and survival is poor in these patients (Matthay 2009). The SH-SY5Y 
neuroblastoma cell line consists of N-type, S-type and I-type cells, which exhibit 
varying levels of tumourigenicity in vivo (Picacentini 1996; Walton 2004) and thereby 
may possess potential differences in retinoic acid-induced differentiation responses. 
Determining variations in the differentiation responses between cell phenotypes may 
help identify sub-populations of cells that are able to evade proliferation-halting 
therapies and will contribute to our understanding of acquired resistance that may 
facilitate disease progression. In this chapter, the phenotype-specific differentiation 
responses of neuroblastoma cells were characterised as a prelude to the phenotype-
specific Ca2+ signalling studies presented in subsequent chapters.  
 
Treatment of SH-SY5Y (N-type) cell populations and S-enriched (S-type) populations 
with 1 µM 9cRA for 7 days induced both morphological and biochemical 
differentiation, with N-type cells becoming more neuronal-like and S-type cells 
becoming more epithelial-like. This is consistent with previous studies, including from 
this laboratory (Bell et al., 2013), which have shown that N-type cells differentiate 
towards a neuronal phenotype, (Lovat 1997; Simpson 2001; Brown 2005; Armstrong 
2012; Dwane 2013; N. Bell 2013) that express neuronal markers such as β-tubulin III 
and NF-68 (Messi 2008; N. Bell 2013). In the present study, there was a significant 
increase in the extent of N-type cell neurite outgrowth and an increase in the 
percentage of differentiated N-type cells. The percentage of differentiation in 9cRA 
treated cells (18%) was, however, likely to be underestimated since only cells with fully 
visible neurites were measured and so neurites with cells that had grown over them 
will not have been included. There were areas of cells that continued to proliferate and 
grow in aggregates despite 9cRA treatment, which has previously been observed 
(Brown 2005) even in cells that were treated over a longer time period (N. Bell 2013). 
This implies that neuroblastoma cells can respond differently to 9cRA or even fail to 
respond altogether. This heterogeneity is a characteristic feature of neuroblastoma cell 
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lines (Biedler 1973; Ciccarone 1989; Acosta 2009) and of neuroblastoma disease 
(Valent 1999; Coco 2005), however the underlying reasons are unknown. 
Heterogeneity in response to retinoic acid treatment may be, at least in part, caused 
by the heterogeneic nature of neuroblastoma cells, particularly when considering that 
neuroblastoma cell phenotypes are known to transdifferentiate in culture (Ciccarone 
1989; Gaitonde 2001; Cimmino 2015).  
 
This study attempted to define and quantify sub-populations of S-type cells based on 
their morphology. Although S-type cell populations have been shown to become more 
flattened with differentiation (Bell et al. 2013) this is the first time, to our knowledge, 
that morphological changes in sub-populations of S-type cells have been reported. 
There are three sub-populations of S-type cells that can be distinguished 
morphologically; SO, SA and SE (Introduction 1.4). The diameter of SO cells as well as the 
length of SE cells were significantly increased with differentiation, demonstrating that 
these morphological changes can be used as a morphological marker of differentiation 
in the S-phenotype. S-type cells have previously been shown to differentiate to 
Schwann cells (Tsokos 1987) and melanocytes (Tsokos 1987; Ciccarone 1989). Non-
neuronal neural crest cells such as Schwann and glial cells express the intermediate 
filament protein vimentin (Ciccarone 1989), which is also expressed by S-type cells (N. 
Bell 2013), indicating their non-neuronal nature. However, S-type cells also express the 
neuronal microtubule component β-tubulin III and the neurofilament protein NF-68 
(Messi 2008; Acosta 2009; N. Bell 2013) and β-tubulin III expression becomes down-
regulated with differentiation of S-type cells (N. Bell 2013). These protein expression 
profiles indicate that proliferating S-type cells share some biochemical characteristics 
with immature, neuronal-like N-type cells but commit to a non-neuronal lineage by 
differentiating away from the neuronal phenotype that is seen with N-type 
differentiation. 
 
I-type cells are difficult to morphologically distinguish and characterise given that they 
possess characteristics of both N-type and S-type cells. In differentiating conditions, I-
type cell cytoplasm became more abundant and cell margins spread out like that of S-
type cells whilst processes became elongated like that of N-type cells. I-type cells are 
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recognised as a potential multipotent progenitor or cancer stem cell population in 
neuroblastoma cells that give rise to the neuronal N-type or non-neuronal S-type 
lineage (Ciccarone 1989; Ross 1995; Walton 2004). They are the most malignant 
phenotype in culture and in vivo (Picacentini 1996; Walton 2004) and retinoic acid 
resistance has been observed in these cells (Lasorella 1995; Messi 2008). It has also 
been shown that bidirectional transdifferentiation occurs between N- and S-phenotype 
(Ross 1983; Ciccarone 1989) and this may come about with the I-type as an 
intermediate cell type. The I-phenotype may not actually signify a specific cell 
population and instead reflect a transient morphology of direct N- and S-type 
interconversion associated with the cell phenotype at a particular point mid-transition. 
The observation in this study that I-type cells exhibited morphological characteristics 
of both N-type and S-type cells would be consistent with this notion. At present, the 
true identity of the putative I-type population is unclear as is the common pathway for 
spontaneous transdifferentiation, however this may play a role in the heterogeneic 
nature of the retinoic acid-induced differentiation response. 
 
The neuronal marker β-tubulin III and non-neuronal marker vimentin have previously 
been used to distinguish N-type and S-type cells, respectively (Whitworth 2012; Bell 
2011). Expression of both markers was not altered with differentiation of N-type or S-
type populations suggesting that these markers are unable to distinguish between the 
differentiation state of each cell phenotype. 
 
Bcl-2 is a proto-oncogene and its product, the anti-apoptotic protein Bcl-2, promotes 
cell survival by preventing mitochondrial cytochrome c release (Zhang et al., 1996). Bcl-
2 expression has previously been shown to be regulated during differentiation of 
neuroblastoma cells (Hanada et al., 2010) and to directly regulate the differentiation of 
neural crest cells (Zhang 1996; Liang 2003) and neuronal cells (Middleton 1998; Suzuki 
1998). Bcl-2 expression was increased with differentiation of N-type populations, 
consistent with previous studies in these cells (Lasorella 1995; Riddoch 2007; N. Bell 
2013), and was expressed at much lower levels in both proliferating and differentiating 
S-type populations, as shown in other S-type neuroblastoma cell lines (Hanada 1993). 
Bcl-2 was slightly down-regulated with differentiation of S-type cells. Hence, Bcl-2 was 
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used as a biochemical marker of differentiation in this study. Differentiation of 
neuroblastoma cell lines with phorbol ester also increased Bcl-2 expression (Hanada 
1993), indicating that changes in Bcl-2 expression is associated with differentiation 
rather than as a direct effect of treatment used. It is noteworthy that Bcl-2 up-
regulation, which has been observed in differentiated N-type populations and 
associated with lability of caffeine-sensitive ER Ca2+ store depletion (Riddoch 2007), 
has also been shown to decrease activity of the SERCA pump (Dremina 2004), increase 
ER membrane Ca2+ permeability (Foyouzi-Youssefi 2000), as well as down-regulate 
SOCE (Pinton 2000; Abeele 2002). This will be discussed in more depth in the next 
chapter (Discussion 4). 
 
The cell surface glycoprotein CD133 (prominin-1) is a known neuronal and cancer stem 
cell marker in a variety of malignancies (Collins 2005; Olempska 2007; Ricci-Vitiani 
2007; Yin 2007) and has been shown to suppress neuroblastoma differentiation and 
regulate proliferation (Takenobu 2011). Interestingly, we found a 40% decrease in 
CD133 expression in differentiating S-type populations. Although marginally non-
significant, a down-regulation as S-type cells differentiate towards a lineage specific, 
mature population would be consistent with a role for CD133 as a possible suppressor 
of differentiation in this multi-potent precursor cell population. Since there was no 
change in CD133 expression with differentiation of N-type cell populations, this could 
correspond to the N-phenotype possessing more tumourigenic characteristics or being 
closer to the stem cell I-phenotype which, again, may influence the efficacy of retinoic 
acid.  
 
The micropthalmia-associated transcription factor (MiTF) is known to induce 
melanocyte differentiation (Tachibana 1996; Li 2003; Loercher 2005; Levy 2006) and 
we hypothesised that MiTF expression would increase with S-type differentiation since 
these cells are thought to be melanocyte precursors (Tsokos 1987; Ciccarone 1989). 
However, MiTF was found to be expressed by both N-type and, to a lesser extent, S-
type populations, with no significant effect of differentiation on MiTF expression. This 
could be explained by MiTF actually consisting of several isoforms, of which only MiTF-
M is melanocyte specific (Tachibana 1996; Li 2003). Other isoforms of MiTF could be 
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down-regulated with differentiation which may obscure a simultaneous up-regulation 
of MiTF-M expression however at present, there are no readily available MiTF-M 
specific antibodies to investigate this further.  
 
Using the morphological and biochemical differentiation markers specific to N-type 
and S-type cells discussed in this chapter, it was possible to investigate phenotype-
specific Ca2+ signals associated with the differentiation response.  
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Chapter 4: SOCE in N-type, S-type and I-type cells 
Chapter 4 – Introduction 
SOCE is the process by which Ca2+ enters the cell via plasma membrane SOCs to 
replenish depleted ER Ca2+ stores. SOCE has previously been shown to be down-
regulated in differentiating SH-SY5Y and N-type enriched populations (N. Bell 2013; 
Brown 2005), with no change in differentiating S-type enriched populations (N. Bell 
2013). Since SH-SY5Y populations consist predominantly of N-type cells (Introduction) 
and there was no difference in Ca2+ signals or differentiation response of SH-SY5Y 
populations and N-type enriched populations (Bell 2011), this study has used  SH-SY5Y 
populations to represent N-type populations. SH-SY5Y populations that are S-enriched 
four times (Methods) consist predominantly of S-type cells (Introduction) and there 
was no difference in the Ca2+ signals or differentiation response of S-type enriched 
populations enriched between four and up to twelve times (Bell 2011) therefore S4 
populations were used to represent S-type populations. N-type and S-type populations 
were treated for 7 days with 1 µM 9cRA to induce a differentiating phenotype or with 
an equivalent volume of EtOH as a control for a proliferating phenotype. 
 
Given the heterogeneity in the SH-SY5Y neuroblastoma cell line and the differences in 
differentiation response between N-type and S-type populations, this chapter aimed to 
dissect the differentiation-associated phenotype-specific Ca2+ signalling responses 
underlying N-type and S-type population differentiation responses and determine the 
effect of predominant cell environment on Ca2+ signals through establishment and 
utilisation of live, single cell fura-2 imaging. 
 
All experiments in this chapter were performed on N-type or S-type populations that 
had been treated for 7 days with 1 µM 9cRA (differentiating) or an equivalent volume 
of EtOH as a control (proliferating). Proliferating N-type and S-type populations will be 
referred to as PN and PS, respectively, whilst differentiating N-type and S-type 
populations will be referred to as DN and DS, respectively. Proliferating and 
differentiating cell populations were loaded with the Ca2+ indicator dye, fura-2/AM, to 
allow measurements of intracellular Ca2+ during Ca2+-addback experiments. Under 
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Ca2+-free conditions, TG (200 nM) was applied to trigger ER Ca2+ store release whilst 
subsequent CaCl2 (2 mM) ‘addback’ induced SOCE to replenish depleted Ca
2+ stores.  
 
Overall Ca2+ responses as well as dynamics of the Ca2+ responses were also 
investigated through analysis of trace characteristics. The area under the trace peaks 
for Ca2+ store release and SOCE were used to determine total cytosolic Ca2+ entry. Peak 
height was used to determine maximal cytosolic Ca2+ entry. Any changes in Ca2+ store 
release must be taken into account when determining alterations in SOCE activity as 
Ca2+ store release and SOCE are closely related.  The response to TG and CaCl2 was 
calculated as a relative measure of SOCE. The response value from proliferating cells 
was taken as 100% and the ratio from differentiating cells was determined as a 
percentage of SOCE activity in proliferating cells. Total rate of rise and decline of Ca2+ 
store release and SOCE were used to determine the speed and efficiency of cytosolic 
Ca2+ entry and deactivation of the response. Given that there were often two phases of 
SOCE decay, the initial rate of decline from the first 300 seconds following maximal 
SOCE response and the late rate of decline of the SOCE response following this initial 
300 seconds were determined. All measurements were conducted over a similar time-
course therefore any changes in rate reflect a change in duration of response. 
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Chapter 4 - Results 
4.1. SOCE is down-regulated in differentiating N-type and S-type populations 
Initially, population analysis was utilised to confirm previous findings using the 
fluorimetry technique (Methods: 2.13). In N-type populations, Ca2+-addback traces of 
changes in fura-2 fluorescence that were calibrated to show [Ca2+]i indicated that there 
was a reduction in SOCE in differentiating compared to proliferating N-type 
populations (Figure 4.1.1A). There was a 49% increase in Ca2= store release in 
differentiating N-type populations (14.71 ± 1.62 µMs) however, this was non-
significant compared to proliferating N-type populations (9.87 ± 1.74 µMs, P=0.148, 
Figure 4.1.1B). Nevertheless, taking Ca2+ store size into account (see Introduction, 
above), SOCE was reduced by 34% in differentiating N-type populations (Figure 4.1.1B). 
These results indicate that 9cRA-induced differentiation of N-type populations causes 
an uncoupling of Ca2+ release and SOCE, corresponding with previous findings (Brown 
2005; Whitworth 2012; N. Bell 2013). 
 
In S-type populations, Ca2+-addback traces indicated an increase in Ca2+ store release 
and a reduction in SOCE in differentiating S-type populations compared to proliferating 
S-type populations (Figure 4.1.2A). Ca2+ store release was significantly up-regulated by 
94% in differentiating S-type populations (19.88 ± 4.01 µMs) compared to proliferating 
S-type populations (10.23 ± 2.04 µMs, P=0.049) and total SOCE was down-regulated by 
41% (Figure 4.1.2B). These results indicate that 9cRA-induced differentiation of S-type 
populations causes an uncoupling of Ca2+ release and SOCE and are in contrast to those 
described previously (N. Bell 2013). 
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Figure 4.1.1. SOCE is down-regulated in differentiating N-type populations 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). (A) Typical calibrated Ca
2+-addback traces from PN (blue trace) and 
DN (red trace) populations. [Ca
2+]i was determined by measuring fura-2 fluorescence at 
an excitation wavelength of 340 nm and an emission wavelength of 510 nm. Following 
addition of thapsigargin (TG, first peak) there was increase in [Ca2+]i in PN and DN 
populations indicating Ca2+ store release. Subsequent Ca2+ addback (CaCl2, second 
peak) caused an increase in [Ca2+]i in PN and DN populations, indicating SOCE to 
replenish depleted stores. (B) The Grynkiewicz formula was used to calibrate 
fluorimetry measurements using Perkin Elmer WinLab software and DMSO (TG 
control) measurements were deducted from the experimental data. Total Ca2+ store 
release was increased by 49.04% in DN populations compared to PN populations (14.71 
± 1.62 µMs and 9.87 ± 1.74 µMs, respectively, P=0.148). Taking into account the 
increase in store release, total SOCE was down-regulated by 34.36% in DN populations 
compared to PN populations. N=12.  
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Figure 4.1.2 SOCE is down-regulated in differentiating S-type populations 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating). (A) Typical calibrated Ca
2+-addback traces from PS (blue trace) and 
DS (red trace) populations. [Ca
2+]i was determined by measuring fura-2 fluorescence at 
an excitation wavelength of 340 nm and an emission wavelength of 510 nm. Following 
addition of thapsigargin (TG, first peak) there was increase in [Ca2+]i in PS and DS 
populations indicating Ca2+ store release. Subsequent Ca2+ addback (CaCl2, second 
peak) caused an increase in [Ca2+]i in PS and DS populations, indicating SOCE to 
replenish depleted stores. (B) The Grynkiewicz formula was used to calibrate 
fluorimetry measurements using Perkin Elmer WinLab software and DMSO (TG 
control) measurements were deducted from the experimental data. Total Ca2+ store 
release was increased by 94.33% in DS populations compared to PS populations (19.88 
± 4.01 µMs and 10.23 ± 2.04 µMs respectively, P=0.049*). Taking into account the 
increase in store release, total SOCE was down-regulated by 41.06% in DS populations 
compared to PS populations. N=11.  
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4.2. Single cell Ca
2+
 signals reflect that obtained using population based data 
collection 
A method for single cell fura-2 imaging acquisition and data analysis has been 
established and optimised in our laboratory for this study (Methods 2.14 and 2.15). 
The previous Ca2+ add-back method for cell population studies using fluorimetry was 
adapted and applied to a single cell ratiometric technique using epifluorescence. The 
ratiometric technique involves use of two excitation wavelengths (340 nm and 380 
nm) from which changes in ratio reflects changes in cytosolic Ca2+, whilst reducing 
error from noise due to uneven cell loading and illumination variations (Methods 2.14 
and 2.15). Fluorimetry analyses the cell population as a whole whilst epifluorescence 
analyses single cells within a cell population. Analysis at the single cell level was used 
to identify Ca2+ signalling changes with the differentiation response specific to N-type, 
S-type and I-type cells within N-type and S-type predominant populations. This section 
has investigated single cell fura-2 imaging in single cells and analysis is of the N-type 
and S-type population as a whole. 
 
In N-type populations, which are SH-SH5Y cells consisting predominantly of N-type 
cells but with S-type and I-type cells present, Ca2+-addback traces of changes in fura-2 
fluorescence ratio indicated that the SOCE response was dampened and of shorter 
duration in DN populations compared to PN populations (Figure 4.2.1A). Total Ca
2+ store 
release was slightly reduced in DN populations relative to PN populations (54.89 ± 1.22 
and 58.73 ± 1.20 FRUs, respectively; P=0.026, Figure 4.2.1B). Taking the change in Ca2+ 
store size into account, total SOCE was reduced by 54% in DN populations relative to PN 
populations (67.02 ± 2.91 and 158.59 ± 5.54 FRUs, respectively, Figure 4.2.1B). These 
results indicate an uncoupling of Ca2+ store release and SOCE in DN populations with a 
similar profile to that which was previously found using a fluorimetry-based cell 
population approach (Figure 4.1.1).  
 
This profile was further confirmed by analysing maximal (as opposed to total) Ca2+ 
store release, using measurements of peak height (Figure 4.2.2A). Maximal Ca2+ store 
release in DN populations was reduced slightly compared to PN populations (P=0.001, 
Figure 4.2.2A), while maximal SOCE was down-regulated by 29% (Figure 4.2.2A). 
92 
 
Additional analysis revealed that there was a 23% decrease in rate of Ca2+ store release 
(P<0.0001) and a 15% increase in rate of SOCE (P<0.0001) in DN populations compared 
to PN populations (Figure 4.2.2B). There was no significant difference in Ca
2+ store 
release decline rate between PN populations and DN populations (P=0.915, Figure 
4.2.2C). The total SOCE decline rate was reduced by 13% in differentiating N-type 
populations compared to proliferating populations (P<0.0001, Figure 4.2.2C). When 
SOCE decline rate  was further analysed, the initial SOCE decline rate was found to 
increase by 12% in DN populations compared to PN populations (P=0.0006, Figure 
4.2.2C) whereas the late decline rate was reduced by 59% in DN populations compared 
to PN populations (P<0.0001, Figure 4.2.2C). 
 
This single cell data not only confirm previous population-based data (Figure 4.2.1; Bell 
et al 2013) that Ca2+ release and SOCE become uncoupled in DN compared to PN 
populations, but extend these findings by showing that the reduction in SOCE in DN 
populations is accompanied by increases in the rates at which SOCE is activated and 
deactivated, leading to a shorter and smaller SOCE response compared to PN 
populations. 
 
In S-type populations, consisting of predominantly S-type cells but N-type and I-type 
cells were also present, Ca2+-addback traces of changes in fura-2 fluorescence ratio 
indicated that the SOCE response was dampened and of shorter duration in DS 
populations relative to PS populations (Figure 4.2.3A). Total Ca
2+ store release in DS 
populations (47.76 ± 1.19 FRUs) was 26% higher compared to PS populations (38.05 ± 
0.79 FRUs, P<0.0001, Figure 4.3.2B). In addition, total SOCE was down-regulated by 
66% in DS compared to PS populations (54.56 ± 2.87 and 127.73 ± 3.47 FRUs, 
respectively, Figure 4.2.3B). These results indicate an uncoupling of Ca2+ store release 
and SOCE in DS populations using single cell analysis with a similar profile to that which 
was previously found using a fluorimetry-based cell population approach (Figure 
4.1.3). 
 
This profile was examined further by analysing maximal (as opposed to total) Ca2+ store 
release, using measurements of peak height (Figure 4.2.4A). Maximal Ca2+ store 
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release in DS populations was 27% higher compared to PS populations (P<0.0001, 
Figure 4.2.4A) while maximal SOCE was down-regulated by 59% (Figure 4.2.4A). 
Additional analysis revealed that there was a 28% increase in rate of Ca2+ store release 
(P<0.0001) and a 10% increase in rate of SOCE (P<0.0001) in DS populations compared 
to PS populations (Figure 4.2.4.B). There was an 18% increase in Ca
2+ store release 
decline rate in DS compared to PS populations (P<0.0001, Figure 4.2.4C). The total SOCE 
decline rate was reduced by 9% in DS compared to PS populations (P=0.0017, Figure 
4.2.4C). When SOCE decline rate was further analysed, the initial SOCE decline rate 
was reduced by 18% in DS compared to PS populations (P<0.0001, Figure 4.2.4C) and 
the late decline phase was reduced by 26% in DS compared to PS populations 
(P<0.0001, Figure 4.2.4C). 
 
This single cell data not only confirms previous population-based data (Figure 4.1.3) 
that Ca2+ release and SOCE become uncoupled in DS compared to PS populations, but 
extend these findings by showing that the rates at which SOCE is activated seem to be 
faster than that in PS populations, whilst the rates of SOCE deactivation appear to be 
slower. Thus, although the SOCE response in DS populations is smaller than that in PS 
populations, it is maintained for longer. In addition, this single cell data also indicates 
that differentiation of S-type populations leads to increases in the amount of Ca2+ store 
release and the rate at which the store is depleted. This suggests a potential increase 
in the size of the ER Ca2+ store and/or an increased sensitivity to TG.  
 
In light of the previous analysis, the single cell technique can be used to analyse Ca2+ 
signals related to specific cell types and sub-phenotypes, allowing for potential 
detection of a sub-population of cells that may exhibit different Ca2+ signalling 
characteristics. Given that both N- and S-type populations consist of three individual 
cell types; N-type, S-type and I-type, as well as possible S sub-phenotypes; SO, SA and 
SE, it is unsurprising that there is wide variability in the Ca
2+ signalling response 
between individual cells within an experiment. Observing the responses of five cells 
within one experiment highlights this variability within a particular cell type and 
potentially could be attributed to specific sub-phenotypes (Figure 4.2.1A and 4.2.3A). 
Phenotype-specific Ca2+ signals were therefore investigated (Results 4.3 and 4.4). 
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Figure 4.2.1. Single cell Ca
2+
 signals from N-type populations similar to those 
previously observed using a population analysis technique 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). TG represents the addition of the SERCA inhibitor thapsigargin to 
induce Ca2+ store release and CaCl2 represents Ca
2+ addback to induce SOCE. (A) 
Typical Ca2+-addback traces from 5 individual cells within one experiment in PN (blue) 
and DN populations (red) exhibit variability in Ca
2+ responses. (B) Typical average Ca2+-
addback traces from PN (blue trace) and DN (red trace) populations. Traces represent 
an average from 20 cells ± S.E.M from one experiment. Fura-2 fluorescence was 
95 
 
measured at excitation wavelengths of 340 nm and 380 nm and an emission 
wavelength of 510 nm, with changes in fluorescence ratio (FR) reflective of changes in 
[Ca2+]i. Following addition of thapsigargin (TG, first peak) there was increase in FR in PN 
and DN populations indicating Ca
2+ store release. Subsequent Ca2+-addback (CaCl2, 
second peak) caused an increase in FR in PN and DN populations, indicating SOCE to 
replenish depleted stores. The SOCE response was dampened and shorter in DN cells. 
(C) DMSO (TG control) measurements were deducted from the experimental data. 
Fluorescence ratio units (FRUs) represent a change in [Ca2+]i. There was a 6.54% 
decrease in total Ca2+ store release in DN populations compared to PN populations 
(54.89 ± 1.22 and 58.73 ± 1.20 FRUs, respectively, P=0.0264*). Taking this change in 
Ca2+ store release into account, total SOCE was down-regulated by 54.79% in DN 
populations compared to PN populations (67.02 ± 2.91 and 158.59 ± 5.54 FRUs, 
respectively). PN: n=783, DN: n=911. N=6. 
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Figure 4.2.2. There is a change in SOCE dynamics with differentiation of N-type 
populations 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.  
(A) DMSO (TG control) measurements were deducted from the experimental data. 
There was an 11.76% decrease in maximal Ca2+ store release in DN populations 
compared to PN populations (0.15 ± 0.003 and 0.17 ± 0.002 FRUs, respectively, 
P=0.001**). Taking this change in Ca2+ store release into account, maximal SOCE was 
down-regulated by 29.04% in DN populations compared to PN populations (0.21 ± 0.01 
and 0.33 ± 0.01 FRUs, respectively). (B) There was a 23.15% decrease in rate of Ca2+ 
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store release (P<0.0001****) and a 15.33% increase in rate of SOCE (P<0.0001****) in 
DN populations compared to PN populations. (C) There was no change in Ca
2+ store 
release decline rate with differentiation of N-type populations (P=0.915). The total 
SOCE decline rate was reduced by 12.46% in DN populations (P<0.0001****). The initial 
SOCE decline rate was increased by 12.14% (P=0.0006***) whilst the later decline 
phase was reduced by 59.12% (P<0.0001****) in DN populations. PN: n=783, DN: n=911. 
N=6. 
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Figure 4.2.3. Single cell analysis of S-type populations exhibit Ca
2+
 signals similar to 
those previously observed using a population analysis technique 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating). TG represents the addition of the SERCA inhibitor thapsigargin to 
induce Ca2+ store release and CaCl2 represents Ca
2+ addback to induce SOCE. (A) 
Typical Ca2+-addback traces from 5 individual cells within one experiment in PS (blue) 
and DS populations (red) exhibit variability in Ca
2+ responses. (B) Typical Ca2+-addback 
traces from PS (blue trace) and DS (red trace) populations. Traces represent an average 
from 20 cells ± S.E.M from one experiment. Fura-2 fluorescence was measured at 
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excitation wavelengths of 340 nm and 380 nm and an emission wavelength of 510 nm, 
with changes in fluorescence ratio (FR) reflective of changes in [Ca2+]i. Following 
addition of thapsigargin (TG, first peak) there was increase in FR in PS and DS 
populations indicating Ca2+ store release. Subsequent Ca2+-addback (CaCl2, second 
peak) caused an increase in FR in PS and DS populations, indicating SOCE to replenish 
depleted stores. The SOCE response was dampened and shorter in DS cells. (C) DMSO 
(TG control) measurements were deducted from the experimental data. Fluorescence 
ratio units (FRUs) represent a change in [Ca2+]i. There was a 25.52% increase in total 
Ca2+ store release in DS populations compared to PS populations (47.76 ± 1.19 and 
38.05 ± 0.79 FRUs, respectively, P<0.0001****). Taking this change in Ca2+ store 
release into account, total SOCE was down-regulated by 65.97% in DS populations 
compared to PS populations (54.56 ± 2.87 and 127.73 ± 3.47 FRUs, respectively). 
Proliferating n=1092, differentiating n=1002. N=8. 
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Figure 4.2.4. There is a change in SOCE dynamics with differentiation of S-type 
populations 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores. (A) 
DMSO (TG control) measurements were deducted from the experimental data. There 
was a 27.27% increase in maximal Ca2+ store release in DS populations compared to PS 
populations (0.14 ± 0.003 and 0.11 ± 0.002 FRUs, respectively, P<0.0001****). Taking 
this change in Ca2+ store release into account, maximal SOCE was down-regulated by 
58.58% in DS populations compared to PS populations (0.17 ± 0.02 and 0.43 ± 0.03 
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FRUs, respectively). (B) There was a 27.57% increase in rate of Ca2+ store release 
(P<0.0001****) and a 9.61% increase in rate of SOCE (P<0.0001****) in DS populations 
compared to PS populations. (C) There was an 18.00% increase in Ca
2+ store release 
decline rate with differentiation of S-type populations (P<0.0001****). In DS 
populations, there was a reduction in total (by 9.05%, P=0.0017**), initial (by 17.70%, 
P<0.0001****) and late (by 26.05% P<0.0001****) SOCE decline rates. PS: n=1092,  
DS: n=1002. N=8.  
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4.3. There is an effect of predominant cell environment on SOCE differentiation 
responses 
Thus far, single cell Ca2+ signals have been measured from all cell types within a 
predominantly N-type environment and in a predominantly S-type environment.  
Despite establishment of N-type and S-type predominant populations, N-type, S-type 
and I-type cells were always present (Methods 2.3). This could be reflective of 
transdifferentiation or a need for all three phenotypes to be present to support 
growth, for example S-type enrichment has been found to reduce cell growth and 
result in cell death (Acosta 2009). It may be that it is simply not possible to completely 
eliminate other phenotypes from the population, particularly given the presence of I-
type cells which are thought to represent a stem cell population that may give rise to 
N-type or S-type cells within an S-type population or N-type population respectively. 
Changes in phenotype-specific Ca2+ signal responses may therefore be influenced by 
the environment in which the cells are grown (i.e an N-type or S-type predominant 
environment). One advantage of the single cell technique is that it can be used to 
analyse Ca2+ signals related to specific phenotypes (or sub-phenotypes) within the 
background environment. The effect of background environment on the Ca2+ signal 
response with differentiation was therefore investigated. The area under the trace 
peaks for Ca2+ store release and SOCE were used to determine total relative Ca2+ entry 
into the cytosol expressed as fluorescence ratio units (FRUs). The results discussed 
below are summarised in Table 4.3. 
 
4.3.1. Ca
2+
 signals in single cells in an N-type predominant cell environment 
For N-type cells grown within N-type populations, total Ca2+ store release was reduced 
by 12% in DN N-type compared to PN N-type cells (P=0.0007, Figure 4.3.1) and total 
SOCE was reduced by 53% (Figure 4.3.1). Consistent with this, there was a 14% 
decrease in maximal Ca2+ store release in DN N-type compared to PN N-type cells 
(P<0.0001, Figure 4.3.2A) and maximal SOCE was down-regulated by 21% (Figure 
4.3.2A). There was a 29% decrease in rate of Ca2+ store release (P<0.0001) and a 19% 
increase in rate of SOCE (P=0.0016) in DN N-type compared to PN N-type cells (Figure 
4.3.2B) with no change in Ca2+ store release decline rate (P=0.387, Figure 4.3.2C). The 
total and late SOCE decline rate were reduced in DN N-type cells (16% and 66% 
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respectively, both P<0.0001, Figure 4.3.2C). The initial SOCE decline rate was increased 
by 20% in DN N-type cells compared to PN N-type cells (P<0.0001, Figure 4.3.2C).  
 
These results are consistent with those previously seen with single cell analysis of N-
type populations as a whole (Results 4.2) which show that, although Ca2+ store release 
remains unchanged or is slightly reduced, it becomes uncoupled from SOCE. This is 
unsurprising given that previous measurements were also made in an N-type 
background which consists of 66% N-type cells (Introduction 1.3). 
 
For S-type cells grown within N-type populations, there was no difference in total Ca2+ 
store release between PN S-type and DN S-type cells (P=0.331, Figure 4.3.1) and there 
was a 60% reduction in total SOCE in DN S-type compared to PN S-type cells (P<0.0001, 
Figure 4.3.1). Consistent with this, there was no difference in maximal Ca2+ store 
release between PN S-type and DN S-type cells (P=0.056, Figure 4.3.2A) and maximal 
SOCE was significantly down-regulated by 55% in DN S-type compared to PN S-type cells 
(P<0.0001, Figure 4.3.2A). There was an 18% decrease in rate of Ca2+ store release 
(P=0.0002) but no change in rate of SOCE (P=0.750) in DN S-type compared to PN S-type 
cells (Figure 4.3.2B). Ca2+ store release decline rate and total SOCE decline rate were 
reduced in DN S-type compared to PN S-type cells (14%, P=0.0038 and 16%, P<0.0004, 
respectively, Figure 4.3.2C). There was no significant difference in the initial SOCE 
decline rate between PN S-type and DN S-type cells (P=0.072) whilst the later decline 
phase was reduced by 47% (P<0.0001) in DN S-type cells (Figure 4.3.2C).  
 
Interestingly, these results differ from single cell analysis of the S-type population as a 
whole (Results 4.2). In DS populations, Ca
2+ store release was increased compared to PS 
populations (Figures 4.1.3 & 4.2.3), whereas in single S-type cells in an N-type 
environment, Ca2+ store release in is unchanged (Figure 4.3.1). This observation 
indicates that S-type cells may display a plasticity that can be influenced by the 
background environment. The reasons underlying this putative plasticity in Ca2+ store 
release are investigated further in Section 4.4. The reduction in SOCE that was seen in 
DS populations (Results 4.1 and 4.2) was also present in DN S-type cells (Figure 4.3.1), 
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indicating that Ca2+ release and SOCE are uncoupled in S-type cells in an N-type 
environment, as well as in an S-type environment. 
 
For I-type cells grown within N-type populations, total Ca2+ store release in DN I-type 
cells was 51% greater than that of PN I-type cells (P<0.0001, Figure 4.3.1) and DN I-type 
cells had a  63% reduction in total SOCE compared to PN I-type cells (Figure 4.3.1). 
Consistent with this, maximal Ca2+ store release was increased by 52% in DN I-type 
compared to PN I-type cells (P<0.0001, Figure 4.3.2A). Taking this change in Ca
2+ store 
release into account, maximal SOCE was down-regulated by 53% in DN I-type 
compared to PN I-type cells (Figure 4.3.2A). There was a 24% increase in rate of Ca
2+ 
store release (P=0.020) and a 50% increase in rate of SOCE (P=0.024) in DN I-type 
compared to PN I-type cells (Figure 4.3.2B). Ca
2+ store release decline rate and total 
SOCE decline were significantly increased by 50% and 40% respectively in DN I-type 
compared to PN I-type cells (P=0.0003 and P<0.0007, respectively, Figure 4.3.2C). The 
initial SOCE decline rate was increased by 35% in DN I-type cells compared to PN I-type 
cells (P<0.0001) but there was no difference in late SOCE decline rate (P=0.571, Figure 
4.4.2C). These results show that overall Ca2+ store release in I-type cells is increased 
and that rate of activation and emptying is faster in DN conditions, indicating a 
potential increase in store size or sensitivity to TG, in contrast to the N-type and S-type 
cell response. The extent of SOCE down-regulation in DN I-type cells was greater than 
that of N-type cells and similar to that of S-type cells in the same environment. The 
rate of SOCE activation and deactivation was increased with differentiation, suggesting 
a smaller and shorter SOCE response. 
 
4.3.2. Ca
2+
 signals in single cells in an S-type predominant cell environment 
For N-type cells grown within S-type predominant populations, total Ca2+ store release  
in DS N-type cells was increased by 65% compared to PS N-type cells (P<0.0001, Figure 
4.3.3) and total SOCE in DS N-type cells was reduced by 68% compared to PS N-type 
cells (Figure 4.3.3). Consistent with this, there was a 68% increase in maximal Ca2+ 
store release in DS N-type compared to PS N-type cells (P<0.0001) and maximal SOCE 
was down-regulated by 62% in DS N-type compared to PS N-type cells (Figure 4.3.4A). 
There was an increase in Ca2+ store release rate (66%, P<0.0001, Figure 4.3.4B), decline 
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rate (51%, P<0.0001, Figure 4.3.4C) and rate of SOCE (25%, P=0.0039, Figure 4.3.4B) in 
DS N-type compared to PS N-type cells. There was no difference in total (P=0.122) or 
initial (P=0.768) SOCE decline rate between PS N-type and DS N-type cells, however, the 
late decline phase was reduced by 27% (P=0.0088) in DS N-type cells (Figure 4.3.4C).  
 
These results differ from an N-type population and single N-type cells grown in an N-
type environment (Results 4.2 and 4.3.1). In an N-type environment, total Ca2+ store 
release was unchanged or slightly reduced with differentiation (Results 4.2, Figure 
4.3.1), whereas for N-type cells grown in an S-type environment, total Ca2+ store 
release is significantly increased (Figure 4.3.2). In addition, the Ca2+ store has higher 
rates of activation and emptying in DS conditions, suggesting an increase in store size 
or an increased sensitivity to TG. This observation indicated that N-type cells may 
display a plasticity in Ca2+ store release that can be influenced by the background 
environment. The reduction in SOCE that was seen in DN N-type cells (Figure 4.3.1) was 
also present in DS N-type cells (Figure 4.3.2), indicating that Ca
2+ release and SOCE are 
uncoupled in N-type cells in an S-type environment, as well as an N-type environment. 
 
For S-type cells grown within S-type populations, there was no change in total Ca2+ 
store release between PS S-type and DS S-type cells (P=0.973, Figure 4.3.3) and a 68% 
reduction in total SOCE in DS S-type compared to PS S-type cells (P<0.0001, Figure 
4.3.3). There was no difference in maximal Ca2+ store release between PS S-type and DS 
S-type cells (P=0.845, Figure 4.3.4A) and maximal SOCE was significantly down-
regulated by 61% in DS S-type compared to PS S-type cells (P<0.0001, Figure 4.3.4A). 
There was no change in rate of Ca2+ store release (P=0.456), rate of SOCE (P=0.127) or 
Ca2+ store release decline rate (P=0.502) between DS S-type and PS S-type cells (Figure 
4.3.4B and C). Total, initial and late SOCE decline rate were reduced by 23% 
(P<0.0001), 30% (P<0.0001) and 23% (P=0.0086), respectively in DS S-type cells 
compared to PS S-type cells (Figure 4.3.4C).  
 
These results show that Ca2+ store release is unaffected in S-type cells within DS 
conditions. Interestingly, this result differs from those observed previously in S-type 
predominant populations, where there was an increase in Ca2+ store release in 
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differentiated cells (Figures 4.1.2 & 4.2.3). This indicates a variability in S-type response 
that is independent from, but additional to, that caused by background environment 
(Results 4.3.1). This variability is investigated further in Results 4.4. This also suggests 
that the N-type cells within the S-type predominant population may be driving the Ca2+ 
store release increase observed at the population level. The reduction in SOCE that 
was seen in DN S-type cells (Figure 4.3.1) was also present in DS S-type cells (Figure 
4.3.3), indicating that Ca2+ release and SOCE are uncoupled in S-type cells in an S-type 
environment, as well as in an N-type environment. 
 
For I-type cells grown within S-type populations, there was no difference in total Ca2+ 
store release between to PS I-type and DS I-type cells (P=0.568, Figure 4.3.3) and total 
SOCE was reduced by 61% in DS I-type compared to PS I-type cells (P<0.0001, Figure 
4.3.3). Consistent with this, there was no difference in maximal Ca2+ store release 
between PS I-type and DS I-type cells (P=0.709, Figure 4.3.4A) and maximal SOCE was 
down-regulated by 47% in DS I-type compared to PS I-type cells (P=0.0006, Figure 
4.3.4A). There was no change in rate of Ca2+ store release (P=0.344) and a 32% 
increase in rate of SOCE (P=0.027) in DS I-type cells compared to PS I-type cells (Figure 
4.3.4B). There was no difference Ca2+ store release decline rate between PS I-type cells 
and DS I-type cells (P=0.247, Figure 4.3.4C). Total, initial and late SOCE decline rates 
were reduced by 22% (P=0.0012), 28% (P<0.0001) and 39% (P=0.006), respectively in 
DS I-type cells compared to PS I-type cells (Figure 4.3.4C).  
 
These results differ from I-type cells in an N-type environment. In an N-type 
environment, total Ca2+ store release was significantly increased with differentiation 
(Figure 4.3.1), whereas in an S-type environment total Ca2+ store release is unchanged 
with differentiation (Figure 4.3.3). This observation indicates that I-type cells may 
display a plasticity in Ca2+ store release that can be influenced by the background 
environment. The reduction in SOCE that was seen in DN I-type cells (Figure 4.3.1) was 
also present in DS I-type cells (Figure 4.3.3), indicating that Ca
2+ release and SOCE are 
uncoupled in I-type cells in an S-type environment, as well as in an N-type 
environment. 
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Table 4.3. Summary of N-type, S-type and I-type single cell Ca
2+
 signals determined 
by predominant background environment 
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Figure 4.3.1. An uncoupling of Ca
2+
 store release and SOCE occurs with differentiation 
of N-, S- and I-type cells grown in an N-predominant environment 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.   
There was a significant down-regulation of total Ca2+ store release by 12.10% in DN N-
type cells compared to PN N-type cells (49.34 ± 1.33 and 56.13 ± 1.49 FRUs, 
respectively, P=0.0007***). Taking this change in store release into account, total 
SOCE (CaCl2) was reduced by 53.23% in DN N-type cells compared to PN N-type cells 
(66.56 ± 3.44 and 161.92 ± 7.11 FRUs, respectively). Proliferating n=509, differentiating 
n=668. Compared to PN S-type cells, DN S-type cells showed no change in total Ca
2+ 
store release (66.35 ± 2.48 and 62.72 ± 2.80 FRUs, respectively, P=0.331) and a 60.44% 
reduction in total SOCE (171.50 ± 10.39 and 64.14 ± 5.95 FRUs, respectively, 
P<0.0001****). PN S-type n=187, DN S-type n=163. Compared to PN I-type cells, DN I-
type cells had a 50.47% increase in total Ca2+ store release (59.10 ± 3.73 and 88.93 ± 
4.80 FRUs, respectively, P<0.0001****) and a 62.85% reduction in total SOCE (123.17 ± 
16.22 and 68.85 ± 11.40 FRUs, respectively). PN I-type n=72, DN I-type n=73. N=6.  
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Figure 4.3.2 SOCE dynamics with differentiation of N-, S- and I-type cells grown in an 
N-predominant environment 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.  
(A) DMSO (TG control) measurements were deducted from the experimental data. 
There was a slight but significant decrease in maximal Ca2+ store release in DN N-type 
cells (0.14 ± 0.004 FRUs) compared to PN N-type cells (0.16 ± 0.14 FRUs, 
P<0.0001****). Taking this change in Ca2+ store release into account, maximal SOCE 
was down-regulated by 21.40% in DN N-type cells (0.22 ± 0.01 FRUs) compared to PN N-
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type cells (0.32 ± 0.02 FRUs). There was no difference in maximal Ca2+ store release 
between PN S-type cells (0.19 ± 0.01 FRUs) and DN S-type cells (0.17 ± 0.01 FRUs, 
P=0.056) . Maximal SOCE was significantly down-regulated by 54.94% in DN S-type cells 
(0.17 ± 0.03 FRUs) compared to PN S-type cells (0.39 ± 0.02 FRUs, P<0.0001****). 
Maximal Ca2+ store release was significantly increased in DN I-type cells (0.25 ± 0.02 
FRUs) compared to PN I-type cells (0.16 ± 0.01 FRUs, P<0.0001****). Taking this change 
in Ca2+ store release into account, maximal SOCE was down-regulated by 52.64% in DN 
I-type cells (0.18 ± 0.08 FRUs) compared to PN I-type cells (0.25 ± 0.05 FRUs). (B) There 
was a significant decrease in rate of Ca2+ store release (P<0.0001) and a significant 
increase in rate of SOCE (P=0.0016) in DN N-type cells compared to PN N-type cells. 
There was a significant decrease in rate of Ca2+ store release (P=0.0002) but no change 
in rate of SOCE (P=0.750) in DN S-type cells compared to PN S-type cells. There was a 
significant increase in rate of Ca2+ store release (P=0.020*) and a significant increase in 
rate of SOCE (P=0.024*) in DN I-type cells compared to PN I-type cells. (C) There was no 
change in Ca2+ store release decline rate between PN N-type cells and DN N-type cells 
(P=0.387). The total SOCE decline rate was significantly reduced in DN N-type cells 
(P<0.0001). The initial SOCE decline rate was significantly increased in DN N-type cells 
compared to PN N-type cells (P<0.0001) whilst the later decline phase was significantly 
reduced (P<0.0001) in DN N-type cells. Ca
2+ store release decline rate and total SOCE 
decline rate were significantly reduced in DN S-type cells compared to PN S-type cells 
(P=0.0038 and P<0.0004, respectively). There was no difference in the initial SOCE 
decline rate was between PN S-type cells and DN S-type cells (P=0.072) whilst the later 
decline phase was significantly reduced (P<0.0001) in DN S-type cells. Ca
2+ store release 
decline rate and total SOCE decline were significantly increased in DN I-type cells 
compared to PN I-type cells (P=0.0003 and P<0.0007, respectively). The initial SOCE 
decline rate was significantly increased in DN I-type cells compared to PN I-type cells 
(P<0.0001) but there was no difference in late SOCE decline rate (P=0.571). 
In PN populations: N-type n=509, S-type n=187, I-type n=72.In DN populations: N-type 
n=668, S-type n=163, I-type n=73. N=6. 
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Figure 4.3.3. An uncoupling of Ca
2+
 store release and SOCE occurs with differentiation 
of N-, S- and I-type cells grown in an S-predominant environment 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.   
Compared to PS N-type cells, in DS N-type cells there was a 65.12% increase in total 
Ca2+ store release (38.31 ± 1.44 and 63.25 ± 2.45 FRUs, respectively, P<0.0001****) 
and taking this change into account, total SOCE was reduced by 67.54% (134.57 ± 6.56 
and 72.12 ± 5.47 FRUs, respectively). PS N-type cells n=397, DS N-type cells n=346. 
Compared to PS S-type cells, DS S-type cells showed no change in total Ca
2+ store 
release (36.86 ± 0.99 and 36.80 ± 1.30 FRUs, respectively, P=0.973) and a 67.54% 
reduction in total SOCE (120.28 ± 4.21 and 40.02 ± 3.66 FRUs, respectively, 
P<0.0001****). PS S-type cells n=586, DS S-type cells n=468. Compared to PS I-type 
cells, DS I-type cells showed no change in total Ca
2+ store release (44.03 ± 2.70 and 
46.17 ± 2.37 FRUs, respectively, P=0.568) and total SOCE was reduced by 61.13% 
(142.47 ± 11.13 and 58.07 ± 5.41 FRUs, respectively, P<0.0001****). PS I-type cells 
n=106, DS I-type cells n=186. N=8. 
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Figure 4.3.4 SOCE dynamics with differentiation of N-, S- and I-type cells grown in an 
N-predominant environment 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating). Changes in fluorescence ratio units (FRU) are reflective of changes 
in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release and 
subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.  
(A) DMSO (TG control) measurements were deducted from the experimental data. 
There was a significant increase in maximal Ca2+ store release in DS N-type cells (0.19 ± 
0.008 FRUs) compared to PS N-type cells (0.11 ± 0.01 FRUs, P<0.0001****). Taking this 
change in Ca2+ store release into account, maximal SOCE was down-regulated by 
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61.76% in DS N-type cells (0.29 ± 0.04 FRUs) compared to PS N-type cells (0.46 ± 0.02 
FRUs). There was no difference in maximal Ca2+ store release between PS S-type cells 
(0.10 ± 0.004 FRUs) and DS S-type cells (0.11 ± 0.003 FRUs, P=0.845). Maximal SOCE 
was significantly down-regulated by 61.16% in DS S-type cells (0.15 ± 0.02 FRUs) 
compared to PS S-type cells (0.39 ± 0.01 FRUs, P<0.0001****). There was no difference 
in maximal Ca2+ store release between PS I-type cells (0.14 ± 0.01 FRUs) and DS I-type 
cells (0.13 ± 0.01 FRUs, P=0.709). Maximal SOCE was down-regulated by 47.38% in DS I-
type cells (0.25 ± 0.04 FRUs) compared to PS I-type cells (0.48 ± 0.05 FRUs, 
P=0.0006***). (B) There was a significant increase in rate of Ca2+ store release 
(P<0.0001) and rate of SOCE (P=0.0039) in DS N-type cells compared to PS N-type cells.  
There was no change in rate of Ca2+ store release (P=0.456) or in rate of SOCE 
(P=0.127) in DS S-type cells compared to PS S-type cells. There no change in rate of Ca
2+ 
store release (P=0.344) and a significant increase in rate of SOCE (P=0.027) in DS I-type 
cells compared to PS I-type cells. (C) There was a significant increase in Ca
2+ store 
release decline rate in DS N-type cells compared to PS N-type cells (P<0.0001). There 
was no difference in total SOCE decline rate between PS N-type cells and DS N-type 
cells (P=0.122). There was no difference in the initial SOCE decline rate (P=0.768) 
however, the late decline phase was significantly reduced (P=0.0088) in DS N-type cells. 
There was no difference in Ca2+ store release decline rate between PS S-type cells and 
DS S-type cells rate (P=0.502). Total SOCE decline rate was significantly reduced in DS S-
type cells compared to PS S-type cells (P<0.0001).The initial and late SOCE decline rate 
was significantly reduced in DS S-type cells compared to PS S-type cells (P<0.0001 and 
P=0.0086, respectively). There was no difference Ca2+ store release decline rate 
between PS I-type cells and DS I-type cells (P=0.247). Total SOCE decline was 
significantly decreased in DS I-type cells compared to PS I-type cells (P=0.0012). The 
initial and late SOCE decline rates were significantly reduced in DS I-type cells 
compared to PS I-type cells (P<0.0001 and P=0.006, respectively). In PS populations: N-
type n=397, S-type n=586, I-type n=106.In DS populations: N-type n=346, S-type n=468, 
I-type n=186. N=8. 
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4.4. Sub-populations of S-type cells exhibit variable SOCE responses in N-type and S-
type predominant environments 
The S-phenotype is comprised of three sub-populations; SO, SA and SE (Introduction 
1.4). The overall S-type Ca2+ signalling response may therefore be influenced by sub-
population-specific Ca2+ signals. Since Ca2+ signals can be influenced by background 
environment (section 4.3), sub-population Ca2+ signals may in turn also be influenced 
by the environment in which the cells are grown (i.e an N-type or S-type predominant 
environment). We investigated whether sub-population-specific Ca2+ signals and 
background environment could play a role in the responses of S-type cells, including 
the observed variability (Figure 4.2.3A). 
 
4.4.1. Ca
2+
 signals in SO, SA and SE cells in an N-type predominant cell environment 
In N-type predominant populations, total Ca2+ store release was increased by 17% in 
DN SO compared to PN SO cells (P=0.034) and total SOCE was reduced by 66% (Figure 
4.4.1). There was no difference in maximal Ca2+ store release in DN SO compared to PN 
SO cells (P=0.375), whilst maximal SOCE was down-regulated by 55% in DN SO compared 
to PN SO cells (P<0.0001, Figure 4.4.2A). There was no difference in rate of Ca
2+ store 
release (P=0.217), rate of SOCE (P=0.132), total (P=0.426) or initial (P=0.709) SOCE 
decline rate between PN SO and DN SO cells (Figure 4.4.2A and B). There was a decrease 
in Ca2+ store release decline rate (by 12%, P=0.031) and late SOCE decline rate (by 34%, 
P=0.0089) in DN SO compared to PN SO cells (Figure 4.4.2C). These results show for SO 
cells, Ca2+ store release was increased and there was a slower rate of store emptying in 
DN conditions suggesting a prolonged store release and possible increase in store size 
or TG sensitivity. SOCE was down-regulated in DN conditions however the rate of 
activation and de-activation and were unaffected except a reduced late SOCE decline 
phase, therefore response duration was shortened. 
 
DN SA cells had a 22% decrease in total Ca
2+ store release compared to PN SA cells 
(P=0.015) and total SOCE was reduced by 53% (Figure 4.4.1). Consistent with this, 
there was a 21% decrease in maximal Ca2+ store release in DN SA compared to PN SA 
cells (P=0.003) and maximal SOCE was down-regulated by 39% (Figure 4.4.2A). There 
was a 26% decrease in rate of Ca2+ store release (P=0.0005) but no difference in rate of 
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SOCE (P=0.735) in DN SA compared to PN SA cells (Figure 4.4.2B). There was a reduction 
in Ca2+ store release decline rate (by 16%, P=0.041), total SOCE decline rate (by 17%, 
P<0.049) and late SOCE decline rate (by 55%, P<0.0001) in DN SA cells compared to PN 
SA cells (Figure 4.4.2C). There was no difference in initial SOCE decline rate between PN 
SA cells and DN SA cells (P=0.540, Figure 4.4.2C). Overall, DN SA cells have reduced Ca
2+ 
store release with reduced rate of store release and emptying, indicating a reduced 
store size or decrease in TG sensitivity with differentiation. SOCE was down-regulated 
in DN SA cells to a greater extent than DN SO cells and, whilst the rate of SOCE activation 
and early de-activation was unaffected, late SOCE decline rate was reduced, suggesting 
a shortened SOCE response. 
 
Compared to PN SE cells, DN SE cells had a 42% reduction in total Ca
2+ store release 
(P=0.064) and total SOCE was reduced by 61% (Figure 4.4.1). There was no difference 
in maximal Ca2+ store release between PN SE compared to DN SE cells (P=0.212) and 
maximal SOCE was down-regulated by 73% in DN SE compared to PN SE cells (P=0.005, 
Figure 4.4.2A). There was no difference in rate of Ca2+ store release (P=0.129) or rate 
of SOCE (P=0.176) in PN SE compared to DN SE cells (Figure 4.4.2B). There was no 
difference in Ca2+ store release decline rate between PN SE and DN SE cells (P=0.681) 
and there was a reduction in total SOCE decline rate (by 52%, P=0.0021), initial (by 
42%, P=0.046) and late (by 70%, P<0.0001) SOCE decline rate in DN SE compared to PN 
SE cells (Figure 4.4.2C). Taken together, these results show that, whilst Ca
2+ store 
release was reduced in DN SE cells, indicating a reduction of store size, there was no 
change in speed of activation or store emptying. SOCE was down-regulated in DN SE 
cells and, whilst there no change in rate of activation, de-activation rate was reduced 
which indicates a smaller but longer SOCE response. 
 
All of this data confirms that SO, SA and SE cells can be identified by sub-population 
specific Ca2+ signals (Table 4.4). 
 
4.4.2. Ca
2+
 signals in SO, SA and SE cells in an S-type predominant cell environment 
In S-type predominant populations, compared to PS SO cells, there was no change in 
total Ca2+ store release in DS SO cells (P=0.092) and total SOCE was reduced by 64% 
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(P<0.0001, Figure 4.4.3). Consistent with this, maximal Ca2+ store release was reduced 
by 15% in DS SO compared to PS SO cells (P=0.025) and maximal SOCE was down-
regulated by 53% in DS SO compared to PS SO cells (Figure 4.4.4A). There was a decrease 
in rate of Ca2+ store release (14%, P=0.042) and rate of SOCE (24% P=0.0018) in DS SO 
compared to PS SO cells (Figure 4.4.4B). There was a 21% decrease in Ca
2+ store release 
decline rate in DS SO compared to PS SO cells (P<0.0001) and a reduction in total and 
initial SOCE decline rate in DS SO compared to PS SO cells (by 37.02% and 48.42% 
respectively, both P<0.0001, Figure 4.4.4C). There was no difference in late SOCE 
decline rate between PS SO and DS SO cells (P=0.560, Figure 4.4.4C). This unchanged 
Ca2+ release response of SO cells in DS conditions differs from that seen in DN 
conditions, where total Ca2+ store release was increased (Figure 4.4.1). In addition, the 
rate of Ca2+ release was reduced in DS conditions, perhaps suggesting a reduced 
sensitivity to TG. The reduction in SOCE that was seen in DN conditions (Figure 4.4.1) 
was also present in DS conditions, though it was a shortened response (Figure 4.4.4) 
indicating that Ca2+ release and SOCE are uncoupled in SO cells in an S-type 
environment, as well as in an N-type environment. 
 
Compared to PS SA cells, there was no change in total Ca
2+ store release in DS SA 
compared to PS SA cells (P=0.087) and total SOCE was reduced by 73% (P<0.0001, 
Figure 4.4.3). Consistent with this, there was no difference in maximal Ca2+ store 
release between PS SA and DS SA cells (P=0.097) and maximal SOCE was down-regulated 
by 71% in DS SA compared to PS SA cells (P<0.0001, Figure 4.4.4A). There was a 27% 
increase in rate of Ca2+ store release (P=0.0009) but no difference in rate of SOCE 
(P=0.274) between DS SA and PS SA cells (Figure 4.4.4B). Ca
2+ store release decline rate 
was increased by 17% in DS SA compared to PS SA cells (P=0.061) whilst there was no 
difference in the total SOCE decline rate between PS SA and DS SA cells (P=0.329, Figure 
4.4.4C). The initial and late SOCE decline rates were both reduced (by 11.60%, P=0.061 
and 22.31%, P=0.098, respectively) in DS SA cells compared to PS SA cells (Figure 4.4.4C). 
The unchanged Ca2+ release response of SA cells in DS conditions differs from that seen 
in DN conditions, where total Ca
2+ store release was decreased (Figure 4.4.1). In 
addition, the rate of Ca2+ release was reduced in DS conditions. The reduction in SOCE 
that was seen in DN conditions (Figure 4.4.1) was also present in DS conditions, though 
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it was a shorter response (Figure 4.4.4), indicating that Ca2+ release and SOCE are 
uncoupled in SO cells in an S-type environment, as well as in an N-type environment. 
 
Compared to PS SE cells, there was no change in total Ca
2+ store release in DS SE cells 
(P=0.663) and total SOCE was reduced by 65% (P<0.0001, Figure 4.4.3). There was no 
difference in maximal Ca2+ store release between PS SE compared to DS SE cells 
(P=0.908) and maximal SOCE was down-regulated by 51% in DS compared to PS SE cells 
(P=0.00016, Figure 4.4.4A). There was no significant difference in rate of Ca2+ store 
release (P=0.369) between PS SE and DS SE cells but there was a 31% decrease in rate of 
SOCE in DS SE compared to PS SE cells (P=0.086 Figure 4.4.3B). There was no difference 
in Ca2+ store release decline rate between PS SE and DS SE cells (P=0.447) however, 
compared to PS SE cells, DS SE cells had significantly reduced total SOCE decline rate (by 
41.30%, P=0.0003), initial SOCE decline rate (by 34.02%, P=0.0049) and late SOCE 
decline rate (by 60.80%, P=0.0011, Figure 4.4.4C). The unchanged Ca2+ release 
response of SE cells in DS conditions differs from that seen in DN conditions, where total 
Ca2+ store release was decreased (Figure 4.4.1). The reduction in SOCE that was seen in 
DN conditions (Figure 4.4.1) was also present in DS conditions, though it was a smaller, 
slower and extended response (Figure 4.4.4). This indicates that Ca2+ release and SOCE 
are uncoupled in SO cells in an S-type environment, as well as in an N-type 
environment. 
 
All of this data confirms that sub-population-specific Ca2+ signals in SO, SA and SE cells 
can each be influenced by background cell environment (Table 4.4). 
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Table 4.4. Summary of SO, SA and SE single cell Ca
2+
 signals determined by 
predominant background environment 
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Figure 4.4.1. An uncoupling of Ca
2+
 store release and SOCE occurs with differentiation 
of SO, SA and SE cells grown in an N-type predominant environment 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores. 
Compared to PN SO cells, DN SO cells had a 16.58% increase in total Ca
2+ store release 
(62.42 ± 3.08 and 72.77 ± 3.80 FRUs, respectively, P=0.034*) and, taking this change 
into account, total SOCE was reduced by 65.70% (155.80 ± 13.64 and 62.29 ± 7.77 
FRUs, respectively). Compared to PN SA cells, DN SA cells had a 21.77% decrease in total 
Ca2+ store release (71.46 ± 4.15 and 55.91 ± 4.73 FRUs, respectively, P=0.015*) and 
total SOCE was reduced by 52.93% (188.28 ± 16.36 and 69.33 ± 11.79 FRUs, 
respectively). Compared to PN SE cells, DN SE cells had a 42.17% reduction in total Ca
2+ 
store release (77.10 ± 20.02 and 44.58 ± 6.07 FRUs, respectively, P=0.064) and total 
SOCE was reduced by 61.38% (251.18 ± 38.17 and 56.09 ± 14.06 FRUs, respectively). 
PN: SO n=108, SA n=75, SE n=4. DN: SO n=82, SA n=57, SE n=24. N=6. 
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Figure 4.4.2 SOCE dynamics with differentiation of SO, SA and SE cells grown in an N-
predominant environment 
N-type populations were treated for 7 days with EtOH (PN, proliferating) or 1 µM 9cRA 
(DN, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.  
(A) DMSO (TG control) measurements were deducted from the experimental data. 
There was no difference in maximal Ca2+ store release in DN SO cells (0.19 ± 0.01 FRUs) 
compared to PN SO cells (0.18 ± 0.01 FRUs, P=0.375). Maximal SOCE was down-
regulated by 54.52% in DN SO cells (0.17 ± 0.05 FRUs) compared to PN SO cells (0.37 ± 
0.02 FRUs, P<0.0001****). There was a significant 21.43% decrease in maximal Ca2+ 
store release in DN SA cells (0.15 ± 0.01 FRUs) compared to PN SA cells (0.19 ± 0.01 FRUs, 
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P=0.003**). Taking this change into account, maximal SOCE was down-regulated by 
39.34% in DN SA cells (0.19 ± 0.03 FRUs) compared to PN SA cells (0.40 ± 0.03 FRUs). 
There was no difference in maximal Ca2+ store release between PN SE cells (0.21 ± 0.01 
FRUs) compared to DN SE cells (0.14 ± 0.02 FRUs, P=0.212). Maximal SOCE was down-
regulated by 73.25% in DN SE cells (0.13 ± 0.04 FRUs) compared to PN SE cells (0.48 ± 
0.07 FRUs, P=0.005**). (B) There was no significant change in rate of Ca2+ store release 
(P=0.217) or rate of SOCE (P=0.132) between PN SO cells and DN SO cells. There was a 
significant 26.04% decrease in rate of Ca2+ store release (P=0.0005) but no significant 
change in rate of SOCE (P=0.735) in DN SA cells compared to PN SA cells. There was no 
significant difference in rate of Ca2+ store release (P=0.129) or rate of SOCE (P=0.176) 
in PN SE cells compared to DN SE cells. (C) There was a significant 12.33% decrease in 
Ca2+ store release decline rate in DN SO cells compared to PN SO cells (P=0.031). There 
was no difference in total or initial SOCE decline rate (P=0.426, P=0.709, respectively) 
between PN SO cells and DN SO cells. Late SOCE decline rate was significantly reduced by 
34.19% (P=0.0089) in DN SO cells compared to PN SO cells. Ca
2+ store release decline 
rate and total SOCE decline rate were both significantly reduced by 16.16% and 16.51% 
in DN SA cells compared to PN SA cells (P=0.041 and P<0.049, respectively). There was 
no difference in the initial SOCE decline rate between PN SA cells and DN SA cells 
(P=0.540) whilst the late decline rate was significantly reduced by 54.47% (P<0.0001) in 
DN SA cells. There was no difference in Ca
2+ store release decline rate between PN SE 
cells and DN SE cells (P=0.681) and total SOCE decline rate was significantly reduced by 
52.19% in DN SE cells compared to PN SE cells (P=0.0021). The initial and late SOCE 
decline rate was significantly reduced by 41.77% and 69.54% respectively in DN SE cells 
compared to PN SE cells (P=0.046 and P<0.0001, respectively). In PN populations: SO 
n=108, SA n=75, SE n=4. In DN populations: SO n=82, SA n=57, SE n=24. N=6. 
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Figure 4.4.3. An uncoupling of Ca
2+
 store release and SOCE occurs with differentiation 
of SO, SA and SE cells grown in an S-predominant environment 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating).  Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores. 
Compared to PS SO cells, there was no change in total Ca
2+ store release in DS SO cells 
(40.54 ± 1.82 and 36.50 ± 1.55 FRUs, respectively, P=0.092) and total SOCE was 
reduced by 63.85% (120.04 ± 7.14 and 43.40 ± 3.35 FRUs, respectively, p<0.0001****). 
Compared to PS SA cells, there was no change in total Ca
2+ store release in DS SA cells 
(35.05 ± 1.22 and 39.19 ± 2.39, respectively FRUs, P=0.087) and total SOCE was 
reduced by 72.88% (118.79 ± 5.42 and 32.22 ± 7.45 FRUs, respectively, p<0.0001****). 
Compared to PS SE cells, there was no change in total Ca
2+ store release in DS SE cells 
(34.04 ± 3.83 and 31.62 ± 3.19, respectively FRUs, P=0.663) and total SOCE was 
reduced by 64.52% (138.28 ± 17.99 and 49.07 ± 5.37 FRUs, respectively, 
P<0.0001****). PS: SO n=199, SA n=356, SE n=31. DS: SO n=200, SA n=190, SE n=75. N=8. 
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Figure 4.4.4. SOCE dynamics with differentiation of SO, SA and SE cells grown in an S-
predominant environment 
S-type populations were treated for 7 days with EtOH (PS, proliferating) or 1 µM 9cRA 
(DS, differentiating). Changes in fluorescence ratio units (FRUs) are reflective of 
changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ store release 
and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish depleted stores.  
(A) DMSO (TG control) measurements were deducted from the experimental data. 
Maximal Ca2+ store release was significantly reduced by 14.61% in DS SO cells (0.10 ± 
0.01 FRUs) compared to PS SO cells (0.12 ± 0.01 FRUs, P=0.025*). Taking this change 
into account, maximal SOCE was down-regulated by 53.26% in DS SO cells (0.17 ± 0.02 
FRUs) compared to PS SO cells (0.43 ± 0.03 FRUs). There was no significant difference in 
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maximal Ca2+ store release between PS SA cells and DS SA cells (0.10 ± 0.004 and 0.11 ± 
0.01 FRUs, respectively, P=0.097). Maximal SOCE was down-regulated by 71.36% in DS 
SA cells (0.11 ± 0.04 FRUs) compared to PS SA cells (0.37 ± 0.02 FRUs, P<0.0001****). 
There was no difference in maximal Ca2+ store between PS SE cells (0.09 ± 0.01 FRUs) 
compared to DS SE cells (0.09 ± 0.01 FRUs, P=0.908). Maximal SOCE was down-
regulated by 50.72% in DS SE cells (0.23 ± 0.03 FRUs) compared to PS SE cells (0.46 ± 
0.05 FRUs, P=0.00016***). (B) There was a significant decrease in rate of Ca2+ store 
release (13.90%, P=0.042) and rate of SOCE (24.05% P=0.0018) in DS SO cells compared 
to PS SO cells. There was a significant 26.66% increase in rate of Ca
2+ store release 
(P=0.0009) but no significant change in rate of SOCE (P=0.274) in DS SA cells compared 
to PS SA cells. There was no significant difference in rate of Ca
2+ store release (P=0.369) 
between PS SE cells and DS SE cells but there was a 31.16% decrease in rate of SOCE in 
DS SE cells compared to PS SE cells (P=0.086). (C) There was a significant 21.12% 
decrease in Ca2+ store release decline rate in DS SO cells compared to PS SO cells 
(P<0.0001). There was a significant reduction in total and initial SOCE decline rate in DS 
SO cells compared to PS SO cells (37.02% and 48.42% respectively, both P<0.0001). 
There was no difference in late SOCE decline rate between PS SO cells and DS SO cells 
(P=0.560). Ca2+ store release decline rate was significantly increased by 17.32% in DS SA 
cells compared to PS SA cells (P=0.061). There was no difference in the total SOCE 
decline rate was between PS SA cells and DS SA cells (P=0.329). The initial and late SOCE 
decline rates were both significantly reduced (by 11.60%, P=0.061 and 22.31%, 
P=0.098, respectively) in DS SA cells. There was no difference in Ca
2+ store release 
decline rate between PS SE cells and DS SE cells (P=0.447). Compared to PS SE cells, DS SE 
cells had significantly reduced total SOCE decline rate (by 41.30%, P=0.0003), initial 
SOCE decline rate (by 34.02%, P=0.0049) and late SOCE decline rate (by 60.80%, 
P=0.0011). In PS populations: SO n=199, SA n=356, SE n=31. In DS populations: SO n=200, 
SA n=190, SE n=75. N=8. 
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4.5. There is an effect of media from differentiating N-type and S-type populations  
As previously discussed (Results 4.3-4.4) the Ca2+ responses of cells within an N-type 
and S-type population are affected by the surrounding cell environment. This may be 
due to local effects such as cell-cell contacts or the release of factors by surrounding 
cells that may alter cell characteristics. To investigate this further, media from 
proliferating and differentiating S-type populations was applied to N-type populations 
whilst media from proliferating or differentiating N-type populations was applied to S-
type populations. 
 
4.5.1 Applying S-type conditioned media to N-type populations 
N-type predominant populations were treated for 7 days with EtOH (PN, proliferating), 
1 µM 9cRA (DN, differentiating), media from proliferating S-type populations (PN+PS), 
media from differentiating S-type populations (PN+DS) or with 1 µM 9cRA plus media 
from differentiating S-type populations (DN+DS).  As shown previously, PN cells possess 
short neurite-like processes and neurites become elongated with differentiation 
(Figure 4.5.1A and B). PN+PS cells grow in a similar fashion to PN cells and possess short 
neurite-like processes whilst PN+DS cells and DN+DS cells grow in a similar manner to DN 
cells and possess elongated neurite-like processes (Figure 4.5.1C, D and E). 
 
Compared to PN cells, DN cells had a 20% increase in total Ca
2+ store release (P<0.0001) 
and total SOCE was reduced by 53% (Figure 4.5.2A and B). Consistent with this, there 
was a 10% increase in maximal Ca2+ store release in DN compared to PN cells (P=0.004) 
and maximal SOCE was down-regulated by 61% (Figure 4.5.3A). There was an 11% 
increase in rate of Ca2+ store release (P=0.003) but no difference in rate of SOCE 
(P=0.948), Ca2+ store release decline rate (P=0.997), total SOCE decline rate (P=0.579) 
or initial SOCE decline rate (P=0.166, Figure 4.5.3B and C). Late SOCE decline rate was 
reduced by 19% (P<0.0001, Figure 4.5.3C). These results confirm an uncoupling of Ca2+ 
store release and SOCE in DN populations as described previously (Results 4.2). 
 
Total Ca2+ store release in PN+PS cells was 13% lower than PN cells (P<0.00001) but 
there was no change in total SOCE (Figure 4.5.2A and B). There was a 7% increase in 
maximal Ca2+ store release in PN+PS compared to PN cells (P=0.034) and maximal SOCE 
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was down-regulated by 14% (Figure 4.5.3A). There was a 49% increase in rate of Ca2+ 
store release (P<0.0001) and 46% down-regulation of SOCE (P<0.0001, Figure 4.5.3B). 
Ca2+ store release decline rate was increased by 16% and total SOCE decline rate was 
reduced by 28% (both P<0.0001, Figure 4.5.3C). There was no difference in the initial 
SOCE decline rate (P=0.517) and late SOCE decline rate was reduced by 37% (P=0.072, 
Figure 4.5.3C). These results indicate that treatment of PN cells with PS media induces a 
reduction in Ca2+ store release and increases rate of store release activation and rate 
of store emptying and therefore a smaller, shorter store release that may represent a 
decrease in store size. Whilst Ps media does not affect the overall extent of PN SOCE, 
the activation and late de-activation of SOCE are dampened indicating an extended 
SOCE response. PS media therefore, at least in part, maintains the PN SOCE response. 
 
Compared to PN cells, total Ca
2+ store release of PN+DS cells was increased by 50% 
(P<0.0001) and total SOCE was reduced by 48% (Figure 4.5.2A and B). Consistent with 
this, maximal Ca2+ store release of PN+DS cells was increased by 35% compared to PN 
cells (P<0.0001) and maximal SOCE was down-regulated by 24% in PN+DS (Figure 
4.5.3A). There was a 29% increase in rate of Ca2+ store release (P<0.0001) but no 
difference in rate of SOCE (P>0.999, Figure 4.5.3B). Ca2+ store release decline rate was 
increased by 13% (P<0.0001) but there was no difference in total SOCE decline rate 
(P=0.268, Figure 4.5.3C). The initial SOCE decline rate was increased by 97% (P<0.0001) 
whilst late SOCE decline rate was reduced by 39% (P<0.0001, Figure 4.5.3C). These 
results indicate that treatment of PN cells with DS media induces an increase in Ca
2+ 
store release and rate of store release activation and emptying, suggesting an increase 
in store capacity and sensitivity to TG, like that seen in DN cells. Whilst Ds media 
reduced the overall extent of PN SOCE, rate of initial SOCE decline was increased, 
suggesting a smaller, shorter SOCE response. DS media therefore induces Ca
2+ 
responses in PN cells that more reflect a DN response than a PN response. 
 
There was a 25% increase in total Ca2+ store release in PN+DS cells compared to DN cells 
(P<0.0001) but no difference in total SOCE (Figure 4.5.2A and B) and an increase in 
maximal Ca2+ store release (22%, P<0.0001) and maximal SOCE (93%, Figure 4.5.3A). 
There was an increase in rate of Ca2+ store release (15%, P<0.0001) and rate of SOCE 
127 
 
(8%, P<0.0001, Figure 4.5.3B). Ca2+ store release decline rate and total SOCE decline 
rate were significantly increased (12%, P<0.0001 and 15% P=0.019, respectively, Figure 
4.6.3C). The initial SOCE decline rate was increased (64%, P<0.0001) whilst late SOCE 
decline rate was reduced (24%, P<0.0001, Figure 4.5.3C). These results show that 
treatment of PN cells with DS media increases Ca
2+ store release, rate of activation and 
emptying to a greater extent than that DN cells, suggesting an increase in store 
capacity and sensitivity to TG. There was no difference in extent of SOCE, confirming 
that DS media induces SOCE down-regulation in PN like that of DN cells. However, this 
effect is not fully DN-like since there was an overall shortened SOCE response to a 
greater extent than that of DN cells. 
 
Compared to PN cells, total Ca
2+ store release in DN+DS cells was increased by 14% 
(P<0.0001) and total SOCE was reduced by 35% (Figure 4.5.2A and B). Consistent with 
this, maximal Ca2+ store release was increased by 22% (P<0.0001) and maximal SOCE 
was reduced by 36% (Figure 4.5.3A). There was a 67% increase in rate of Ca2+ store 
release (P<0.0001) and 47% decrease in rate of SOCE (P<0.0001, Figure 4.5.3B). There 
was a reduction in Ca2+ store release decline rate (10%), total SOCE decline rate (23%) 
and late SOCE decline rate (56%, all P<0.0001), whilst initial SOCE decline rate was 
increased (47%, P<0.0001, Figure 4.5.3C). Treating DN cells with DS media therefore 
induces a similar uncoupling effect to that of PN cells treated with DS media, although 
to a lesser extent, implying that inducing differentiation of N-type cell populations 
alongside DS media application somehow dampens the full effect of DS media. The 
extent of change in rates of activation and deactivation are also more similar to PN+PS 
cells, with a seemingly increased sensitivity to TG, slower SOCE activation and 
increased SOCE deactivation. 
 
Total Ca2+ store release in DN+DS cells was no different to that of DN cells (P=0.084) and 
total SOCE was increased by 17% (P=0.028, Figure 4.5.2A and B). Maximal Ca2+ store 
release was increased (10%, P=0.004) and maximal SOCE was increased (62%, Figure 
4.5.3A). There was a 50% increase in rate of Ca2+ store release (P=0.0001) and 57% 
decrease in rate of SOCE (P=0.0008, Figure 4.5.3B). There was a reduction in Ca2+ store 
release decline rate (10%, P=0.0008), total SOCE decline rate (18%, P=0.0014) and late 
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SOCE decline rate (46%, P<0.0001) whilst initial SOCE decline rate was increased (22%, 
P=0.033, Figure 4.5.3C). These results confirm that the extent of uncoupling when 
inducing differentiation of N-type cell populations alongside DS media application 
dampens the full effect of DS media. 
 
All of this data confirms that the Ca2+ signals of N-type populations can be influenced 
by S-type conditioned media (Table 4.5.1). 
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Table 4.5.1. Summary of N-type population single cell Ca
2+
 signals determined by S-
type conditioned media 
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4.5.2 Applying N-type conditioned media to S-type populations 
S-type predominant populations were treated for 7 days with EtOH (PS, proliferating), 
1 µM 9cRA (DS, differentiating), media from proliferating N-type populations (PS+PN), 
media from differentiating N-type populations (PS+DN) or with 1 µM 9cRA plus media 
from differentiating N-type populations (DS+DN). As previously described, PS cells 
possess abundant cytoplasm with a flattened morphology and become more flattened 
and spread out with differentiation (Figure 4.5.4A and B). PS+PN cells grow in a similar 
manner to PS cells whilst PS+DN cells and DS+DN cells grow in a similar manner to DS 
cells (Figure 4.5.4A, B and C). 
 
Compared to PS cells, in DS cells there was a 37% increase in total Ca
2+ store release 
(P<0.0001) and total SOCE was reduced by 83% (Figure 4.5.5A and B). Consistent with 
this, there was a 21% increase in maximal Ca2+ store (P<0.0001) and maximal SOCE was 
down-regulated by 79% (Figure 4.5.6A). There was an 18% increase in rate of Ca2+ 
store release (P=0.003) and a 20% decrease in rate of SOCE (P=0.003, Figure 4.5.6.B). 
There was no change in Ca2+ store release decline rate (P=0.863), a decrease in total 
and late SOCE decline rate (15% and 80%, respectively) and a 67% increase in initial 
SOCE decline rate (all P<0.0001, Figure 4.5.6C). These results confirm an uncoupling of 
Ca2+ store release and SOCE in DS populations as described previously (Results 4.2). 
 
Total Ca2+ store release in PS+PN cells was 37% higher than that of PS cells (P<0.00001) 
and there was a 42% decrease in total SOCE (Figure 4.5.5A and B). Maximal Ca2+ store 
release was increased (21% P<0.001) and maximal SOCE was down-regulated (33%, 
Figure 4.5.6A). There was a 41% increase in rate of Ca2+ store release (P<0.0001) and 
55% decrease in rate of SOCE (P<0.0001, Figure 4.5.6B). There was a reduction in Ca2+ 
store release decline rate (9%, P=0.037), total (21%) and late (76%) SOCE decline rate 
whilst initial SOCE decline was increased by 50% (all P<0.0001, Figure 4.5.6C). These 
results show that treatment of PS cells with PN media induces an uncoupling of Ca
2+ 
store release and SOCE similar to that seen in DS cells, although SOCE down-regulation 
occurred to a much lesser extent. 
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Compared to PS cells, there was no difference in total Ca
2+ store release of PS+DN cells 
and total SOCE was reduced by 49% (P<0.0001, Figure 4.5.5A and B). There was no 
difference in maximal Ca2+ store release (P=0.789) and maximal SOCE was reduced by 
98% (P<0.0001, Figure 4.5.6A). There was no difference in rate of Ca2+ store release 
(P=0.404) or rate of SOCE (P=0.071, Figure 4.5.6B). There was a reduction in Ca2+ store 
release decline rate (12%, P=0.0006), total (9%, P=0.042) and late (52%, P<0.0001) 
SOCE decline rate whilst initial SOCE decline rate was increased by 56% (P<0.0001, 
Figure 4.5.6C). Treating PS cells with DN media therefore does not affect store size or 
sensitivity to TG like PN media however, it does induce changes in the SOCE response 
similar to that of PN media, thereby causing an uncoupling of store release and SOCE to 
a lesser extent than in DS cells. 
 
There was a 28% reduction in total Ca2+ store release in PS+DN cells compared to DS 
cells (P<0.0001) and a two-fold increase in total SOCE (Figure 4.5.5A and B). There was 
a reduction in maximal Ca2+ store release (22%, P<0.0001) and maximal SOCE (90%, 
Figure 4.5.6A). There was no difference in rate of Ca2+ store release (P=0.143) and a 
41% increase in rate of SOCE (P<0.0001, Figure 4.5.6B). Ca2+ store release decline rate 
was reduced by 9% (P=0.021), late SOCE decline rate was increased by 1.5 fold 
(P<0.0001) and here was no difference in total (P=0.134) or initial (P=0.425) SOCE 
decline rate (Figure 4.5.6C). This confirms that effect of DN media on PS cells does not 
induce a fully differentiating Ca2+ response, largely influenced by an increase in rate of 
SOCE activation and late deactivation. 
 
Compared to PS cells, there was no difference in total Ca
2+ store release in DS+DN cells 
(P=0.775) and total SOCE was reduced by 63% (p<0.0001, Figure 4.5.5A and B). There 
was no difference in maximal Ca2+ store release whilst maximal SOCE was reduced by 
52% (P<0.0008, Figure 4.5.6.A). There was an increase in rate of Ca2+ store release 
(16%, P=0.017) and SOCE (23%, P=0.0004, Figure 4.5.6.B). Ca2+ store release decline 
rate, total and late SOCE decline rate were reduced (26%, 27% and 70% respectively, 
all P<0.0001) whilst initial SOCE decline rate was increased by (26%, P=0.003, Figure 
4.5.6C). These results show that differentiating S-type cells alongside DN media 
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application induces a differentiation response similar to that seen in PS+DN cells, with a 
greater extent of SOCE down-regulation. 
 
Total Ca2+ store release was reduced by 28% in DS+DN cells compared to DS cells 
(P<0.0001) and total SOCE was 1 fold greater (Figure 4.5.5A and B). Maximal Ca2+ store 
release was reduced by 21% (P<0.0001) and maximal SOCE was increased by 1.5 fold 
(Figure 4.5.6A). There was no difference in rate of Ca2+ store release (P=0.986) or rate 
of SOCE (P=0.981, Figure 4.5.6B). Ca2+ store release decline rate, total and initial SOCE 
decline rate were reduced (23%, P<0.0001, 14%, P=0.004 and 24%, P<0.0001, 
respectively) whilst late SOCE decline rate was increased by 51% (P=0.021, Figure 
4.5.6C). This confirms that differentiating S-type cells alongside DN media application 
does not induce a fully differentiating response but brings the cells closer to a 
differentiating response than that seen in PS+DN cells. 
 
All of this data confirms that the Ca2+ signals of S-type populations can be influenced 
by N-type conditioned media (Table 4.5.2). 
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Table 4.5.2. Summary of S-type population single cell Ca
2+
 signals determined by N-
type conditioned media 
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Figure 4.5.1. Effect of S media on N-type populations morphology 
N-type populations were treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA 
(DN, differentiating), media from proliferating S-type populations (PN+PS), media from 
differentiating S-type populations (PN+DS) or with 1 µM 9cRA plus media from 
differentiating S-type populations (DN+DS). (A) P cells possess short neurite-like 
processes and (B) upon differentiation, neurites become elongated and cell numbers 
decrease. (C) PN+PS cells grow in a similar aggregated fashion to PN cells and possess 
short neurite-like processes. (D) PN+DS cells and (E) DN+DS cells grow in a similar 
manner to DN cells and possess elongated neurite-like processes. Scale bar represents 
of phase contrast images represents 20 µm.  
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Figure 4.5.2. Effect of S media on Ca
2+
 responses of N-type populations 
N-type populations were treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA 
(DN, differentiating), media from proliferating S-type populations (PN+PS), media from 
differentiating S-type populations (PN+DS) or with 1 µM 9cRA plus media from 
differentiating S-type populations (DN+DS). Changes in fluorescence ratio units (FRUs) 
are reflective of changes in [Ca2+]i following addition of thapsigargin (TG) indicating 
Ca2+ store release and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish 
depleted stores. (A) Compared to PN cells, in DN cells there was a 19.75% increase in 
total Ca2+ store release (67.11 ± 1.17 and 80.37 ± 1.50 FRUs, respectively, 
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P<0.0001****) and, taking this change into account, total SOCE was reduced by 
52.79% (271.87 ± 10.65 and 171.87 ± 13.22 FRUs, respectively). Total Ca2+ store release 
in PN+PS cells (58.15 ± 1.20 FRUs) was 13.36% lower than that of PN cells 
(P<0.00001****) and there was no change in total SOCE (243.60 ± 5.99 FRUs). 
Compared to PN cells, total Ca
2+ store release of PN+DS cells was increased by 49.88% 
(100.59 ± 2.43 FRUs, P<0.0001****) and total SOCE was reduced by 47.55% (213.72 ± 
9.18 FRUs). There was a 25.16% increase in total Ca2+ store release in PN+DS cells 
compared to DN cells (P<0.0001****) but no difference in total SOCE. Compared to PN 
cells, total Ca2+ store release in DN+DS cells (76.66 ± 1.43 FRUs) was increased by 
14.22% (P<0.0001****) and total SOCE (200.57 ± 6.05 FRUs) was reduced by 35.41%. 
Total Ca2+ store release in DN+DS cells was no different to that of DN cells (P=0.084) and 
total SOCE was increased by 16.70% (P=0.028*). (B) When taking into account any 
changes in total Ca2+ store release, compared to PN cells, all other treatments caused a 
down-regulation of total SOCE, except PN+PS. PN: n=597, DN: n=311, PN+PS: n=456, 
PN+DS: n=386, DN+DS: n=476. N=3. 
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Figure 4.5.3. Effect of S media on Ca
2+
 response dynamics of N-type populations 
N-type populations were treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA 
(DN, differentiating), media from proliferating S-type populations (PN+PS), media from 
differentiating S-type populations (PN+DS) or with 1 µM 9cRA plus media from 
differentiating S-type populations (DN+DS). Changes in fluorescence ratio units (FRUs) 
are reflective of changes in [Ca2+]i following addition of thapsigargin (TG) indicating 
Ca2+ store release and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish 
depleted stores. (A) DMSO (TG control) measurements were deducted from the 
experimental data. There was a 10.30% increase in maximal Ca2+ store release in DN 
cells (0.17 ± 0.003 FRUs) compared to PN cells (0.16 ± 0.003 FRUs, P=0.004**). Taking 
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this change in Ca2+ store release into account, maximal SOCE was down-regulated by 
60.72% in DN cells (0.19 ± 0.05 FRUs) compared to PN cells (0.43 ± 0.03 FRUs). There 
was a 7.39% increase in maximal Ca2+ store release in PN+PS cells (0.17 ± 0.002 FRUs) 
compared to PN cells (P=0.034*) . Taking this change in Ca
2+ store release into account, 
maximal SOCE was down-regulated by 14.39% in PN+PS cells (0.39 ± 0.01 FRUs) 
compared to PN cells. Maximal Ca
2+ store release was increased by 34.68% in PN+DS 
cells (0.21 ± 0.01 FRUs) compared to PN cells (P<0.0001****). Taking this change in 
Ca2+ store release into account, maximal SOCE was down-regulated by 24.36% in PN+DS 
(0.44 ± 0.02 FRUs) compared to PN cells. Compared to DN cells, there was a 22.10% 
increase in maximal Ca2+ store release in PN+DS cells (P<0.0001****) and, taking this 
change in Ca2+ store release into account, maximal SOCE was increased by 92.58%. 
Compared to PN cells, maximal Ca
2+ store release in DN+DS cells (0.19 ± 0.003 FRUs) was 
increased by 21.58% (P<0.0001****) and, taking this this change in Ca2+ store release 
into account, maximal SOCE (0.33 ± 0.02 FRUs) was reduced by 36.25%. Maximal Ca2+ 
store release in DN+DS cells was increased by 10.23% compared to that of DN cells 
(P=0.004**) and taking this this change in Ca2+ store release into account, maximal 
SOCE was increased by 62.31%. (B) There was an 11.41% increase in rate of Ca2+ store 
release (P=0.003) and but no difference in rate of SOCE (P=0.948) in DN cells compared 
to PN cells. There was a 48.66% increase in rate of Ca
2+ store release (P<0.0001) and 
45.72% down-regulation of SOCE (P<0.0001) in PN+PS cells compared to PN cells. There 
was a 28.59% increase in rate of Ca2+ store release (P<0.0001) but no difference in rate 
of SOCE (P>0.999) in PN+DS cells compared to PN cells. There was a 15.41% increase in 
rate of Ca2+ store release (P<0.0001) and 8.36% increase in rate of SOCE (P<0.0001) in 
PN+DS cells compared to DN cells. There was a 67.04% increase in rate of Ca
2+ store 
release (P<0.0001) and 46.57% decrease in rate of SOCE (P<0.0001) in DN+DS cells 
compared to PN cells. There was a 49.93% increase in rate of Ca
2+ store release 
(P=0.0001) and 57.32% decrease in rate of SOCE (P=0.0008) in DN+DS cells compared to 
DN cells. (C) There was no change in Ca
2+ store release decline rate (P=0.997) between 
PN cells and DN cells or total SOCE decline rate (P=0.579). There was no difference in 
initial SOCE decline rate (P=0.166) whilst late SOCE decline rate was reduced by 19.25% 
in DN cells compared to PN cells (P<0.0001). Ca
2+ store release decline rate was 
increased by 15.69% and total SOCE decline rate was reduced by 27.99% in PN+PS cells 
139 
 
compared to PN cells (both P<0.0001). There was no difference in the initial SOCE 
decline rate (P=0.517) and late SOCE decline rate was reduced by 36.83% in PN+PS cells 
compared to P cells (P=0.072). Ca2+ store release decline rate was increased by 12.63% 
in PN+DS cells compared to PN cells (P<0.0001) but there was no difference in total 
SOCE decline rate (P=0.268). The initial SOCE decline rate was increased by 96.76% in 
PN+DS cells compared to PN cells (P<0.0001) whilst late SOCE decline rate was 
significantly reduced by 38.58% (P<0.0001). Ca2+ store release decline rate and total 
SOCE decline rate were significantly increased in PN+DS cells compared to DN cells (by 
12.11%, P<0.0001 and 14.65% P=0.019, respectively). The initial SOCE decline rate was 
increased by 63.84% in PN+DS cells compared to DN cells (P<0.0001) whilst late SOCE 
decline rate was reduced by 23.94% (P<0.0001). Ca2+ store release decline rate and 
total SOCE decline rate were significantly reduced in DN+DS cells compared to PN cells 
(9.58% and 23.28%, respectively, both P<0.0001). The initial SOCE decline rate was 
increased by 47.06% in DN+DS cells compared to PN cells (P<0.0001) whilst late SOCE 
decline rate was reduced by 56.23% (P<0.0001). Ca2+ store release decline rate and 
total SOCE decline rate were significantly reduced in DN+DS cells compared to DN cells 
(by 9.99%, P=0.0008 and 18.32%, P=0.0014, respectively). The initial SOCE decline rate 
was increased by 22.45% in DN+DS cells compared to DN cells (P=0.033) whilst late 
SOCE decline rate was reduced 45.80% (P<0.0001). PN: n=597, DN: n=311, PN+PS: 
n=456, PN+DS
: n=386, DN+DS: n=476. N=3. 
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Figure 4.5.4. There is an effect of N-type media on S-type populations morphology 
S-type populations were treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA 
(DS, differentiating), media from proliferating N-type populations (PS+PN), media from 
differentiating N-type populations (PS+DN) or with 1 µM 9cRA plus media from 
differentiating N-type populations (DS+DN). (A) PS cells possess abundant cytoplasm 
with a flattened morphology and (B) upon differentiation, cells become more flattened 
and spread out. (C) PS+PN cells grow in a similar manner to PS cells whilst (D) PS+DN cells 
and (E) DS+DN cells grow in a similar manner to DS cells. Scale bar represents of phase 
contrast images represents 20 µm.  
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Figure 4.5.5. There is an effect of N-type media on Ca
2+
 responses of S-type 
populations 
S-type populations were treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA 
(DS, differentiating), media from proliferating N-type populations (PS+PN), media from 
differentiating N-type populations (PS+DN) or with 1 µM 9cRA plus media from 
differentiating N-type populations (DS+DN). Changes in fluorescence ratio units (FRUs) 
are reflective of changes in [Ca2+]i following addition of thapsigargin (TG) indicating 
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Ca2+ store release and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish 
depleted stores. (A) Compared to PS cells, in DS cells there was a 37.01% increase in 
total Ca2+ store release (46.92 ± 1.04 and 64.29 ± 1.73, respectively, P<0.0001****) 
and, taking this change into account, total SOCE was reduced by 82.59% (224.17 ± 
12.23 and 53.47 ± 10.08, respectively). Total Ca2+ store release in PS+PN cells (64.09 ± 
1.02) was 36.61% higher than that of PS cells (P<0.00001****) and, taking this change 
into account, there was a 42.25% decrease in total SOCE (176.85 ± 8.66). Compared to 
PS cells, there was no difference in total Ca
2+ store release of PS+DN cells (46.21 ± 1.22, 
P=0.692) and total SOCE was reduced by 48.55% (113.58 ± 15.11, P<0.0001****). 
There was a 28.12% reduction in total Ca2+ store release in PS+DN cells compared to DS 
cells (P<0.0001****) and, taking this change into account, a two-fold increase in total 
SOCE. Compared to PS cells, there was no difference in total Ca
2+ store release in DS+DN 
cells (46.41 ± 1.44, P=0.775) and total SOCE (81.61 ± 10.69) was reduced by 63.19% 
(p<0.0001****). Total Ca2+ store release was reduced by 27.81% in DS+DN cells 
compared to DS cells (P<0.0001****) and, taking this change into account, total SOCE 
was 1 fold greater. (B) When taking into account any changes in total Ca2+ store 
release, compared to PS cells, all other treatments caused a down-regulation of total 
SOCE. PS: n=345, DS: n=379, PS+PN: n=682, PS+DN
: n=605, DS+DN: n=373. N=3. 
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Figure 4.5.6. There is an effect of N-type media on Ca
2+
 response dynamics of S-type 
populations 
S-type populations were treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA 
(DS, differentiating), media from proliferating N-type populations (PS+PN), media from 
differentiating N-type populations (PS+DN) or with 1 µM 9cRA plus media from 
differentiating N-type populations (DS+DN). Changes in fluorescence ratio units (FRUs) 
are reflective of changes in [Ca2+]i following addition of thapsigargin (TG) indicating 
Ca2+ store release and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish 
depleted stores. (A) DMSO (TG control) measurements were deducted from the 
experimental data. There was a 20.50% increase in maximal Ca2+ store release in DS 
cells (0.17 ± 0.002 FRUs) compared to PS cells (0.14 ± 0.003 FRUs, P<0.0001****). 
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Taking this change in Ca2+ store release into account, maximal SOCE was down-
regulated by 79.31% in DS cells (0.12 ± 0.05 FRUs) compared to PS cells (0.48 ± 0.03 
FRUs). There was a 21.09% increase in maximal Ca2+ store release in PS+PN cells (0.17 ± 
0.002 FRUs) compared to PS cells (P<0.001****). Taking this change in Ca
2+ store 
release into account, maximal SOCE was down-regulated by 32.68% in PS+PN cells (0.39 
± 0.03 FRUs) compared to PS cells. There was no difference in maximal Ca
2+ store 
release between PS and PS+DN cells (0.13 ± 0.004 FRUs, P=0.789) and maximal SOCE 
was reduced by 98.04% in PS+DN cells (0.01 ± 0.04 FRUs) compared to PS cells 
(P<0.0001****). Compared to DS cells, there was a 21.51% decrease in maximal Ca
2+ 
store release in PS+DN cells (P<0.0001****) and, taking this change in Ca
2+ store release 
into account, maximal SOCE was reduced by 90.13%. There was no difference in 
maximal Ca2+ store release in DS+DN cells (0.13 ± 0.005 FRUs) compared to PS cells and 
maximal SOCE was reduced by 51.74% in DS+DN cells (0.23 ± 0.04 FRUs, P<0.0008***). 
Maximal Ca2+ store release in DS+DN cells was reduced by 21.43% compared to that of 
DS cells (P<0.0001****) and, taking this this change in Ca
2+ store release into account, 
maximal SOCE was increased by 1.5 fold. (B) There was an 18.18% increase in rate of 
Ca2+ store release (P=0.003) and a 19.70% decrease in rate of SOCE (P=0.003) in DS cells 
compared to PS cells. There was a 41.29% increase in rate of Ca
2+ store release 
(P<0.0001) and 55.12% decrease in rate of SOCE (P<0.0001) in PS+PN cells compared to 
PS cells. There was no difference in rate of Ca
2+ store release (P=0.404) or rate of SOCE 
(P=0.071) in PS+DN cells compared to PS cells. There was no difference in rate of Ca
2+ 
store release (P=0.143) and a 40.74% increase in rate of SOCE (P<0.0001) in PS+DN cells 
compared to DS cells. There was a 15.66% increase in rate of Ca
2+ store release 
(P=0.017) and 22.73% increase in rate of SOCE (P=0.0004) in DS+DN cells compared to 
PS cells. There was no difference in rate of Ca
2+ store release (P=0.986) or rate of SOCE 
(P=0.981) in DS+DN cells compared to DS cells. (C) There was no change in Ca
2+ store 
release decline rate (P=0.863) between PS cells and DS cells. There was a decrease in 
total and late SOCE decline rate (by 15.42% and 80.29%, respectively) and a 66.64% 
increase in initial SOCE decline rate in DS cells compared to PS cells (all P<0.0001). Ca
2+ 
store release decline rate was reduced by 8.53% in PS+PN cells compared to PS cells 
(P=0.037). Total and late SOCE decline rate were reduced by 21.34% and 75.88% 
respectively whilst initial SOCE decline was increased by 50.18% in PS+PN cells 
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compared to PS cells (all P<0.0001). Ca
2+ store release decline rate was reduced by 
12.39% in PS+DN cells compared to PS cells (P=0.0006). Total and late SOCE decline rate 
were reduced by 8.51% (P=0.042) and 51.84% (P<0.0001) respectively whilst initial 
SOCE decline rate was increased by 55.72% (P<0.0001) in PS+DN cells compared to PS 
cells. Ca2+ store release decline rate was reduced by 9.37% (P=0.021) and late SOCE 
decline rate was increased by 1.5 fold (P<0.0001) in PS+DN cells compared to DS cells. 
There was no difference in total or initial SOCE decline rate (P=0.134 and P=0.425) 
between PS+DN cells and DS cells. Ca
2+ store release decline rate and total SOCE decline 
rate were significantly reduced in DS+DN cells compared to PS cells (25.74% and 
26.95%, respectively, both P<0.0001). The initial SOCE decline rate was increased by 
26.19% in DS+DN cells compared to PS cells (P=0.003) whilst late SOCE decline rate was 
reduced by 70.17% (P<0.0001). Ca2+ store release decline rate, total and initial SOCE 
decline rate were significantly reduced in DS+DN cells compared to DS cells (by 23.18%, 
P<0.0001, 13.63%, P=0.004 and 24.27%, P<0.0001, respectively). The late SOCE decline 
rate was increased by 51.34% (P=0.021) in DS+DN cells compared to DS cells. 
PS: n=345, DS: n=379, PS+PN: n=682, PS+DN: n=605, DS+DN: n=373. N=3. 
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Chapter 4: Discussion 
It has previously been shown that 9cRA-induced differentiation of N-type populations 
induces down-regulation of SOCE which does not occur in S-type populations (N. Bell 
2013). The aim of this chapter was to investigate the Ca2+ signalling responses of the 
cell phenotypes underlying these populations and determine the effects of the 
predominant cell environment on minority cell responses using single cell Ca2+ analysis 
to study relative changes in the extent and dynamics of the Ca2+ store release and 
SOCE response. 
 
An uncoupling of Ca2+ store release and SOCE occurred in differentiating N-type 
populations, correlating with previous findings (Brown 2005; N. Bell 2013). N-type cells 
differentiate towards a neuronal phenotype and it has been shown that the SOCE 
response that is present in proliferating cells is dampened with neuronal 
differentiation. SOCE was found to be necessary for adult neural progenitor cell 
proliferation (Li 2012) and there was a reduction in voltage-independent Ca2+ entry 
and an increase in TG-sensitive Ca2+ ATPase activity in differentiating neurons 
compared to proliferating progenitors isolated from embryonic rat cortex (Maric 
2000). Similarly, differentiation of neural stem cells of the neuroepithelium to neuronal 
cells involves a down-regulation of SOCE, which is replaced with voltage-operated 
channel activity (Yamashita 2013). Voltage-operated channel activity was also shown 
to increase as SOCE decreased in neurons derived from mouse embryonic stem cells 
(Hao 2014). These results show that SOCE is present in proliferating neural progenitors 
and is dampened with differentiation towards a neuronal phenotype, as has been 
shown in this study. However, there is some evidence to suggest that an increase in 
SOCE is associated with the initial differentiation response (Wu 2004; Shin 2010; Hao 
2014) and this will be investigated in a subsequent chapter (Chapter 6: Differentiation 
time-course). 
 
An uncoupling of Ca2+ store release and SOCE also occurred with differentiation of S-
type populations, and actually to a greater extent than that seen in N-type 
populations, in contrast to previous findings that uncoupling does not occur in S-type 
populations (N. Bell 2013). The reasons for this contrast with previous findings are 
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unclear. One possibility is that the variability seen in S-type responses has affected the 
overall population response between investigations. Indeed, the Ca signals observed in 
SO, SA and SE cells demonstrate the extent of variability underlying the Ca
2+ signals 
observed at the population level. Of course, these results also raise the possibility that 
the current S-type populations are simply behaving in a different manner to that 
previously observed. An important point to note, however, is that SOC protein 
expression is consistent with the SOCE responses of both the N-type and S-type 
population, as will be discussed in a later chapter (Chapter 5: SOCE machinery). 
 
It is noteworthy that there was a slight decrease in Ca2+ store release in differentiating 
N-type populations whereas in S-type populations, Ca2+ store release was significantly 
increased with differentiation. Previously, Ca2+ store release was unchanged with N-
type and S-type differentiation (N. Bell 2013). The changes observed in this study 
suggest that the capacity of the Ca2+ store may be altered or there might be a change 
in sensitivity to TG with differentiation. Bcl-2 expression has previously been 
associated with changes in Ca2+ store release. Bcl-2 is able to bind to IP3Rs, enhancing 
sensitivity, so that resting levels of InsP3 induced channel opening and thereby 
increased release of Ca2+ from internal stores at rest (Li 2007; Eckenrode 2010). This 
lead to a reduction in TG-stimulated Ca2+ store size and was associated with apoptotic 
resistance (Li 2007; Eckenrode 2010), consistent with the increase in Bcl-2 expression 
(Results 3.3) and reduction in Ca2+ store release in differentiating N-type populations 
observed in this study. Bcl-2 up-regulation with differentiation of N-type populations 
has previously been associated with lability of caffeine-sensitive ER Ca2+ store 
depletion (Riddoch 2007). Bcl-2 expression has also been shown to decrease activity of 
the SERCA pump (Dremina 2004) and increase ER membrane Ca2+ permeability leading 
to a reduction in TG-stimulated Ca2+ store release (Foyouzi-Youssefi 2000; Pinton 
2000). Therefore the increase in Bcl-2 expression in differentiating N-type populations 
may explain the reduced Ca2+ store release observed in this study and down-regulated 
Bcl-2 expression in differentiating S-type populations may explain the increased Ca2+ 
store release observed. Additionally, up-regulation of Bcl-2 expression causes a down-
regulation in SOCE activity in HeLa cells and prostate cancer epithelial cells (Pinton 
2000; Abeele 2002). Bcl-2 expression was up-regulated with differentiation of N-type 
148 
 
populations but slightly down-regulated with differentiation of S-type populations, yet 
SOCE was down-regulated in both cases, suggesting that, potentially, the mechanisms 
underlying the down-regulation of SOCE with differentiation may not be the same in 
N-type and S-type populations. 
 
Within N-type and S-type populations, there are always N-type, S-type and I-type cells 
present, regardless of extent of enrichment (Introduction 1.3 and Methods 2.3), and 
these cells are known to transdifferentiate in culture, both of which are important 
points to consider when examining cell population responses.  A major benefit of 
adopting the single cell imaging technique is that specific Ca2+ responses can by 
identified and attributed to each cell phenotype within a population, therefore the 
Ca2+ responses of the cell phenotypes underlying the population responses were 
extracted and analysed from the previous population data. It was clear that an 
uncoupling of Ca2+ store release and SOCE occurred in all cell types grown within an N-
type or an S-type population yet there were distinct differences in the Ca2+ signalling 
responses and extent of SOCE down-regulation between the two environments.  
 
Within an N-type population, the Ca2+ signalling profile of N-type cells reflect that 
which was observed at overall N-type population level. The extent of Ca2+ store release 
was slightly reduced with differentiation and SOCE was down-regulated by 53%, with 
an increase in SOCE activation and deactivation rate, leading to a dampened and 
shortened SOCE response with differentiation. However, N-type cells within an S-type 
population exhibited Ca2+ store release that was significantly increased by 65% and 
SOCE was down-regulated by 68% with differentiation, reflecting that which was seen 
at the S-type population level. This indicates that N-type Ca2+ signalling responses are 
either influenced by the surrounding cell population or that N-type cells influence the 
population level response, regardless of whether they are the minority phenotype. By 
resolving the responses of the S-type and I-type cells, the explanation for these results 
becomes clearer. 
 
S-type cells grown within both an N-type population and an S-type population 
maintain the same extent of Ca2+ store release with differentiation and SOCE is down-
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regulated by a slighter greater extent in differentiating S-type populations (68%) 
compared to differentiating N-type populations (60%). The rate of SOCE activation is 
unaltered whilst rate of SOCE deactivation is reduced by a greater extent in 
differentiating S-type populations (23%) compared to differentiating N-type 
populations (15%). The S-type cell SOCE response is therefore dampened but 
deactivated at a slower rate with differentiation in both N-type and S-type 
predominant environments. These results indicate that the S-type cell response is not 
greatly influenced by the surrounding cell population like that seen in N-type cells. 
These responses also suggest that the N-type cell response is influenced by the 
surrounding cell population and has driven the increase in Ca2+ store release observed 
at the S-type population level. 
 
I-type cells in an N-type population exhibit significantly increased Ca2+ store release 
(51%) with differentiation with an increase in rate of activation and emptying which is 
different to that seen in both N-type and S-type cells and at the N-type population 
level. SOCE was down-regulated by a greater extent (63%) than that observed at the N-
type population level (54%) and rate of SOCE activation and deactivation were 
increased (by 50% and 40%, respectively) to a greater extent than that of N-type and S-
type cells within a differentiating N-type population, indicating that the I-type SOCE 
response is much faster and shorter with differentiation of N-type populations. In 
contrast, however, I-type cells grown in an S-type predominant environment have no 
change in Ca2+ store release with differentiation and, whilst the extent of SOCE down-
regulation was similar to that in differentiating S-type populations, the extent of the 
increase in rate of SOCE activation was less (32%) and rate of SOCE deactivation was 
reduced (by 22%), indicating a dampened but extended I-type SOCE response in 
differentiating S-type populations. 
 
Taken together, these results indicate that N-type and I-type cells, but not S-type cells, 
exhibit a plasticity in their Ca2+ signal responses with differentiation that is influenced 
by the predominant cell phenotype in the surrounding environment. Given that 
spontaneous transdifferentiation occurs in these cells in culture (Biedler 1975; Ross 
1983; Ciccarone 1989), this Ca2+ signal plasticity may be indicative of events associated 
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with phenotypic interconversion that are induced by the surrounding predominant cell 
phenotype. This conclusion is in line with the speculation that I-type cells represent a 
stem cell population within SH-SY5Y cell line (Ciccarone 1989; Ross 1995) and 
therefore may be more flexible in changing their differentiation response according to 
environmental influence. The dependency of phenotype-specific differentiation 
responses on the surrounding cellular environment may represent an intrinsic change 
in a particular phenotypic behaviour to cause it to differentiate towards the phenotype 
of the predominant cell type. This could be caused by factors released extracellularly 
by the predominant phenotype or through local cell-cell interactions and influences.  
 
The S-phenotype consists of three sub-phenotypes (SO, SA and SE) that may be 
indicative of S-type sub-populations (Chapter 1: Introduction). The Ca2+ responses of 
these sub-phenotypes were therefore extracted and analysed from the previous N-
type and S-type population data. Within an S-type population, the overall S-type cell 
response with differentiation involves no change in extent or rate of Ca2+ store release 
and a down-regulation of SOCE by 68%, with a 23% decrease in deactivation rate but 
no change in SOCE activation rate. There were subtle differences in rates of activation 
and deactivation of Ca2+ store release and SOCE in SO, SA and SE cells, however the 
overall maintenance of Ca2+ store release extents SOCE down-regulation were similar 
in all three sub-phenotypes and reflected that seen in S-type compartment of the S-
type population response, with SA cells exhibiting a greater extent of SOCE down-
regulation (73%). The extent of change in the S-type cell differentiation response is 
similar when grown in N-type populations, however, the underlying SO SA and SE cells 
exhibit more variability in their responses. Specifically, SA cells and SE show a reduction 
in Ca2+ store release (by 22% and 42%, respectively) whilst SO show a 17% increase, 
driving the overall response to exhibit unchanged Ca2+ store release with 
differentiation. All three sub-phenotypes exhibit SOCE down-regulation but the SA cells 
exhibit the least extent of down-regulation (53%) in a differentiating N-type population 
in contrast to that seen in S-type populations. Also, SE cells show a considerable 
decrease in rate of SOCE deactivation compared to SO and SA cells. This shows that S-
type cells also exhibit plasticity in their Ca2+ signal response with differentiation 
dependent on the environment in which they are grown and that this plasticity is 
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masked when considering the overall S-type compartment. S-type sub-populations 
grown within N-type predominant environments also exhibit more variability in their 
responses. Collectively, these results further highlight the variability in Ca2+ signal 
responses underlying those seen at the population level, and may therefore explain 
the differing observations from S-type populations in Bell et al (2013), and reinforce 
the notion that the surrounding cell environment can affect the differentiation 
response of minority phenotypes. 
 
The possibility that the predominant cell phenotype in a population could release 
factors extracellularly that can influence the differentiation response of minority 
phenotypes was therefore investigated through experiments involving media from 
proliferating and differentiating S-type populations being applied to N-type 
populations whilst media from proliferating or differentiating N-type populations was 
applied to S-type populations.  
 
In N-type populations, uncoupling of store release and SOCE occurred with 
differentiation, confirming previous findings (Results 4.2). Proliferating S-type media 
partly maintained the proliferating N-type response whilst applying differentiating S-
type media to proliferating N-type populations induced a response similar to that of 
differentiating N-type populations. Differentiating N-type populations alongside 
application of differentiating S-type media resulted in a dampened differentiating 
response and dampened the effect of just applying differentiating S-type media. 
 
In S-type populations, uncoupling of store release and SOCE occurred with 
differentiation, confirming previous findings (Results 4.2). Both proliferating N-type 
media and differentiating N-type media induced a dampened differentiating response 
in proliferating S-type, although SOCE down-regulation occurred to a lesser extent 
than what was observed in differentiating S-type populations. Differentiating S-type 
populations alongside application of differentiating N-type media did not induce a fully 
differentiating response but brought the cells closer to a differentiating response than 
that seen with just differentiating N-type media application. 
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Taken together, these results confirm that there is an effect of media application on 
the Ca2+ response of the other phenotype, suggesting that the predominant phenotype 
within the cell environment may be releasing factors that can influence the Ca2+ 
responses associated with differentiation and, potentially, transdifferentiation.  
 
It is currently unclear whether the down-regulation of SOCE in all differentiating 
environments is caused by partial SOCE down-regulation and reduced function in all 
differentiating cells or if differentiating cells fully suppress their SOCE response and the 
observed SOCE that remains is caused by proliferating cell that are unresponsive to the 
differentiating agent. Although out of the scope of this study, this can now be 
investigated in our laboratory through re-analysis of the single cell data that has been 
collected, by pairing of individual cell SOCE responses with the extent of N-type cell 
neurite outgrowth or S-type cell diameter as morphological markers of differentiation 
(Final Discussion 7.2). 
 
A likely explanation for the down-regulation of SOCE observed here is a change in 
expression or function of, or a lack of, SOCE machinery components. It was previously 
observed that N-type differentiation-induced down-regulation of SOCE is accompanied 
by reduced expression of both the Ca2+ sensing protein, STIM1 and the CRAC channel 
protein Orai1, both of which were expressed in proliferating N-type cells with a robust 
SOCE response (N. Bell 2013). It was also shown that both proliferating and 
differentiating S-type cells expressed STIM1 and Orai1 alongside a robust SOCE 
response (N. Bell 2013). To confirm that the differentiation-associated SOCE down-
regulation observed in this study could be attributed to a potential alteration in Orai1, 
the effect of treatment with the CRAC inhibitor BTP2 was investigated (Appendix I). 
Treatment of proliferating N-type populations with varying concentrations (100 nM – 
20 µM) of BTP2 for 24 hours induced a drastically significant down-regulation of SOCE 
activity, confirming that the SOCE-downregulation observed here could in fact be due 
to potential dampening of Orai1 function (Appendix). The expression and localisation 
of the SOCE-associated proteins STIM1 and Orai1 has therefore been investigated 
further in this study (Chapter 5: SOCE machinery and Chapter 6: Differentiation time-
course).   
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Additionally, RNAseq analysis was performed in proliferating and differentiating N-type 
populations under a collaboration with Professor Caroline Austin and Lauren Harkin. 
The preliminary data for overall gene expression, genes of interest that include 
markers discussed in chapter 3 and those associated with Ca2+ signalling and the SOCE 
response discussed in this chapter and chapter 5 as well as calcium signalling pathway 
analysis are presented in Appendix II. 
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Chapter 5: SOCE machinery 
Chapter 5 -Introduction 
The proteins STIM1, Orai1 and TRPC1 have been shown to be involved in SOCE 
(Introduction). Dampened SOCE activity was associated with differentiation of N-type 
and S-type populations in this study (Chapter 4) therefore this chapter aimed to 
investigate the expression of SOCE associated proteins in the 9cRA-induced 
differentiation response. 
 
All experiments in this chapter were performed on N-type or S-type populations that 
had been treated for 7 days with 1 µM 9cRA (differentiating) or an equivalent volume 
of EtOH as a control (proliferating). Proliferating N-type and S-type populations will be 
referred to as PN and PS, respectively, whilst differentiating N-type and S-type 
populations will be referred to as DN and DS, respectively. 
 
Chapter 5 – Results 
5.1 Expression of three key SOCE proteins; STIM1, Orai1 and TRPC1, is altered with 
differentiation of N-type and S-type populations 
The Ca2+ sensing protein STIM1 alters gating of SOCs at the PM to induce Ca2+ entry 
and replenish depleted ER Ca2+ stores (Hoover 2011; Sauc 2015). STIM1 was expressed 
by both proliferating and differentiating N-type and S-type populations (Figure 5.1.1A). 
Expression of STIM1 was 36% higher in PS populations than PN populations (P=0.045, 
Figure 5.1.1B). Overall STIM1 expression was down-regulated by 18% in DN populations 
and DS populations compared to PN and PS populations but quantitatively, this was not 
significant (P=0.211 and P=0.232, respectively, Figure 5.1.1B). However, two scenarios 
of STIM1 expression were observed in DN and DS populations. In some cases, there was 
a down-regulation of STIM1 expression (Figure 5.1.1Ai) and in others, STIM1 was 
expressed at a slightly higher molecular weight, as detected by a slight upward band 
shift (Figure 5.1.1Aii). This shift in molecular weight could be indicative of the presence 
of a different isoform of STIM1 or of phosphorylation events or some other post-
translational modification that could alter STIM1 function. Both scenarios could 
contribute to the dampened SOCE activity observed in DN and DS populations and 
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indicate that STIM1 is involved in SOCE in N-type and S-type populations. Occasionally, 
STIM1 expression could be observed as a double band (Figure 5.1.1Aiii), though this 
was not always present and could not be associated solely with proliferation or 
differentiation or with either either phenotype. This further indicates that STIM1 may 
exist in multiple states that could affect its function and thereby SOCE activity. 
 
Orai1 is a PM protein that forms the SOC channel pore and is gated by STIM1 for SOCE 
regulation (Demuro 2011; Hoover 2011; Mignen 2008). Orai1 was expressed by both 
proliferating and differentiating N-type and S-type populations (Figure 5.1.2A) and was 
significantly down-regulated by 44% in DN populations compared to PN populations 
(P=0.037) and by 69% in DS populations compared to PS populations (P=0.003, Figure 
5.1.2B). This down-regulation would likely contribute to the dampened SOCE observed 
in DN and DS populations. The extent of SOCE down-regulation was 54% in N-type 
populations and 66% in S-type populations (Section 4.2), which is consistent with the 
extent of Orai1 down-regulation and indicates that Orai1 is involved in SOCE in N-type 
and S-type populations. Orai1 expression was 26% lower in PS populations than PN 
populations (P=0.252) which may, at least in part, explain the lower Ca2+ permeability 
found in S-type predominant populations (Results 4.2).   
 
TRPC1 channels are Ca2+ permeable and, through STIM1 interactions, may function as 
a SOCs (Alicia 2008; Jardin 2008; Yuan 2007). TRPC1 was expressed in both 
proliferating and differentiating N-type and S-type populations but there was no 
significant difference in TRPC1 expression between PN and PS populations (P=0.823, 
Figure 5.1.3A and B). TRPC1 was down-regulated by 36% in DN populations compared 
to PN populations (P=0.451) and by 27% in DS populations compared to PS populations 
(P=0.702) though non-significantly (Figure 5.1.3B). TRPC1 expression was however, 
highly variable and unfortunately, the TRPC1 antibody was unreliable. 
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Figure 5.1.1. STIM1 expression is down-regulated or modified with differentiation of 
N-type and S-type populations 
Western blots were performed on protein samples from N-type and S-type 
populations that were treated for 7 days with 1 µM 9cRA (DN and DS respectively, 
differentiating) or an equivalent volume of EtOH (PN and PS respectively, proliferating). 
Blots were probed with anti-STIM1 antibody which detected a band at 84 kDa and β-
actin antibody which was used as a loading control and detected a band at 42 kDa. 
Quantitative band measurements were performed using densitometry in ImageJ. (A) 
STIM1 was expressed in both proliferating and differentiating N-type and S-type 
populations. STIM1 expression was (A.i) down-regulated in some DN and DS 
populations compared to PN and PS populations or (A.ii) was expressed at a slightly 
higher molecular weight isoform in other DN and DS populations compared to PN and PS 
populations. (A.iii) STIM1 expression was occasionally observed as a double band 
though this was not associated solely with differentiation or phenotype. (B) STIM1 
expression was down-regulated by 18% in DN populations and DS populations 
compared to PN and PS populations, but this was not significant (P=0.211 and P=0.232, 
respectively). STIM1 expression was 36.16% higher in PS populations compared to PN 
populations (P=0.045*). For N-type populations N=14, for S-type populations N=12. 
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Figure 5.1.2 Orai1 expression is down-regulated with differentiation of N-type and S-
type populations 
Western blots were performed on protein samples from N-type and S-type 
populations that were treated for 7 days with 1 µM 9cRA (DN and DS respectively, 
differentiating) or an equivalent volume of EtOH (PN and PS respectively, proliferating). 
Blots were probed with anti-Orai1 antibody which detected a band at 50 kDa and β-
actin antibody which was used as a loading control and detected a band at 42 kDa. 
Quantitative band measurements were performed using densitometry in ImageJ. (A) 
Orai1 was expressed in both proliferating and differentiating N-type and S-type 
populations. Orai1 band intensity was reduced in DN and DS populations compared to 
PN and PS populations. (B) Orai1 expression was significantly down-regulated by 
43.50% in DN populations compared to PN populations (P=0.037*) and by 68.90% in DS 
populations compared to PS populations (P=0.003**). Orai1 expression was 25.84% 
higher in PN populations than PS populations, though this was not significant (P=0.252). 
For N-type populations N=7, for S-type populations N=4. 
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Figure 5.1.3 TRPC1 expression is variable with differentiation of N-type and S-type 
populations 
Western blots were performed on protein samples from N-type and S-type 
populations that were treated for 7 days with 1 µM 9cRA (DN and DS respectively, 
differentiating) or an equivalent volume of EtOH (PN and PS respectively, proliferating). 
Blots were probed with anti-TRPC1 antibody which detected a band at 90 kDa and β-
actin antibody which was used as a loading control and detected a band at 42 kDa. 
Quantitative band measurements were performed using densitometry in ImageJ. (A) 
TRPC1 was expressed in both proliferating and differentiating N-type and S-type 
populations. (B) TRPC1 expression was down-regulated, although not significantly, by 
35.92% in DN populations compared to PN populations (P=0.451) and by 26.96% in DS 
populations compared to PS populations (P=0.702). There was no significant difference 
in the level of TRPC1 expression between PN and PS populations (P=0.823). For N-type 
populations N=3, for S-type populations N=2. 
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5.2. Localisation of STIM1 and Orai1 is altered with differentiation of N-type and S-
type populations 
Since the expression of STIM1 and Orai1 were altered with differentiation of N-type 
and S-type populations, localisation of these SOCE proteins in the differentiation 
response were investigated.  
 
There was widespread expression of STIM1 throughout the cytoplasm and neurites of 
PN cells and there was evidence of localisation into foci (Figure 5.2.1A). There was a 
similar expression pattern in DN cells although there appeared to be an increased 
occurrence of STIM1 clustering (Figure 5.2.1B). STIM1 was present throughout PS cells 
and DS cells, with no apparent areas of clustering, however there were clear examples 
of DS cells with an accumulation of STIM1 at the cell membrane (Figure 5.2.1C and D). 
There was no obvious change in the overall intensity of fluorescence of STIM1 
between proliferating and differentiating cells, consistent with the extent of 
expression (Results 5.1). Clearly, these changes in localisation of STIM1 with 
differentiation of N-type and S-type populations may affect STIM1 function and its 
ability to contribute to SOCE activity. 
 
Orai1 was expressed throughout the cytoplasm and neurites of PN and DN cells and 
formed foci in PN cells and, seemingly less frequently, in DN cells (Figure 5.2.2A and B). 
There was diffuse expression of Orai1 in PS and DS cells and Orai1 formed foci in PS cells 
that were more dispersed and granular in DS cells (Figure 5.2.2C and D). Although 
these changes in Orai1 localisation with differentiation are subtle, they may affect the 
extent of SOCE activity. 
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Figure 5.2.1. STIM1 expression is diffuse in proliferating N-type and S-type cells and 
localises into clusters in differentiating N-type cells and at the membrane of S-type 
cells 
N-type and S-type populations were treated for 7 days with 1 µM 9cRA (DN and DS, 
respectively) or an equivalent volume of EtOH (PN and PS, respectively) and cells were 
stained with anti-STIM1 primary antibody followed by FITC-conjugated secondary 
antibody. Images were captured using laser scanning confocal microscopy. (A) In PN 
cells, STIM1 was present throughout the cell and neurite like processes and there were 
some examples of localisation into foci (white arrows) and in (B) DN cells there 
appeared to be a higher occurrence of STIM1 clustering (white arrows). (C) In PS cells, 
STIM1 was present throughout the cell, with no apparent areas of clustering and in (D) 
DS cells STIM1 was present throughout the cell however, there were clear examples of 
cells that expressed higher levels of STIM1 at the cell membrane (dashed arrows). 
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Scale bars represent 20 µm. Images are representative of >20 images and taken using a 
x63 objective. N=5.  
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Figure 5.2.2. Orai1 localisation is altered with differentiation of N-type and S-type 
cells 
N-type and S-type populations were treated for 7 days with 1 µM 9cRA (DN and DS, 
respectively) or an equivalent volume of EtOH (PN and PS, respectively) and cells were 
stained with anti-Orai1 primary antibody followed by TRITC-conjugated secondary 
antibody. Images were captured using laser scanning confocal microscopy. (A) In PN 
cells, Orai1 was present throughout the cell and there were some examples of 
localisation into foci (white arrows) and in (B) DN cells there appeared to be a less 
occurrence of Orai1 clustering (white arrows). (C) In PS cells, there was some 
localisation of Orai1 into clusters arranged close to the cell nucleus (white arrows) and 
in (D) DS cells some Orai1 clustering was present but this appeared more dispersed 
(white arrow) than in proliferating S-type cells. Some cells were observed to have an 
accumulation of Orai1 at the cell membrane (dashed arrow). Scale bars represent 20 
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µm. Images are representative of >20 confocal images and taken using a x63 objective. 
N=5.  
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5.3. Localisation of STIM1 is altered following Ca
2+
 store depletion and SOCE in N-
type cells but not S-type cells 
STIM1 localisation was altered with differentiation of N-type and S-type cells (Results 
5.2). Given the role of STIM1 in regulating SOCE, that SOCE activity was dampened in 
differentiating N-type and S-type cells (Results 4.2) and that expression as well as 
localisation of STIM1 were altered with differentiation of N-type and S-type cells, 
localisation of STIM1 over the Ca2+-addback time-course was investigated. 
 
 
At a resting state, there was widespread expression of STIM1 throughout the 
cytoplasm and neurites of PN cells and there was evidence of localisation into foci 
(Figure 5.3.1A). Following TG exposure there was a similar distribution of STIM1 
expression and occurrence of STIM1 clustering (Figure 5.3.1B and C) whilst upon Ca2+-
addback, STIM1 expression became more diffuse, with minimal clustering (Figure 5.3.1 
D and E), indicating that there may be a redistribution of STIM1 following SOCE and 
Ca2+ store replenishment. In DN cells at rest, STIM1 was expressed throughout the cell 
and neurites and there were many examples of STIM1 clustering (Figure 5.3.2A). 
Following TG exposure and Ca2+-addback, there was a similar occurrence of STIM1 
clustering (Figure 5.3.2B-E), suggesting that differentiation of N-type cells may prevent 
STIM1 redistribution following Ca2+ store replenishment. 
 
At rest, STIM1 was expressed diffusely throughout PS cells (Figure 5.3.3A). Following TG 
exposure and Ca2+-addback, there was a similar diffuse expression of STIM1 with some 
evidence of STIM1 localisation at the cell membrane, though this was minimal (Figure 
5.3.3B-E). In DS cells, STIM1 was present throughout the cell and there were examples 
STIM1 accumulation at the membrane that remained following TG and CaCl2 exposure 
(Figure 5.3.4). These results indicate that the distribution of STIM1 is not altered during 
Ca2+ store release and SOCE in S-type cells.  
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Figure 5.3.1. STIM1 becomes more diffuse in proliferating N-type cells over the Ca
2+
 
add-back time-course 
Proliferating N-type populations (PN, EtOH treated for 7 days) were exposed to 200 nM 
thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by exposure to 2 
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mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various time-points 
throughout and stained with anti-STIM1 primary antibody followed by FITC-conjugated 
secondary antibody. Images were captured using laser scanning confocal microscopy. 
(A) In PN cells, STIM1 was present throughout the cell and there were some examples 
of localisation into foci (white arrows). Following TG exposure for (B) 5 minutes and (C) 
15 minutes, there was a similar occurrence of STIM1 clustering (white arrows). 
Following CaCl2 exposure for (D) 2 minutes and (E) 20 mins, STIM1 expression became 
more diffuse, with minimal clustering (white arrows). Scale bars represent 20 µm. 
Images are representative of >15 images and taken using a x63 objective. N=3. 
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Figure 5.3.2. STIM1 is localised into clusters in differentiating N-type cells throughout 
the Ca
2+
 add-back time-course 
Differentiating N-type populations (DN, 1 µM 9cRA treated for 7 days) were exposed to 
200 nM thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by 
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exposure to 2 mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various 
time-points throughout and stained with anti-STIM1 primary antibody followed by 
FITC-conjugated secondary antibody. Images were captured using laser scanning 
confocal microscopy. (A) In DN cells, STIM1 was present throughout the cell and there 
were many examples STIM1 clustering (white arrows). Following TG exposure for (B) 5 
minutes and (C) 15 minutes, there was a similar occurrence of STIM1 clustering (white 
arrows). Following CaCl2 exposure for (D) 2 minutes and (E) 20 mins, there was a 
similar occurrence of STIM1 clustering (white arrows). Scale bars represent 20 µm. 
Images are representative of >15 images and taken using a x63 objective. N=3. 
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Figure 5.3.3. STIM1 localisation is relatively unchanged in proliferating S-type cells 
over the Ca
2+
 add-back time-course 
Proliferating S-type populations (PS, EtOH treated for 7 days) were exposed to 200 nM 
thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by exposure to 2 
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mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various time-points 
throughout and stained with anti-STIM1 primary antibody followed by FITC-conjugated 
secondary antibody. Images were captured using laser scanning confocal microscopy. 
(A) In PS cells, STIM1 was present throughout the cell. Following TG exposure for (B) 5 
minutes and (C) 15 minutes, there was a similar diffuse expression of STIM1 with a few 
examples STIM1 localisation at the cell membrane (white arrow). Following CaCl2 
exposure for (D) 2 minutes and (E) 20 mins, there was a similar diffuse pattern of 
STIM1 expression. Scale bars represent 20 µm. Images are representative of >15 
images and taken using a x63 objective. N=3. 
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Figure 5.3.4. STIM1 expression is relatively unchanged in differentiating S-type cells 
over the Ca
2+
 add-back time-course 
Differentiating S-type populations (DS, 1 µM 9cRA treated for 7 days) were exposed to 
200 nM thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by 
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exposure to 2 mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various 
time-points throughout and stained with anti-STIM1 primary antibody followed by 
FITC-conjugated secondary antibody. Images were captured using laser scanning 
confocal microscopy. (A) In DS cells, STIM1 was present throughout the cell and there 
were examples STIM1 accumulation at the membrane (white arrows). Following TG 
exposure for (B) 5 minutes and (C) 15 minutes, there was a similar extent of diffuse 
STIM1 expression with some examples of accumulation at the membrane that 
remained following CaCl2 exposure for (D) 2 minutes and (E) 20 mins (white arrows). 
Scale bars represent 20 µm. Images are representative of >15 images and taken using a 
x63 objective. N=3. 
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5.4. Localisation of Orai1 is not altered following Ca
2+
 store depletion and SOCE in N-
type and S-type cells 
Orai1 localisation was altered with differentiation of N-type and S-type cells (Results 
5.2). Given the role of Orai1 as a SOC channel, that SOCE activity was dampened in 
differentiating N-type and S-type cells (Results 4.2) and that expression as well as 
localisation of Orai1 were altered with differentiation of N-type and S-type cells, 
localisation of STIM1 over the Ca2+-addback time-course was investigated. 
 
In PN cells at rest, Orai1 was expressed throughout the cell and there were some 
examples of localisation into foci, which remained following TG exposure and Ca2+-
addback (Figure 5.4.1). In resting DN cells, Orai1 was expressed throughout the cell 
with minimal examples of Orai1 foci and this expression pattern remained following TG 
exposure and Ca2+-addback (Figure 5.4.2). This suggests that there is no detectable 
redistribution of Orai1 with Ca2+ store release or SOCE in N-type cells. 
 
In resting PS cells, Orai1 was expressed throughout the cell and the majority of cells 
exhibited localisation into foci whilst cells with a more flattened morphology could be 
observed that exhibited dispersed clusters of Orai1 (Figure 5.4.3A). This expression 
pattern for Orai1 remained the same following TG exposure and Ca2+-addback (Figure 
5.4.3B-E). In DS cells at rest, Orai1 was expressed throughout the cell and there were 
examples of localisation into dispersed clusters and accumulation of Orai1 at the cell 
membrane (Figure 5.4.4A). This expression pattern remained similar following TG 
exposure and Ca2+-addback (Figure 5.4.4B-E). These results indicate that there is no 
detectable redistribution of Orai1 with Ca2+ store release or SOCE in N-type cells. 
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Figure 5.4.1. Orai1 localisation is not altered in proliferating N-type cells over the 
Ca
2+
 add-back time-course 
Proliferating N-type populations (PN, EtOH treated for 7 days) were exposed to 200 nM 
thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by exposure to  
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2 mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various time-points 
throughout and stained with anti-Orai1 primary antibody followed by TRITC-
conjugated secondary antibody. Images were captured using laser scanning confocal 
microscopy. (A) In PN cells, Orai1 was expressed throughout the cell and there were 
some examples of localisation into foci (white arrows). S-type cells could be observed 
with similar Orai1 localisation to N-type cells (dashed arrows). This expression pattern 
remained following TG exposure for (B) 5 minutes and (C) 15 minutes and following 
CaCl2 exposure for (D) 2 minutes and (E) 20 mins. Scale bars represent 20 µm. Images 
are representative of >15 images and taken using a x63 objective. N=3. 
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Figure 5.4.2 Orai1 localisation is not altered in differentiating N-type cells over the 
Ca
2+
 add-back time-course 
Differentiating N-type populations (DN, 1 µM treated for 7 days) were exposed to 200 
nM thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by exposure 
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to 2 mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various time-points 
throughout and stained with anti-Orai1 primary antibody followed by TRITC-
conjugated secondary antibody. Images were captured using laser scanning confocal 
microscopy. (A) In DN cells, Orai1 was expressed throughout the cell. S-type cells could 
be observed with dispersed clusters of Orai1 (dashed arrows). This expression pattern 
remained following TG exposure for (B) 5 minutes and (C) 15 minutes and following 
CaCl2 exposure for (D) 2 minutes and (E) 20 mins. Scale bars represent 20 µm. Images 
are representative of >15 images and taken using a x63 objective. N=3. 
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Figure 5.4.3. Orai1 localisation is not altered in proliferating S-type cells over the Ca
2+
 
add-back time-course 
Proliferating S-type populations (PS, EtOH treated for 7 days) were exposed to 200 nM 
thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by exposure to 2 
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mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various time-points 
throughout and stained with anti-Orai1 primary antibody followed by TRITC-
conjugated secondary antibody. Images were captured using laser scanning confocal 
microscopy. (A) In PS cells, Orai1 was expressed throughout the cell and there were 
some examples of localisation into foci (white arrows). S-type cells with a more 
flattened morphology could be observed that exhibited dispersed clusters of Orai1 
(dashed arrows) This expression pattern remained following TG exposure for (B) 5 
minutes and (C) 15 minutes and following CaCl2 exposure for (D) 2 minutes and (E) 20 
mins. Scale bars represent 20 µm. Images are representative of >15 images and taken 
using a x63 objective. N=3. 
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Figure 5.4.4 Orai1 localisation is not altered in differentiating S-type cells over the 
Ca
2+
 add-back time-course 
Differentiating S-type populations (DS, 1 µM 9cRA treated for 7 days) were exposed to 
200 nM thapsigargin (TG) for 15 minutes to induce Ca2+ store release followed by 
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exposure to 2 mM CaCl2 for 20 minutes to induce SOCE. Cells were fixed at various 
time-points throughout and stained with anti-Orai1 primary antibody followed by 
TRITC-conjugated secondary antibody. Images were captured using laser scanning 
confocal microscopy. (A) In DS cells, Orai1 was expressed throughout the cell and there 
were examples of localisation into dispersed clusters (dashed arrows) and 
accumulation at the cell membrane (white arrows). This expression pattern remained 
following TG exposure for (B) 5 minutes and (C) 15 minutes and following CaCl2 
exposure for (D) 2 minutes and (E) 20 mins. Scale bars represent 20 µm. Images are 
representative of >15 images and taken using a x63 objective. N=3. 
 
 
 
 
 
 
 
 
 
 
  
182 
 
5.5. Conditioned media from proliferating and differentiating N-type and S-type 
populations alters the expression of STIM1 and Orai1 
There was an uncoupling of SOCE with differentiation of N-type and S-type populations 
(Results 4.2). Conditioned media from S-type populations affected SOCE activity of N-
type populations and conditioned media from N-type populations affected SOCE 
activity of S-type populations (Results 4.5). Media from PS populations did not alter the 
PN population SOCE response whilst media from DS populations induced down-
regulation of SOCE in PN populations. Media from DS populations dampened the SOCE 
down-regulation observed in DN populations. In PS populations, media from PN and DN 
populations induced partial down-regulation of SOCE whilst media from DN 
populations also dampened the extent of SOCE down-regulation seen in DS 
populations. Given the effect of conditioned media on SOCE activity and the 
involvement of STIM1 and Orai1 in SOCE, the expression of STIM1 and Orai1 in cells 
grown in a conditioned media environment was investigated. 
 
N-type populations were treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA 
(DN, differentiating), media from proliferating S-type populations (PN+PS), media from 
differentiating S-type populations (PN+DS) or with 1 µM 9cRA plus media from 
differentiating S-type populations (DN+DS). There was no significant difference in the 
level of expression of STIM1 between PN and DN populations (P=0.999) however there 
was a slight increase in molecular weight of STIM1 in DN populations (Figure 5.5.1). 
This is consistent with previously observed STIM1 expression in N-type populations 
(Results 5.1) and involvement of STIM1 in SOCE since SOCE was down-regulated in DN 
populations (Results 4.2 and 4.5). There was a ~40% increase in STIM1 expression in 
PN+PS populations compared to PN cells (Figure 5.5.1), although this was not significant 
(P=0.384), consistent with the previous finding that SOCE activity in PN populations was 
not affected by PS conditioned media (Results 4.5). There was no significant difference 
in the level of expression of STIM1 between PN and PN+DS populations (P=0.275) and 
no change in STIM1 molecular weight (Figure 5.5.1), therefore the previously observed 
down-regulation of SOCE induced in PN populations by DS conditioned media (Results 
4.5) is not attributed to a change in STIM1 expression. There was a ~40% increase in 
STIM1 expression in DN+DS populations compared to PN populations, but this was not 
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significant (P=0.300), however there was a slight increase in STIM1 molecular weight, 
similar to that of DN populations (Figure 5.5.1). This is consistent with the previous 
finding that SOCE activity was down-regulated in DN populations treated with DS 
conditioned media (Results 4.5) and a role for STIM1 in SOCE in N-type populations. 
There was a 51% increase in STIM1 expression in DN+DS populations compared to DN 
populations, although this was not significant (P=0.214) but given that there was a 
similar increase in STIM1 molecular weight (Figure 5.5.1), this is consistent with the 
previous finding that there was no difference in SOCE activity between DN+DS 
populations and DN populations (Results 4.5). 
 
There was a slight but non-significant 9% decrease in Orai1 expression in DN compared 
to PN populations (P>0.999, Figure 5.5.2) whilst Orai1 expression and SOCE was 
previously observed to be significantly down-regulated in DN populations (Results 4.2, 
4.5 and 5.1). There was a ~150% increase in Orai1 expression in PN+PS populations 
compared to PN cells (Figure 5.5.2), although this was not significant (P=0.333), 
consistent with the previous finding that SOCE activity in PN populations was not 
down-regulated by PS conditioned media (Results 4.5). There was a slight but non-
significant 9% decrease in the level of expression of Orai1 in PN+DS compared to PN 
populations (P>0.999, Figure 5.5.2), therefore the previously observed down-
regulation of SOCE induced in PN populations by DS conditioned media (Results 4.5) 
may not be attributed to a change in Orai1 expression. There was a 32% decrease in 
Orai1 expression in DN+DS populations compared to PN populations, but this was not 
significant (P=0.989, Figure 5.5.2), however this is consistent with the previous finding 
that SOCE activity was down-regulated in DN populations treated with DS conditioned 
media (Results 4.5) and a role for Orai1 in SOCE in N-type populations. There was a 
26% decrease in Orai1 expression in DN+DS populations compared to DN populations, 
although this was not significant (P=0.997, Figure 5.5.2), yet there was no difference in 
SOCE activity between DN+DS populations and DN populations (Results 4.5) indicating 
that a decrease in Orai1 expression did not induce further SOCE down-regulation. 
 
S-type populations were treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA 
(DS, differentiating), media from proliferating N-type populations (PS+PN), media from 
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differentiating N-type populations (PS+DN) or with 1 µM 9cRA plus media from 
differentiating N-type populations (DS+DN). The level of expression of STIM1 was down-
regulated by 40% in DS populations compared to PS populations, although 
quantitatively this was not significant (P=0.459), and there was a slight increase in 
STIM1 molecular weight (Figure 5.5.3). This is consistent with previously observed 
STIM1 expression in S-type populations (Results 5.1) and involvement of STIM1 in 
SOCE since SOCE was down-regulated in DS populations (Results 4.2 and 4.5). STIM1 
expression was up-regulated by 38% in PS+PN populations compared to PS populations 
(Figure 5.5.3), but non-significantly (P=0.499), therefore the previously observed 
down-regulation of SOCE induced in PS populations by PN conditioned media (Results 
4.5) is not attributed to a change in STIM1 expression. There was no significant 
difference in the level of STIM1 expression in PS+DN populations and DS+DN populations 
compared to PS populations (P=0.989 and P=0.829, respectively) however, an increase 
in the molecular weight was observed in both PS+DN populations and DS+DN 
populations (Figure 5.5.3). This is consistent with the previous finding that SOCE 
activity is down-regulated in PS and DS populations treated with DN conditioned media 
(Results 4.5) and a role for STIM1 in SOCE in S-type populations. STIM1 expression in 
DS+DN populations was up-regulated by 28%, although not significantly, compared to 
DS populations (P=0.930, Figure 5.5.3) consistent with a slight increase in SOCE activity 
(Results 4.5). 
 
The level of expression of Orai1 was down-regulated by 39% in DS populations 
compared to PS populations, although quantitatively this was not significant (P=0.583, 
Figure 5.5.4). This is consistent with previously observed Orai1 expression in S-type 
populations (Results 5.1) and involvement of Orai1 in SOCE since SOCE was down-
regulated in DS populations (Results 4.2 and 4.5). Orai1 expression was up-regulated by 
60% in PS+PN populations compared to PS populations (Figure 5.5.4), but non-
significantly (P=0.258), therefore the previously observed down-regulation of SOCE 
induced in PS populations by PN conditioned media (Results 4.5) is not attributed to a 
decrease in Orai1 expression. There was a 41% decrease in Orai1 expression in PS+DN 
compared to PS populations (Figure 5.5.4) but this was not significant (P=0.537). This is 
consistent with the previous finding that SOCE activity is down-regulated in PS 
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populations treated with DN conditioned media (Results 4.5) and a role for Orai1 in 
SOCE in S-type populations. There was no significant change in Orai1 expression in 
DS+DN populations compared to PS populations (P>0.999, Figure 5.5.4), which indicates 
that the previous finding of SOCE down-regulation in DS populations treated with DN 
conditioned media (Results 4.5) is not attributed to a change in Orai1 expression. Orai1 
expression in DS+DN populations was up-regulated by 61%, although not significantly, 
compared to DS populations (P=0.606, Figure 5.5.4) consistent with the apparent slight 
increase in SOCE activity (Results 4.5). 
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Figure 5.5.1. S-type conditioned media alters STIM1 expression in proliferating and 
differentiating N-type populations 
Western blots were performed on protein samples from N-type populations that were 
treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA (DN, differentiating), media 
from proliferating S-type populations (PN+PS), media from differentiating S-type 
populations (PN+DS) or with 1 µM 9cRA plus media from differentiating S-type 
populations (DN+DS). Blots were probed with anti-STIM1 antibody which detected a 
band at 84 kDa and β-actin antibody which was used as a loading control and detected 
a band at 42 kDa. Quantitative band measurements were performed using 
densitometry in ImageJ. (A) All cell conditions expressed STIM1. There was reduced 
band intensity and a slight increase in molecular weight in DN cells compared to PN 
populations. Band intensity of PN+PS, PN+DS and DN+DS populations was similar to that 
of PN populations. There was a slight band shift in DN+DS populations, similar to that of 
DN cells. (B) There was no significant effect of growth condition on the level of STIM1 
expression (P=0.115). There was no significant difference in the level of expression of 
STIM1 between PN and DN populations (P=0.999) or PN+DS populations (P=0.275). 
There was a ~40% increase in STIM1 expression in PN+PS populations and DN+DS 
populations compared to PN populations, but this was not significant (P=0.384 and 
P=0.300, respectively). There was a 51.53% increase in STIM1 expression in DN+DS 
populations compared to DN populations, but this was not significant (P=0.214). N=2. 
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Figure 5.5.2. S-type conditioned media alters Orai1 expression in proliferating and 
differentiating N-type populations 
Western blots were performed on protein samples from N-type populations that were 
treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA (DN, differentiating), media 
from proliferating S-type populations (PN+PS), media from differentiating S-type 
populations (PN+DS) or with 1 µM 9cRA plus media from differentiating S-type 
populations (DN+DS). Blots were probed with anti-Orai1 antibody which detected a 
band at 50 kDa and β-actin antibody which was used as a loading control and detected 
a band at 42 kDa. Quantitative band measurements were performed using 
densitometry in ImageJ. (A) All cell conditions expressed Orai1. There was an apparent 
reduced band intensity in DN, PN+DS, and DN+DS populations compared to PN 
populations. (B) There was no significant effect of growth condition on the level of 
Orai1 expression (P>0.999). Orai1 expression was down-regulated by 8.89% in DN 
compared to PN populations but this was not significant (P>0.999). There was a non-
significant ~152% increase in Orai1 expression in PN+PS populations compared to PN 
populations (P=0.333). There was a non-significant 9.22% increase in Orai1 expression 
in PN+DS compared to PN populations (P>0.999). Orai1 expression was down-regulated 
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by 32.09% in DN+DS compared to PS populations and by 25.47% in DN+DS populations 
compared to DN populations, but this was not significant (P=989 and P=0.997, 
respectively). N=2. 
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Figure 5.5.3. N-type conditioned media alters STIM1 expression in proliferating and 
differentiating S-type populations 
Western blots were performed on protein samples from S-type populations that were 
treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA (DS, differentiating), media 
from proliferating N-type populations (PS+PN), media from differentiating N-type 
populations (PS+DN) or with 1 µM 9cRA plus media from differentiating N-type 
populations (DS+DN). Blots were probed with anti-STIM1 antibody which detected a 
band at 84 kDa and β-actin antibody which was used as a loading control and detected 
a band at 42 kDa. Quantitative band measurements were performed using 
densitometry in ImageJ. (A) All cell conditions exhibited expression of STIM1. There 
was reduced band intensity in DS populations compared to PS populations. Band 
intensity of PS+PN populations was similar to that of PS populations. There was reduced 
band intensity in PS+DN and DS+DN populations similar to that of DS populations and 
there was a slight increase in molecular weight compared to all other conditions. (B) 
There was no significant effect of growth conditions on the level of STIM1 expression 
(P=0.101). The level of expression of STIM1 was down-regulated by 39.72% in DS 
populations compared to PS populations, although this was not significant (P=0.459). 
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STIM1 expression was up-regulated by 37.72% in PS+PN populations compared to PS 
populations, but non-significantly (P=0.499). There was no significant difference in 
STIM1 expression in PS+DN populations (P=0.989). STIM1 expression in DS+DN 
populations was down-regulated by 22.82% compared to PS populations and up-
regulated by 28.03% compared to DS populations (P=0.829 and P=0.930, respectively). 
N=2. 
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Figure 5.5.4. N-type conditioned media alters Orai1 expression in proliferating and 
differentiating S-type populations 
Western blots were performed on protein samples from S-type populations that were 
treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA (DS, differentiating), media 
from proliferating N-type populations (PS+PN), media from differentiating N-type 
populations (PS+DN) or with 1 µM 9cRA plus media from differentiating N-type 
populations (DS+DN). Blots were probed with anti-Orai1 antibody which detected a 
band at 50 kDa and β-actin antibody which was used as a loading control and detected 
a band at 42 kDa. Quantitative band measurements were performed using 
densitometry in ImageJ. (A) There was reduced band intensity in DS, PS+DN and DS+DN 
populations compared to PS populations. Band intensity of PS+PN populations was 
similar to that of PS populations. (B) There was no significant effect of growth 
conditions on the level of Orai1 expression (P>0.999). The level of expression of Orai1 
was down-regulated by 38.53% in DS populations compared to PS populations, 
although this was not significant (P=0.583). Orai1 expression was up-regulated by 
59.60% in PS+PN populations compared to PS populations, but non-significantly 
(P=0.258). Orai1 expression was non-significantly down-regulated by 40.90% in PS+DN 
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compared to PS populations (P=0.537). There was no significant change in Orai1 
expression in DS+DN compared to PS populations and Orai1 was non-significantly up-
regulated by 60.78% in DS+DN compared to DS populations (P>0.999 and P=0.606, 
respectively). N=2. 
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5.6. Conditioned media from proliferating and differentiating N-type and S-type 
populations alters the expression of a neuronal and a non-neuronal marker 
Due to the interesting changes induced by conditioned media that were observed in 
morphology, SOCE activity (Results 4.6) and STIM1 (Results 5.5), expression of the 
neuronal marker β-tubulin III and the non-neuronal marker vimentin were also 
investigated in cells grown in a conditioned media environment. 
 
N-type populations were treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA 
(DN, differentiating), media from proliferating S-type populations (PN+PS), media from 
differentiating S-type populations (PN+DS) or with 1 µM 9cRA plus media from 
differentiating S-type populations (DN+DS).  
 
There was a ~20% increase in β-tubulin III expression in DN and DN+DS populations 
compared to PN populations (Figure 5.6.1A and B), although this was not significant 
(P=0.923 and P=0.891,respectively). This indicates that differentiation of N-type cells 
may induce a transition towards a neuronal phenotype, as expected, and that this is 
not an affected by DS conditioned media. There was a non-significant ~20% increase in 
β-tubulin III expression in PN+PS populations compared to PN populations (Figure 5.6.1A 
and B), although this was not significant (P=0.927). There was no significant difference 
in β-tubulin III expression between PN+DS and PN populations (P=0.995, Figure 5.6.1A 
and B). This suggests that DS conditioned media does not induce the same effect as PS 
conditioned media, perhaps since DS populations are moving towards a non-neuronal 
phenotype and that DS conditioned media does not induce a more neuronal-like 
phenotype in PN populations. There was no significant difference in in β-tubulin III 
expression between DN+DS and DN populations (P>0.999, Figure 5.6.1A and B), 
indicating that DS conditioned media does not affect the ability of N-type populations 
to differentiate towards a neuronal phenotype.  
 
Vimentin expression was increased ~20-fold in DN populations compared to PN 
populations (Figure 5.6.1A and C), although this was not significant (P=0.414), 
consistent with previous findings (Results 3.3). There was no significant difference in 
vimentin expression between PN populations and PN+PS populations (P>0.999, Figure 
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5.6.1A and C), implying that PS conditioned media does not induce a non-neuronal 
phenotype or differentiation of PN populations. There was a ~6-fold increase in 
vimentin expression in PN+DS populations and a ~10-fold increase in DN+DS populations 
compared to PN populations (Figure 5.6.1A and C). There was a 48% decrease in 
vimentin expression in DN+DS populations compared to DN populations. However, since 
these changes were not significant, further studies will be required to determine 
whether DS conditioned media induces a non-neuronal or differentiating phenotype in 
PN populations while dampening differentiation of N-type populations  
 
S-type populations were treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA 
(DS, differentiating), media from proliferating N-type populations (PS+PN), media from 
differentiating N-type populations (PS+DN) or with 1 µM 9cRA plus media from 
differentiating N-type populations (DS+DN). 
 
There was no significant difference in β-tubulin III expression in DS populations 
compared to PS populations (P=0.973, Figure 5.6.2A and B), confirming that S-type 
populations do not become more neuronal-like with differentiation. There was a 65% 
increase in β-tubulin III expression in PS+PN populations and a 52% increase in PS+DN 
populations compared to PS populations (Figure 5.6.2A and B), but this was non-
significant (P=0.199 and P=0.352, respectively). Therefore further investigation is 
needed to determine whether PN and DN conditioned media may induce a shift 
towards a neuronal phenotype in PS populations. There was no significant difference in 
β-tubulin III expression between DS+DN populations and PS populations (P>0.999) and a 
slight but non-significant decrease in β-tubulin III compared to DS populations 
(P=0.967, Figure 5.6.2A and B). Also, β-tubulin III was down-regulated by 35% in DS+DN 
populations compared to PS+DN populations, but this was non-significant (P=0.341, 
Figure 5.6.2A and B). These results indicate that DS populations are committed to a 
non-neuronal lineage that is not dampened by DN conditioned media.  
 
Vimentin expression was increased by 67% in DS populations compared to PS 
populations (Figure 5.6.2A and C) but this was non-significant (P=0.106), indicating that 
further investigation is needed to ensure S-type differentiation towards a more non-
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neuronal phenotype. There was no significant difference in vimentin expression 
between PS+PN populations and PS populations (P=0.924), implying that PN conditioned 
media does not affect the non-neuronal phenotype of PS populations. There was a 
significant ~2-fold increase in vimentin expression in PS+DN populations compared to PS 
populations (P=0.014) and DS+DN populations compared to PS populations (P=0.034) 
and a slight but non-significant increase in vimentin expression in DS+DN populations 
compared to DS populations (P=0.761 Figure 5.6.2A and C), suggesting that DN 
conditioned media can induce differentiation in PS populations but only slightly 
enhances this effect in DS populations. 
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Figure 5.6.1. S-type conditioned media alters the expression of a neuronal and a non-
neuronal marker in N-type populations 
Western blots were performed on protein samples from N-type populations that were 
treated for 7 days with EtOH (PN, proliferating), 1 µM 9cRA (DN, differentiating), media 
from proliferating S-type populations (PN+PS), media from differentiating S-type 
populations (PN+DS) or with 1 µM 9cRA plus media from differentiating S-type 
populations (DN+DS). Blots were probed with anti-β-tubulin III antibody which detected 
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a band at 50 kDa, anti-vimentin antibody which detected a band at 57 kDa and β-actin 
antibody which was used as a loading control and detected a band at 42 kDa. 
Quantitative band measurements were performed using densitometry in ImageJ. (A) 
All cell conditions exhibited expression of β-tubulin III to a similar extent. All cell 
conditions exhibited vimentin expression though band intensity was minimal in PN 
populations and PN+PS populations. (B) There was no significant effect of growth 
condition on expression of β-tubulin III (P=0.657). There was a ~20% increase in β-
tubulin III expression in DN, PN+PS and DN+DS populations compared to PN populations 
but this was not significant (P=0.923, P=0.927 and P=0.891,respectively). There was no 
significant difference in β-tubulin III expression between PN+DS and PN populations 
(P=0.995). There was no significant difference in in β-tubulin III expression between 
DN+DS and DN populations (P>0.999). N=2. (C) There was no significant effect of growth 
condition on expression of vimentin (P=0.387). There was 20-fold increase in vimentin 
expression in DN populations compared to PN populations, though this was not 
significant (P=0.414). There was no significant difference in vimentin expression 
between PN populations and PN+PS populations (P>0.999). There was a 6-fold increase 
in vimentin expression in PN+DS populations compared to PN populations, but this was 
not significant (P=0.975). There was a 10-fold increase in vimentin expression in DN+DS 
populations compared to PN populations, but this was not significant (P=0.866). There 
was a 47.75% decrease in vimentin expression in DN+DS populations compared to DN 
populations, but this was not significant (P=0.862). N=2. 
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Figure 5.6.2. N-type conditioned media alters expression of a neuronal and a non-
neuronal marker in S-type populations 
Western blots were performed on protein samples from S-type populations that were 
treated for 7 days with EtOH (PS, proliferating), 1 µM 9cRA (DS, differentiating), media 
from proliferating N-type populations (PS+PN), media from differentiating N-type 
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populations (PS+DN) or with 1 µM 9cRA plus media from differentiating N-type 
populations (DS+DN). Blots were probed with anti-β-tubulin III antibody which detected 
a band at 50 kDa, anti-vimentin antibody which detected a band at 57 kDa and β-actin 
antibody which was used as a loading control and detected a band at 42 kDa. 
Quantitative band measurements were performed using densitometry in ImageJ. (A) 
All cell conditions exhibited expression of β-tubulin III to a similar extent except DS+DN 
populations, where band intensity was reduced. All cell conditions exhibited 
expression of vimentin. There was an increase in vimentin band intensity in DS 
populations compared to PS populations. Vimentin band intensity in PS+PN populations 
was reduced to that of DS populations. PS+DN and DS+DN populations expressed 
vimentin to a similar extent. (B) There was no significant effect of growth condition on 
expression of β-tubulin III (P=0.128). There was a 14.37% increase in β-tubulin III 
expression in DS populations compared to PS populations, though this was non-
significant (P=0.973). There was a 65.28% increase in β-tubulin III expression in PS+PN 
populations compared to PS populations, but this was non-significant (P=0.199). There 
was a 51.56% increase in β-tubulin III expression in PS+DN populations compared to PS 
populations, but this was non-significant (P=0.352). There was no significant difference 
in β-tubulin III expression between DS+DN populations and PS populations (P>0.999). 
There was a 13.25% decrease in β-tubulin III in DS+DN populations compared to DS 
populations, but this was non-significant (P=0.967). β-tubulin III was down-regulated 
by 34.54% in DS+DN populations compared to PS+DN populations, but this was non-
significant (P=0.341). N=2. (C) There was a significant effect of growth condition on 
vimentin expression (P=0.011). There was a 67.44% increase in vimentin expression in 
DS populations compared to PS populations, though this was non-significant (P=0.106). 
There was a 16.40% increase in vimentin expression in PS+PN populations compared to 
PS populations, but this was non-significant (P=0.924). There was a significant ~2-fold 
increase in vimentin expression in PS+DN populations compared to PS populations 
(P=0.014*) and DS+DN populations compared to PS populations (P=0.034*). There was a 
14.72% increase in vimentin expression in DS+DN populations compared to DS 
populations (P=0.761), although this was not significant. N=2. 
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Chapter 5: Discussion 
The proteins STIM1 and Orai1 have been shown to be involved in SOCE (Introduction). 
The Ca2+ sensing protein STIM1 is able to detect ER Ca2+ store depletion and localise to 
ER/PM junctions where it gates PM SOCs to induce Ca2+ entry and replenish the 
depleted ER Ca2+ stores (Liou 2005; Hoover 2011; Sauc 2015). Orai1 is a PM protein 
that forms the SOC channel pore and is gated by STIM1 for SOCE regulation (Mignen 
2008; Demuro 2011; Hoover 2011). Dampened SOCE activity was observed with 
differentiation of N-type and S-type populations (Chapter 4). This SOCE down-
regulation was accompanied by either a modification or a down-regulation of STIM1 
expression alongside a down-regulation of Orai1 expression in N-type and S-type 
populations, consistent with their role in SOCE. 
 
The level of STIM1 expression has been extensively associated with extent of SOCE 
activity. Previous findings in this laboratory have shown knockdown of STIM1 to cause 
a down-regulation of SOCE in proliferating N-type populations whilst overexpression of 
STIM1 in differentiating N-type populations restores previously dampened SOCE (Bell 
2011). STIM1 expression in other cell types has a common role in SOCE as knockdown 
of STIM1 in SH-SY5Y cells, HEK293 cells, Jurkat T cells and Drosophila S2 cells (Roos 
2005), as well as endothelial cells (Abdullaev 2008), HeLa cells (Liou 2005), endothelial 
progenitor cells (Kuang 2010) and vascular smooth muscle cells (Takahashi 2007; 
Aubart 2009; Potier 2009) causes a reduction in SOCE. STIM1 expression also affects 
the extent of differentiation. Our laboratory has previously shown that whilst 
knockdown of STIM1 in N-type cells does not induce morphological differentiation, 
overexpression of STIM1 in differentiating N-type populations restores previously 
dampened SOCE and reduces morphological differentiation (Bell 2011). STIM1 
knockdown reduced SOCE and prevented proliferation of neural progenitor cells 
derived from mouse embryonic cells (Hao 2014) and endothelial cells (Abdullaev 
2008). STIM1 is up-regulated in proliferating vascular smooth muscle cells and STIM1 
knockdown inhibits proliferation and SOCE (Takahashi 2007; Aubart 2009; Potier 
2009). Knockdown of STIM1 also prevents endothelial progenitor cell proliferation 
(Kuang 2010) and, similarly, it was also found that hepatocyte growth factor induces 
endothelial progenitor cell differentiation with an in increase in SOCE alongside STIM1 
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expression whilst  knockdown of STIM1 expression inhibits this effect (Shi 2010). Taken 
together, this indicates that STIM1 does not have a direct role in the switch from 
proliferation to differentiation but may be involved in promoting the proliferative cell 
state. 
 
The observed changes in STIM1 expression could be a direct effect of RA treatment. 
However, it has been shown that the promoter region or upstream enhancer region of 
the STIM1 gene does not contain a consensus motif for RAR/RXR binding therefore a 
lack of RA regulatory elements in the STIM1 gene demonstrates that STIM1 expression 
is not altered by RA directly but by an indirect effect of RA on cellular differentiation 
processes (Zhang 2007). 
 
An increase in the molecular weight of STIM1 found in this study suggests that there 
may some sort of modification, such as phosphorylation, that could affect STIM1 
function which is likely to impact on SOCE. STIM1 phosphorylation at multiple serine 
residues has recently been identified and extensively investigated (Manji 2000; Smyth 
2009; Sundivakkam 2012; Pozo-Guisado 2013; Sundivakkam 2013). STIM1 
phosphorylation has been shown to have a role in STIM1 activation during ER Ca2+ 
store depletion (Lopez 2012; Pozo-guisado 2013) but can also inhibit SOCE by 
preventing puncta formation (Smyth 2009; Sundivakkam 2013). This demonstrates that 
STIM1 phosphorylation can greatly affect STIM1 function and therefore may play a role 
in the observed change of expression and SOCE activity in this study. STIM1 can also be 
glycosylated (Manji 2000; Dziadek 2007), which can affect localisation of STIM1 to the 
PM (Williams 2002). Potentially, the shift in molecular weight of STIM1 could indicate 
the presence of an alternative isoform of STIM1 that serves different function. The 
existence of a higher molecular weight isoform of STIM1, coined STIM1L as opposed to 
the more extensively studied STIM1S isoform, has recently been identified (Darbellay 
2011) and is able to activate SOCE in cells lacking STIM1 (Sauc 2015). STIM1L has been 
shown to induce SOCE quicker than STIM1S, attributable to its association with Orai1 
at rest rather than needing to migrate to bind Orai1 following store depletion like that 
of STIM1S (Darbellay 2011; Horinouchi 2012).  
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Consistent with the possibility of a STIM1 modification, STIM1 localisation was altered 
with differentiation of N-type and S-type cells. In N-type cells, there was increased 
clustering STIM1 with differentiation whilst in S-type cells, STIM1 accumulated at the 
PM. This varied distribution of STIM1 was altered in N-type cells following induction of 
SOCE, whereby STIM1 expression became more diffuse in PN cells and remained 
clustered in DN cells but was not altered in PS or DS cells. These differences in STIM1 
localisation with differentiation and between N-type and S-type cells highlight a 
potential differences in STIM1 modification and/or function between phenotypes. 
STIM1 has been shown to redistribute to the PM and co-localise with Orai1 upon Ca2+ 
store depletion in sinoatrial node cells (Liu 2015), Xenopus oocytes (Courjaret 2014) 
and HEK293 cells (Fukushima 2012). Similarly, STIM1 association with the ER and 
redistribution of STIM1 into punctate structures forming within 100 nm of the PM 
following TG stimulation has been observed in HeLa cells whilst a STIM1 mutant 
lacking an EF-hand binding domain failed to reorganise into puncta following TG 
addition (Liou 2005). Phosphorylation of STIM1 is required for associated with PM 
channels and SOCE activation in platelets (Lopez 2012) and therefore may affect 
localisation patterns. N-linked glycosylation within the SAM domain of STIM1 is 
important for STIM1 cell surface trafficking (Williams 2002) and may have a role in 
expression patterns observed here in N-type and S-type cells. 
 
As well as a role for STIM1 in SOCE, the level of Orai1 expression has been associated 
with SOCE. In this study, Orai1 down-regulation was associated with differentiation of 
N-type and S-type cells and a reduction in SOCE. Our laboratory has previously shown 
that Orai1 knockdown causes dampened SOCE in N-type populations and that 
overexpression of Orai1 restores SOCE in differentiating N-type populations (Bell 
2011). Orai1 has a role in SOCE in other cell types, as knockdown of Orai1 induced a 
down-regulation of SOCE activity in neural progenitor cells (Hao 2014), acinar cells 
(Hong 2011), osteoclasts (Zhou 2011), endothelial cells (Abdullaev 2008), Jurkat T cells 
(Gwack 2007) and HEK293 cells (Gwack 2007; Kawasaki 2010). Orai1 overexpression 
causes an increase in SOCE in HEK293 cells (Fukushima 2012) and restores SOCE in 
SCID T cells and fibroblasts (Gwack 2007). Orai1 down-regulation was associated with 
differentiation of N-type and S-type cells in this study and our laboratory has 
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previously shown that overexpression of Orai1 in differentiating N-type populations 
restores SOCE activity and reduces morphological differentiation (Bell 2011), 
suggesting that Orai1 expression drives cells towards a proliferative state. Similarly, 
earlier studies have demonstrated that Orai1 knockdown inhibited proliferation of 
vascular smooth muscle cells (Potier 2009)and endothelial cells (Abdullaev 2008). 
Orai1 expression is suppressed in mitotic HeLa and HEK293 cells, coinciding with a 
down-regulation of SOCE (Smyth 2009). Orai1 also has a known role in the switch from 
proliferation to differentiation as knockdown of Orai1 was sufficient to induce 
differentiation of N-type populations and enhance morphological differentiation of 
9cRA-treated N-type populations (Bell 2011).  Conversely, neural differentiation of 
mouse embryonic stem cells is not affected by Orai1 knockdown (Hao 2014) whilst 
Orai1 down-regulation dampens SOCE but suppresses osteoclast differentiation (Zhou 
2011; Hwang 2012). Therefore evidence suggests that Orai1 may be a negative 
regulator of differentiation in some cell types and promote differentiation in others 
but nevertheless has a direct role in the switch from proliferation to differentiation. 
 
In this study, Orai1 localisation was altered with differentiation of N-type and S-type 
populations. In N-type cells, there was a reduction in Orai1 foci with differentiation 
whilst in S-type cells, there was a dispersion of Orai1 clusters, indicating that there may 
be a modification of Orai1 or a change in function between phenotypes. Indeed, two 
isoforms of Orai1 have been identified in a range of cell types; a longer isoform Orai1α 
and short isoform Orai1β which localise similarly at the PM and interact with STIM1 
but Orai1β is more motile in the PM (Fukushima 2012). Both Orai1 isoforms are 
capable of supporting SOCE in HEK293 cells (Fukushima 2012). Another potential 
explanation for the observed differences in localisation is that Orai1 is heavily post-
translationally glycosylated, however in HEK293 cells, inhibition of glycosylation had no 
effect on Orai1 localisation or SOCE activity (Gwack 2007) and extra bands that would 
indicate glycosylation on western blots were not observed. Alternatively, Orai1 can be 
phosphorylated by protein kinase C, causing inactivation of SOCE however it is unclear 
how Orai1 function is altered by this modification (Kawasaki 2010). 
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TRPC1 channels are Ca2+ permeable and, through STIM1 interactions (Yuan 2007; Alicia 
2008; Jardin 2008), as well as other mechanisms (Putney 2007), may function as a 
SOCs. Indeed, it has been shown that STIM1 is able to bind TRPC1 and induce SOC 
channel functionality (Yuan 2007) and induce SOC rather than ROC function through 
insertion of TRPC1 into lipid raft domains (Alicia 2008). In this study, levels of TRPC1 
expression indicated a down-regulation with differentiation of N-type and S-type 
populations, however this was variable and lack of availability of a reliable TRPC1 
antibody hindered this particular investigation. Previously this laboratory has shown 
TRPC1 expression to be up-regulated with differentiation of N-type populations (N. Bell 
2013), as has been demonstrated in myoblast differentiation (Louis 2008; Zanou 2012) 
and hippocampal neuronal cell differentiation (Wu 2004). Knockdown of TRPC1 did not 
affect SOCE or induce morphological differentiation in proliferating N-type populations 
whilst TRPC1 knockdown prevented SOCE down-regulation and reduced morphological 
differentiation caused by 9cRA treatment (Bell 2011), therefore TRPC1 could have a 
role in SOCE such as compensating for a lack of Orai1. However, inhibition of TRPC1 
was found to suppress proliferation of A549 lung cancer cells whereas overexpression 
of TRPC1 enhanced proliferation (Jiang 2013). Similarly, knockdown of TRPC1 in 
keratinocytes caused a reduction in SOCE and inhibited differentiation (Cai 2006) 
indicating that TRPC1 is involved in keratinocyte differentiation by promoting SOCE 
activity. This conflicting evidence supports that there is a role for TRPC1 in SOCE but 
TRPC1 function in SOCE activity and the differentiation response in neuroblastoma 
cells warrants further investigation.  
 
Conditioned media had an effect on SOCE in N-type and S-type populations (Results 
4.5) and was found to alter the expression of STIM1, Orai1, β-tubulin III and vimentin.  
PS conditioned media did not significantly alter β-tubulin III expression or vimentin 
expression in PN populations. Since vimentin expression was not affected, and a non-
significant increase in vimentin expression was associated with N-type differentiation 
(Results 3.3), and cells retained a PN phenotype (Results 4.5), PS conditioned media 
does not induce differentiation of PN populations. This is consistent with the finding 
that PS conditioned media caused an apparent increase in STIM1 and Orai1 expression 
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in PN populations and did not alter SOCE activity (Results 4.5). PS conditioned media 
was therefore not sufficient to influence the PN phenotype. 
 
DS conditioned media did not affect β-tubulin III expression but caused a 6-fold 
increase in vimentin expression in PN populations, indicating that DS conditioned media 
may induce a non-neuronal phenotype or a differentiating phenotype in PN 
populations. A non-significant up-regulation of vimentin expression was associated 
with N-type differentiation (Results 3.3) and the morphology of PN populations treated 
with DS conditioned media was similar to that of DN populations, indicating that the 
observed increase in vimentin expression was likely due to DS conditioned media 
inducing PN differentiation towards a neuronal phenotype. Since DS conditioned media 
also induced SOCE down-regulation in PN cells (Results 4.5), consistent with the 
discussed induction of neuronal differentiation, but did not affect STIM1 or Orai1 
expression, another mechanism for SOCE (e.g. TRPC1 or Orai3) may be induced by DS 
conditioned media. Taken together these results indicate DS conditioned media, at 
least in part, induces some characteristics of neuronal differentiation in PN 
populations. 
 
DS conditioned media did not affect the expression of β-tubulin III in DN populations, 
suggesting that DS conditioned media does not affect the ability of N-type populations 
to differentiate towards a neuronal phenotype. There was a 10-fold increase in 
vimentin expression in DN populations treated with DS conditioned media however, 
this was dampened compared to DN population vimentin expression implying that DS 
conditioned media may dampen some aspects of the differentiation of N-type 
populations. There was an increase in STIM1 molecular weight and a down-regulation 
of Orai1 expression in DN+DS populations, similar to that of DN populations, and SOCE 
activity was down-regulated compared to PN populations but similar to DN populations 
(Results 4.5). Taken together, these results indicate that DS conditioned media did not 
drastically affect differentiation or the role of STIM1 or Orai1 in SOCE in N-type 
populations but may have subtle differentiation dampening effects.  
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PN conditioned media up-regulated β-tubulin III expression in PS populations but did 
not affect vimentin expression, suggesting that PN conditioned media may induce a 
biochemical shift towards a neuronal phenotype in PS populations but does not 
drastically affect the non-neuronal phenotype of PS populations. PN conditioned media 
caused an apparent up-regulation of STIM1 and Orai1 expression in PS populations, 
therefore the previously observed down-regulation of SOCE induced by PN conditioned 
media was not attributed to a change in STIM1 or Orai1 expression, suggesting a 
possible change in the mechanism of SOCE (e.g. TRPC1 or Orai3). These results indicate 
that PN conditioned media may influence the phenotype of S-type populations to 
become more N-type-like. 
 
DN conditioned media up-regulated β-tubulin III and vimentin expression in PS 
populations suggesting that DN conditioned media may induce a shift towards a 
neuronal phenotype in PS populations, since this expression pattern is characteristic of 
N-type differentiation (Results 3.3)(N. Bell 2013), however morphologically, S-type 
cells were differentiating (Results 4.5). DN conditioned media caused an increase in the 
molecular weight of STIM1 and an apparent down-regulation of Orai1 in PS 
populations, consistent with the previous finding that SOCE activity is down-regulated 
in PS populations treated with DN conditioned media (Results 4.5). These results 
demonstrate that DN conditioned media may induce a differentiating phenotype in PS 
populations. 
 
DN conditioned media did not alter β-tubulin III expression in DS populations but 
expression was down-regulated compared to PS+DN populations, indicating that 
differentiation of S-type populations commits S-type cells to a non-neuronal lineage 
that is not affected by DN conditioned media. There was a 2-fold increase in vimentin 
expression in DS populations treated with DN conditioned media that was slightly 
higher than that observed in DS populations but lower than that of PS+DN suggesting 
that DN conditioned media does not affect differentiation of S-type populations. There 
was no change in Orai1 expression but there was an increase in the molecular weight 
of STIM1 in DS populations treated with DN conditioned media was still present, 
indicating that the previous finding that SOCE activity was also down-regulated 
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(Results 4.5) was attributed to changes in STIM1 expression. The expression of Orai1 
and increase in molecular weight of STIM1 in DS+DN populations was similar to that of 
DS populations but the level of STIM1 and Orai1 expression was up-regulated 
compared to DS populations consistent with a slight increase in SOCE activity (Results 
4.6). This suggests that differentiating S-type populations are committed to a non-
neuronal lineage that may be slightly dampened by DN conditioned media. 
 
Taken together, these results demonstrate that conditioned media from proliferating 
S-type populations does not drastically influence N-type population characteristics 
whilst differentiating S-type populations may influence the phenotype of N-type 
populations by promoting differentiation of N-type populations slightly dampening 
9cRA-induced differentiation of N-type populations. Conditioned media from 
proliferating N-type populations can influence the S-type populations to exhibit more 
N-type-like characteristics, suggesting that N-type cells may exert this influence to 
ensure the neuroblastoma populations remain predominantly N-type in order to 
thrive. Differentiation of S-type populations appears to commit them to a non-
neuronal cell fate that can be slightly dampened by conditioned media from 
differentiating N-type populations. 
 
It is plausible that the effects of DN and DS conditioned media could, at least in part, be 
due to residual 9cRA in the media. However, the observed results do indicate that the 
conditioned media effect is caused by phenotype rather than a direct influence of 
9cRA. For example, DS conditioned media alone did not alter STIM1 molecular weight 
in PN cells, and DN conditioned media caused an increase in β-tubulin III expression that 
was not observed to the same extent in DS populations. Similarly, the application of 
9cRA together with DS and DN condition media as a control identified that the down-
regulation in the level of STIM1 expression seen with N-type differentiation was 
dampened by DS media and that the increase in β-tubulin III expression caused by DN 
conditioned media was not present when S-type populations were differentiated 
alongside treatment. This also suggests that the observed effects were caused by 
phenotype rather than direct effect of residual 9cRA. 
   
208 
 
Alterations in STIM1 and Orai1 expression were found to underlie the down-regulation 
of SOCE associated with 7 day 9cRA-induced differentiation of N-type and S-type 
populations (Chapter 4). The relationship and sequence of these changes were further 
investigated over the time-course of the differentiation response. 
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Chapter 6: Differentiation time-course 
 
Chapter 6 – Introduction 
As previously discussed, treatment of N-type and S-type populations with 1 µM 9cRA 
for 7 days induces morphological and biochemical differentiation. For N-type cells, this 
involves an elongation of neurite-like processes, up-regulation of Bcl-2, uncoupling of 
Ca2+ store release and SOCE and a down-regulation of the SOCE proteins STIM1 and 
Orai1. For S-type cells, this involves cell margin spreading with an increase in cell 
diameter, down-regulation of Bcl-2, uncoupling of Ca2+ store release and SOCE and a 
down-regulation of the SOCE proteins STIM1 and Orai1.  
 
The sequence of these differentiation-associated events is unclear therefore this 
chapter aimed to investigate the differentiation time-course in N-type and S-type 
populations through study of the relationship between these markers of 
differentiation over the 7 days of differentiation induction. The effect of differentiation 
agent withdrawal was also explored to determine the possibility of differentiation 
reversal. 
 
Throughout this chapter, proliferating N-type and S-type populations (EtOH treated) 
will be referred to as PN and PS, respectively, whilst differentiating N-type and S-type 
populations (9cRA treated) will be referred to as DN and DS, respectively. The day of 
treatment will be referred to between days 1-7 of each condition. After 7 days, 
treatment was withdrawn and cells were grown in standard culture media alone for a 
further 5 days (day 12). 
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Chapter 6 – Results 
6.1. Morphological differentiation is induced early in the 9cRA treatment time-course 
9cRA-induced differentiation of N-type cells for 7 days causes elongation of neurite-
like processes and an increase in percentage of differentiated cells, as determined by 
the number of cells with at least one neurite >50 µm in length (Results 3.1). In S-type 
cells, 9cRA-induced differentiation for 7 days causes cell margin spreading and an 
increase in diameter of SO and SA cells and an increase in length of SE cells (Results 3.1). 
Morphological differentiation was observed over the 7 day time-course of 9cRA 
treatment to determine the onset and progression of morphological differentiation.  
 
As described previously, neurite length was used to classify N-type cells as 
morphologically proliferating or differentiated and cells possessing one or more 
neurites >50 μm in length were classed as differentiated. From the first day of 
treatment, elongation of neurites could observed in DN cells compared to the short 
neurites of PN cells and elongation was seen to progress over the treatment time-
course (Figure 6.1.1). Over the treatment time-course, there was a significant increase 
in percentage differentiation and average neurite length of DN cells (both P<0.0001) 
that were not significantly altered in PN cells (P=0.607 and P=0.263, respectively, Figure 
6.1.2A and B). There was a significant increase in percentage differentiation and 
average neurite length in DN cells compared to PN cells over the treatment time-course 
(both P<0.0001 Figure 6.1.2A and B). 
 
From day 1 of treatment, the percentage of differentiated cells and average neurite 
length was significantly higher in DN cells (12% and 40 µm, respectively) compared to 
PN cells (3%, P=0.018 and 25 µm, P=0.0002, respectively, Figure 6.1.2A and B). 
Percentage differentiation and average neurite length progressively increased over the 
treatment time-course, peaking at day 5 of treatment, where percentage 
differentiation and average neurite length in DN cells (25% and 49 µm, respectively) 
were significantly higher than that of PN cells (4%, P<0.0001 and 29 µm, P=0.002, 
respectively, Figure 6.1.2A and B). There was no significant change in percentage 
differentiation between DN cells at day 5 and day 7 (P=0.997 and P=0.719, respectively, 
Figure 6.1.2A and B). Following treatment withdrawal, percentage differentiation and 
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average neurite length were significantly reduced in DN cells (4% and 31 µm) compared 
to DN cells at day 7 (both P<0.0001) and were not significantly different to that of PN 
cells at day 12 (1%, P>0.999 and 23 µm, P=0.417, respectively, Figure 6.1.2A and B). 
 
As described previously, diameter of SO and SA cells and length of SE cells were used to 
classify S-type cells as morphologically proliferating or differentiating. From the first 
day of treatment, there was no noticeable difference in cell margin spreading in DS 
cells compared to PS cells however cell margin spreading can be observed from day 3 
of treatment in DS cells and progresses up to  day 7 of treatment (Figure 6.1.3). Over 
the treatment time-course, there was a significant increase in DS SO and DS SA cell 
diameter and DS SE cell length (all P<0.0001, Figure 6.1.4A, B and C) but no significant 
change in PS SE cell length (P=0.075, Figure 6.1.4 C). There was a slight but significant 
change in PS SO and PS SA cell diameter over the treatment time-course (P=0.0031 and 
P=0.004, respectively) but this was attributed to a small decrease in cell diameter at 
day 4 (Figure 6.1.4A and B). DS SO and DS SA cell diameter and DS SE cell length were 
significantly higher than that of PS SO, PS SA and PS SE cells, respectively over the 
treatment time-course (all P<0.0001, Figure 6.1.4A, B and C). 
 
There was no significant difference between the diameter of PS SO cells (35 µm) and DS 
SO cells (32 µm), PS SA cells (29 µm) and DS SA cells (30 µm) and the length of PS SE cells 
(46 µm) and DS SE cells (46 µm) from day 1 of treatment (all P>0.999, Figure 6.1.4A, B 
and C). By day 4 of treatment the diameter of DS SO cells (39 µm) was significantly 
higher than that of PS SO cells (28 µm, P=0.0032, Figure 6.1.4A). At day 4 of treatment, 
the diameter of DS SA cells (38 µm) and length of DS SE cells (61 µm) were increased 
compared to that of PS SA cells (28 µm) and PS SE cells (41 µm), however this was non-
significant (P=0.167 and P=0.372, respectively, Figure 6.1.4B and C). By day 5 of 
treatment, there was a peak in the diameter of DS SO cells (52 µm) and DS SA cells (46 
µm) whilst the length of DS SE cells continued to increase up to day 7 of treatment (90 
µm). Following treatment withdrawal, compared to day 7 DS cells, there was no 
significant change in cell diameter of DS SO cells (45 µm, P=0.533) or DS SA cells (46 µm, 
P=0.999) and cell diameter remained significantly greater than that of day 12 PS SO cells 
(34 µm, P=0.0005) and PS SA cells (31 µm, P=0.0003), respectively (Figure 6.1.4A and B). 
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Length of PS SA cells was slightly increased at day 12 (31 µm) compared to day 7 (27 
µm) but this was not significant (P=0.183). Following treatment withdrawal, there was 
a significant reduction in cell length of DS SE cells (60 µm) compared to day 7 DS SE cells 
(90 µm, P=0.0018) and this was not significantly different to that of day 12 PS SE cells 
(56 µm, P>0.999). Length of PS SE cells was slightly increased at day 12 (56 µm) 
compared to day 7 (48 µm) but this was not significant (P=0.713). 
 
Taken together, these results indicate that morphological differentiation progressed in 
a multi-step manner in N-type populations that was initiated within the first day of 
9cRA treatment in N-type populations, with a further increase in differentiation and 
peak at day 5 of treatment. For S-type populations, morphological differentiation was 
induced gradually from the third day of treatment, peaking at day 5 for SO and SA cells 
but at day 7 for SE cells. Following 5 days of treatment withdrawal, DN populations 
seem to revert back to a PN phenotype indicating that N-type cells may lose their 
differentiating characteristics following removal of the differentiation stimulus. DS SE 
cells show a potential reversion to a PS phenotype whilst DS SO and DS SA cells retain a 
DS morphology. Given that PS SE cells seem to become more morphologically 
differentiated over time in culture, based on the increase in length between day 7 and 
12, it may be that 9cRA withdrawal does not cause DS SE cells to completely lose their 
differentiating characteristics. This therefore suggests that S-type cells may remain a 
fully differentiating phenotype following removal of the differentiation stimulus. 
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Figure 6.1.1. Neurite elongation in N-type cells can be observed from the first day of 
9cRA treatment 
N-type populations were treated for 7 days (1-7) with 1 µM 9cRA (DN) or an equivalent 
volume of EtOH (PN). After 7 days, treatment was withdrawn from both PN and DN cells, 
which were grown in standard culture media alone for a further 5 days (12). (A-G) PN 
cells possess short neurite-like processes (as demonstrated by dashed arrows in A) and 
grow in aggregates (demonstrated by dashed circle in A). (I-O) DN cells exhibit 
elongated neurites (as demonstrated by dashed arrows in I) and decreased growth. 
This neurite elongation can be observed from (I) the first day of 9cRA treatment and is 
seen to progress (J-O) over the treatment time-course. Five days following treatment 
withdrawal, (P) DN cells exhibit a similar morphology to (H) PN cells. Scale bars of phase 
contrast images represents 50 µm. 
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Figure 6.1.2. 9cRA-induced morphological differentiation of N-type populations is 
induced from the first day of treatment 
N-type populations were treated over 7 days (1-7) with 1 µM 9cRA (DN) or an 
equivalent volume of EtOH (PN). After 7 days, treatment was withdrawn from both PN 
and DN cells, which were grown in standard culture media alone for a further 5 days 
(12). Phase contrast were used for neurite measurements using Metamorph software. 
(A) Neurite length was used to classify N-type cells as morphologically proliferating or 
differentiated. Cells possessing one or more neurites >50 μm in length were classed as 
differentiated. Over the treatment time-course, there was a significant increase in 
percentage differentiation of DN cells (P<0.0001) but was not significantly altered in PN 
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cells (P=0.607). There was a significant increase in percentage differentiation in DN cells 
compared to PN cells over the treatment time-course (P<0.0001). From day 1 of 
treatment, the percentage of differentiated cells was significantly higher in DN cells 
(12.26%) compared to PN cells (2.67%, P=0.018*). At day 2, percentage differentiation 
was higher in DN cells (12.08%) compared to PN cells (3.97%) but this was not 
significant (P=0.560). Percentage differentiation was further increased in DN cells 
compared to PN cells at day 3 (17.34% and 3.33% respectively, P=0.011*) and day 4 
(14.74% and 3.07% respectively, P=0.0002***). There was a further significant increase 
in percentage differentiation in DN cells at day 5 (24.66%) compared to DN cells at day 1 
(P=0.0042) and compared to PN cells at day 5 (4.06%, P<0.0001****). Percentage 
differentiation remained significantly higher in DN cells compared to PN cells at day 6 
(23.48% and 4.51% respectively, P<0.0001****) and day 7 (21.95% and 3.90% 
respectively, P<0.0001****). Following treatment withdrawal, percentage 
differentiation was significantly reduced in DN cells (4.02%) compared to DN cells at day 
7 (P<0.0001****) and was not significantly different to that of PN cells at 12 (1.22%, 
P>0.999). (B) Over the treatment time-course, there was a significant increase in the 
neurite length of DN cells (P<0.0001) whilst neurite length was not significantly altered 
in PN cells (P=0.263). There was a significant increase in neurite length in DN cells 
compared to PN cells over the treatment time-course (P<0.0001). From day 1 of 
treatment, the average neurite length of DN cells (39.63 µm) was significantly longer 
than that of PN cells (24.96 μm, P=0.0002***). At day 2, average neurite length was 
higher in DN cells (40.69 µm) compared to PN cells (30.12 µm) but this was not 
significant (P=0.404).  Neurite length was further increased in DN cells compared to PN 
cells at day 3 (44.38 µm and 27.45 µm respectively, P=0.0099**), day 4 (40.29 µm and 
25.96 µm respectively, P=0.0001***), day 5 (48.83 µm and 28.75 µm respectively, 
P=0.0016**) and day 6 (48.16 µm and 30.74 µm respectively, P=0.0099**) and day 7 
(43.76 µm, and 31.55 µm respectively, P=0.0032**). Following treatment withdrawal, 
neurite length was significantly reduced in DN cells (31.28 µm) compared to that of day 
7 DN cells (P<0.0001****) and was not significantly different to that of day 12 PN cells 
(23.10 µm, P=0.417). PN: 1 n=1084, 2 n=515, 3 n=493, 4 n=1015, 5 n=398, 6 n=515, 7 
n=1043, 12 n=919. DN: 1 n=889, 2 n=611, 3 n=488, 4 n=1192, 5 n=514, 6 n=654, 7 
n=1131, 12 n=926.   
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Figure 6.1.3. Cell margin spreading in S-type cells can be observed from the third day 
of 9cRA treatment 
S-type populations were treated for 7 days (1-7) with 1 µM 9cRA (DS) or an equivalent 
volume of EtOH (PS). After 7 days, treatment was withdrawn from both PS and DS cells, 
which were grown in standard culture media alone for a further 5 days (12).  (A-H) PS 
cells possess abundant cytoplasm and a flattened morphology (as demonstrated by 
dashed arrows in A). At day 1 and 2 of treatment (I-J), DS cells resemble PS cells and 
from day 3 of treatment, (K-P) DS cells are more flattened with spread cell margins (as 
demonstrated by dashed arrows in K). (H and P) Five days following treatment 
withdrawal, (P) DS cells appear to retain a differentiating morphology but less so than 
at (O) day 7 of treatment. Scale bars of phase contrast images represents 50 µm. 
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Figure 6.1.4. 9cRA-induced morphological differentiation of S-type populations is 
induced from the fourth day of treatment 
S-type populations were treated over 7 days (1-7) with 1 µM 9cRA (DS) or an 
equivalent volume of EtOH (PS). After 7 days, treatment was withdrawn from both PS 
and DS cells, which were grown in standard culture media alone for a further 5 days 
(12). Phase contrast were used for cell measurements using Metamorph software. The 
diameter of SO and SA cells and the length of SE cells was used to determine the extent 
of morphological differentiation. (A) There was a slight but significant change in PS SO 
cell diameter over the treatment time-course (P=0.0031) that was attributed to a 
decrease in cell diameter at day 4. There was a significant increase DS SO cell diameter 
over the treatment time-course (P<0.0001). DS SO cell diameter was significantly higher 
than that of PS SO cells over the treatment time-course (P<0.0001). At day 1, 2 and 3, 
there was no significant difference between the diameter of PS SO cells (34.95 µm, 
31.85 µm and 34.04 µm respectively) and DS SO cells (31.63 µm, 33.79 µm and 35.48 
µm respectively, all P>0.999). At day 4, the diameter of DS SO cells (39.40 µm) was 
significantly higher than that of PS SO cells (27.83 µm, P=0.0032**). At day 5, the 
diameter of DS SO cells (52.27 µm) was significantly higher than that of PS SO cells 
(33.36 µm, P<0.0001****) and day 4 DS SO cells (P=0.0019). At day 6, the diameter of 
DS SO cells (46.04 µm) was significantly increased compared to PS SO cells (32.07 µm, 
P<0.0001****). At day 7, the diameter of DS SO cells (50.41 µm) was significantly 
increased compared to PS SO cells (35.12 µm, P<0.0001****) and day 4 DS SO cells 
(P=0.006). Treatment withdrawal led to a slight reduction in cell diameter in DS SO cells 
(44.84 µm) but this was still greater than that of PS SO cells (32.48 µm, P=0.0005***) 
and was not significantly different to that of day 7 DS SO cells (P=0.533). PS SO: 1 n=121, 
2 n=97, 3 n=180, 4 n=226, 5 n=156, 6 n=189, 7 n=194, 12 n=226. DS SO: 1 n=304, 2 
n=194, 3 n=272, 4 n=262, 5 n=235, 6 n=272, 7 n=328, 12 n=297. (B) There was a slight 
but significant change in PS SA cell diameter over the treatment time-course (P=0.004) 
that was attributed to a slight decrease in cell diameter at day 4. There was a 
significant increase DS SA cell diameter over the treatment time-course (P<0.0001). DS 
SA cell diameter was significantly higher than that of PS SA cells over the treatment 
time-course (P<0.0001). At day 1, 2 and 3, there was no significant difference between 
the diameter of PS SA cells (28.78 µm, 28.39 µm and 31.44 µm respectively) and DS SA 
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cells (29.73 µm, 30.89 µm and 34.27 µm respectively, all P>0.999). At day 4, the 
diameter of DS SA cells (38.36 µm) was higher than that of PS SA cells (27.77 µm) but 
non-significantly (P=0.167). At day 5, there was a significant increase in the diameter in 
DS SA cells (45.67 µm) compared to PS SA cells (31.36 µm, P=0.0003***) and day 2 DS SA 
cells (P=0.032). The diameter of DS SA cells at day 6 (43.72 µm) was significantly higher 
than that of PS SA cells (30.11 µm, P=0.003**). At day 7, the diameter of DS SA cells 
(43.90 µm) was significantly higher than that of PS SA cells (28.64 µm, P<0.0001****) 
and day 1 DS SA cells (P=0.007). Treatment withdrawal led to a further increase in cell 
diameter in DS SA cells (46.09 µm) that was significantly higher than that of day 2 DS SA 
cells (P=0.038) and day 12 PS SA cells (31.34 µm, P=0.0003***). PS SA: 1 n=194, 2 n=243, 
3 n=202, 4 n=176, 5 n=307, 6 n=489, 7 n=304, 12 n=354. DS SA: 1 n=453, 2 n=230, 3 
n=172, 4 n=166, 5 n=185, 6 n=127, 7 n=215, 12 n=157. (C) There was no significant 
change in PS SE cell length over the treatment time-course (P=0.075) and a significant 
increase DS SE cell length over the treatment time-course (P<0.0001). DS SE cell length 
was significantly higher than that of PS SE cells over the treatment time-course 
(P<0.0001).  At day 1, 2 and 3, there was no significant difference between the length 
of PS SE cells (45.85 µm, 44.66 µm and 46.26 µm respectively) and DS SE cells (46.32 µm, 
P>0.999, 47.22 µm, P>0.999 and 54.72 µm, P=0.997, respectively). At day 4, the length 
of DS SE cells (60.93 µm) was increased compared to PS SE cells (40.99 µm) but this was 
not significant (P=0.372). At day 5, the length of DS SE cells (71.99 µm) was significantly 
increased compared to PS SE cells (41.32 µm, P=0.0002***) and day 2 DS SE cells 
(P=0.03). At day 6, there was a further increase in length of DS SE cells (82.51 µm) 
compared to PS SE cells (44.69 µm, P<0.0001****) and compared to day 3 DS SE cells 
(P=0.006). At day 7, length of DS SE cells (89.51 µm) was significantly greater than that 
of PS SE cells (47.86 µm, P<0.0001****) and that of day 4 DS SE cells (P=0.003). 
Treatment withdrawal caused a significant reduction in cell length in DS SE cells (60.33 
µm) compared to day 7 DS SE cells (P=0.0018) that was not significantly different to 
that of day 12 PS SE cells (55.51 µm, P>0.999). Length of PS SE cells was slightly 
increased at day 12 compared to day 7 but this was not significant (P=0.713). PS SE: 1 
n=26, 2 n=33, 3 n=36, 4 n=27, 5 n=36, 6 n=65, 7 n=44, 12 n=59. DS SE: 1 n=41, 2 n=31, 3 
n=43, 4 n=37, 5 n=61, 6 n=44, 7 n=55, 12 n=40. 
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6.2. Expression of differentiation markers is altered before day 7 of 9cRA-induced 
differentiation 
As previously described (Chapter 1 and 3), 9cRA-induced differentiation of N-type 
populations for 7 days does not alter β-tubulin III expression but induces up-regulation 
of vimentin and Bcl-2 and a slight increase in levels of CD133 expression whilst 9cRA-
induced differentiation of S-type populations for 7 days does not alter β-tubulin III 
expression but induces up-regulation of vimentin, and apparent down-regulation of 
Bcl-2 and a slight decrease in levels of CD133 expression. The expression of the 
biochemical markers of differentiation; β-tubulin III, vimentin, Bcl-2 and CD133, were 
therefore investigated over the time-course of 9cRA treatment. 
 
β-tubulin III is a microtubule protein expressed in neuronal cells (Katsetos 2003; 
Dráberová 2008) previously used as a marker of N-type population differentiation (Bell 
2011) and was used to determine the neuronal-like nature of N-type and S-type 
populations. Both PN and DN populations expressed β-tubulin III throughout the 
treatment time-course and there was little variation in band intensity (Figure 6.2.1A). 
There was no significant difference in β-tubulin III expression over the treatment time-
course of PN (P=0.908), DN populations (P=0.978) or between PN and DN populations 
(P=0.994, Figure 6.2.1B) indicating that whilst β-tubulin III expression is a marker for 
the neuronal lineage of N-type cells, it does not distinguish between proliferating and 
differentiating N-type cells. Following 5 days of treatment withdrawal, β-tubulin III 
expression was reduced by 35% in DN cells compared to PN cells (Figure 6.2.1B). β-
tubulin III was also expressed in both PS and DS populations over the treatment time-
course (Figure 6.2.2A and B), though to a lesser extent than that of PN and DN 
populations, likely due to S-type cells being of non-neuronal lineage. Following 
treatment withdrawal, β-tubulin III expression was slightly reduced DS cell compared to 
PS cells (Figure 6.2.2B). 
 
The intermediate filament protein vimentin is expressed in non-neuronal neural crest 
cells such as Schwann and glial cells (Ciccarone 1989) and was used to determine the 
non-neuronal nature of N-type and S-type populations. Vimentin was weakly 
expressed by DN populations and PN populations throughout the treatment time-
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course though there was an increase in band intensity in DN populations from day 3 
(Figure 6.2.1A). There was no significant change in vimentin expression over the 
treatment time-course by PN populations (P=0.998), DN populations (P=0.965) or 
between PN and DN populations (P=0.934), however vimentin expression was increased 
over 2-fold from day 3 (P=0.181) to day 7 (P=0.319) of treatment in DN populations 
compared to PN populations (Figure 6.2.1C). Vimentin was expressed by both DS and PS 
populations (Figure 6.2.2A) and to a greater extent than that of PN (P=0.0002) and DN 
populations (P=0.0025). There was a slight but non-significant increase in vimentin 
expression in both PS populations (P=0.414) and DS populations (P=0.101) over the 
treatment time-course (Figure 6.2.2C). There was no significant difference in vimentin 
expression between DS and PS populations over the treatment time-course (P=0.131, 
Figure 6.2.2C). Following 5 days of treatment withdrawal, vimentin expression was 3-
fold higher in DS populations compared to PS populations (Figure 6.2.2C), suggesting 
that DS populations continue to move toward a non-neuronal phenotype despite 
removal of the differentiation stimulus. 
 
These results confirm that, as expected, the neuronal marker β-tubulin III was 
expressed to a greater extent in N-type populations than S-type populations and the 
non-neuronal marker vimentin was expressed to a greater extent in S-type populations 
than N-type populations. The expression of β-tubulin III does not change over the 
differentiation time-course of DN or DS populations, indicating that the level of β-
tubulin III expression is unaffected by the differentiation response of N-type and S-type 
populations. Vimentin expression was slightly higher in DN populations than PN 
populations early in the treatment time-course, correlating with the previous finding 
that vimentin is temporarily up-regulated with neurite outgrowth (Shea 1993). 
A slight increase in vimentin expression in PS populations early in the treatment time-
course implies that these cells may move towards a more non-neuronal phenotype 
over time in culture. Vimentin expression was slightly higher in DS than PS populations 
at day 6 and 7. Although not significant, this could be indicative of S-type populations 
becoming more non-neuronal-like with differentiation. 
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Following treatment withdrawal, potentially, N-type populations move away from a 
neuronal phenotype and possibly revert back to a PN phenotype whilst S-type 
populations seem to retain a differentiating non-neuronal phenotype. 
 
The anti-apoptotic protein Bcl-2 has been used as a marker of differentiation in SH-
SY5Y cells as it is up-regulated with 9cRA-induced differentiation (Riddoch 2007; Bell 
2011). Bcl-2 was clearly expressed from day 2 of treatment of PN and DN populations 
(Figure 6.2.3A). Over the treatment time-course, Bcl-2 expression was increased in PN 
populations (P<0.0001) and DN populations (P=0.0019) and Bcl-2 expression was 
significantly higher in DN than PN populations (P<0.0001, Figure 6.2.3B). Bcl-2 
expression is up-regulated by 51% from day 2 of treatment (P=0.366) and significantly 
by more than 3-fold by day 4 (P<0.0001). By day 7 of treatment, Bcl-2 expression was 
significantly 74% higher in DN populations than PN populations (P=0.002) however, 
following 5 days of treatment withdrawal, there was no difference in Bcl-2 expression 
between PN and DN populations, perhaps suggesting that N-type populations move 
away from a neuronal phenotype after removal of the differentiation stimulus (Figure 
6.2.3B). Bcl-2 was expressed by both PS and DS populations over the treatment time-
course and following treatment withdrawal (Figure 6.2.4A). Over the treatment time-
course, there was no significant difference in Bcl-2 expression in PS populations 
(P=0.762) or DS populations (P=0.246) or between PS and DS populations (P=0.472, 
Figure 6.2.4B). By day 7 of treatment, Bcl-2 expression was slightly reduced in DS 
populations compared to PS populations, though this was non-significant (34%, 
P=0.121, Figure 6.2.4B). Following 5 days of treatment withdrawal, Bcl-2 expression 
was 76% lower in DS populations compared to PS populations (Figure 6.2.4B). These 
results suggest that Bcl-2 is an effective marker for differentiation in N-type 
populations as an increase of expression coincides with the differentiation response of 
N-type populations but not S-type populations. 
 
CD133 is a cell surface glycoprotein that is associated with stem cells (Mizrak 2008) 
and was non-significantly up-regulated in DN populations compared to PN populations 
(Results 3.4). CD133 was expressed in both PN and DN populations over the treatment 
time-course (Figure 6.2.5.A). Over the treatment time-course there was a non-
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significant decrease in CD133 expression in PN populations (P=0.712) and a non-
significant increase in expression in DN populations (P=0.074). However, in DN 
populations, CD133 expression was increased by 84% from day 3 of treatment 
(P=0.219), and was over 4-fold higher by day 7 of treatment (P=0.117) compared to PN 
populations (Figure 6.2.5B). It may be that with differentiation, N-type populations 
may retain stem-cell like properties from the early stages in the differentiation 
response but this remains to be tested. Given the timing of these experiments, 
unfortunately, CD133 expression was not determined over the S-type population 
differentiation response or following treatment withdrawal as there was a lack of 
antibody stock. 
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Figure 6.2.1. Expression of vimentin is altered early in differentiating N-type 
populations whilst β-tubulin III expression remains constant 
Western blots were performed on protein samples from N-type populations that were 
treated over 7 days (1-7) with 1 µM 9cRA (DN) or an equivalent volume of EtOH (PN). 
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After 7 days, treatment was withdrawn from both PN and DN populations, which were 
grown in standard culture media alone for a further 5 days (12). Blots were probed 
with anti-β-tubulin III antibody which detected a band at 50 kDa, anti-vimentin 
antibody which detected a band at 57 kDa or β-actin antibody which was used as a 
loading control and detected a band at 42 kDa. (A) β-tubulin III was expressed at a 
similar level by both PN and DN populations with little variation in band intensity over 
the treatment time-course. β-tubulin III expression was also detected in both PN and 
DN populations following 5 days of treatment withdrawal. Vimentin was barely 
detected in PN populations and DN populations however there was an increase in band 
intensity from day 3 of treatment in DN populations. (B) There was no change in 
expression of β-tubulin III over the treatment time-course in PN populations (P=0.908) 
or DN populations (P=0.978). Throughout the differentiation time-course, there was no 
significant difference in β-tubulin III expression between PN and DN populations 
(P=0.994) though there was a 22% increase in expression at day 5 (P=0.344). After 5 
days of treatment withdrawal, β-tubulin III expression was 35% lower in DN 
populations compared to PN populations. All N≥2 except 12 N=1. (C) There was no 
change in expression of vimentin over the treatment time-course in PN populations 
(P=0.998) or DN populations (P=0.965). Throughout the differentiation time-course, 
there was no significant difference in vimentin expression between PN and DN 
populations (P=0.934), although vimentin expression was 2-fold higher in DN 
populations from day 3 of treatment (P=0.181) and over 2-fold higher by day 7 of 
treatment (P=0.319). All N≥2. 
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Figure 6.2.2. Expression of β-tubulin III and vimentin in differentiating S-type 
populations 
Western blots were performed on protein samples from S-type populations that were 
treated over 7 days (1-7) with 1 µM 9cRA (DS) or an equivalent volume of EtOH (PS). 
After 7 days, treatment was withdrawn from both PS and DS populations, which were 
grown in standard culture media alone for a further 5 days (12). Blots were probed 
with anti-β-tubulin III antibody which detected a band at 50 kDa, anti-vimentin 
antibody which detected a band at 57 kDa or β-actin antibody which was used as a 
loading control and detected a band at 42 kDa. (A) β-tubulin III was expressed by both 
PS and DS populations and was also detected in both PS and DS populations following 5 
days of treatment withdrawal. Vimentin was detected in both PS populations and DS 
populations with a steady increase in band over the treatment time-course. Following 
5 days of treatment withdrawal, vimentin was detected in DS populations but not PS 
populations. (B) From day 3 of treatment β-tubulin III expression was reduced by 39% 
in DS populations and following treatment withdrawal, expression was reduced by 
16%. N≥1. (C) Over the treatment time-course, there was a steady but non-significant 
increase in vimentin expression in both PS populations (P=0.414) and DS populations 
(P=0.101). There was no significant difference in vimentin expression between DS and 
PS populations (P=0.131), although there was a 41% increase in vimentin expression at 
day 5 (P=0.231), 21% increase at day 6 (P=0.197) and 39% increase at day 7 (P=0.134) 
of treatment in DS compared to PS cells. Following 5 days of treatment withdrawal, 
vimentin expression remained over 3-fold higher in DS populations compared to PS 
populations. N≥2 except 12 N=1. 
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Figure 6.2.3 Expression of Bcl-2 is altered early in differentiating N-type populations  
Western blots were performed on protein samples from N-type populations treated 
over 7 days (1-7) with 1 µM 9cRA (DN) or an equivalent volume of EtOH (PN). After 7 
days, treatment was withdrawn and cells were grown in standard culture media for a 
further 5 days (12). Blots were probed with anti-Bcl-2 antibody which detected a band 
at 27 kDa or β-actin antibody which was used as a loading control and detected a band 
at 42 kDa. (A) Bcl-2 was expressed by both PN and DN populations over the treatment 
time-course and following treatment withdrawal, with little to no expression at day 1. 
Band intensity was greater in DN populations compared to PN populations and 
increased over the treatment time-course. (B) Bcl-2 expression increased significantly 
over the treatment time-course in PN populations (P<0.0001) and DN populations 
(P=0.0019). Over the treatment time-course, Bcl-2 expression was significantly higher 
in DN than PN populations (P<0.0001). Bcl-2 expression was increased in DN populations 
compared to PN populations by 51% at day 2 (P=0.366), over 2-fold at day 3 (P=0.060), 
3-fold at day 4 (P<0.0001****), over 2-fold at day 5 (P=0.0002***), 46% at day 6 
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(P=0.045*) and 74% at day 7 (P=0.002**). Following treatment withdrawal, there was 
no difference in Bcl-2 expression between DN and PN populations. N≥4 except 12 N=1. 
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Figure 6.2.4 Expression of Bcl-2 is not altered in differentiating S-type populations  
Western blots were performed on protein samples from S-type populations that were 
treated over 7 days (1-7) with 1 µM 9cRA (DS) or an equivalent volume of EtOH (PS). 
After 7 days, treatment was withdrawn and cells were grown in standard culture 
media alone for a further 5 days (12). Blots were probed with anti-Bcl-2 antibody 
which detected a band at 27 kDa or β-actin antibody which was used as a loading 
control and detected a band at 42 kDa. (A) Bcl-2 was expressed by both PS and DS 
populations over the treatment time-course and following treatment withdrawal. (B) 
There was no significant difference in Bcl-2 expression over the treatment time-course 
in PS populations (P=0.762) or DS populations (P=0.246). There was no significant 
difference in Bcl-2 expression between PS and DS populations over the treatment time-
course (P=0.472), though Bcl-2 was down-regulated by 34% at day 7 (P=0.121) in DS 
populations compared to PS populations. Following treatment withdrawal for 5 days, 
Bcl-2 expression was 76% lower in DS populations compared to PS populations. N≥3 
except 12 N=1. 
  
235 
 
 
Figure 6.2.5. CD133 expression is altered early in differentiating N-type populations 
Western blots were performed on protein samples from N-type populations that were 
treated over 7 days (1-7) with 1 µM 9cRA (DN) or an equivalent volume of EtOH (PN). 
Blots were probed with anti-CD133 antibody which detected a band at 97 kDa or β-
actin antibody which was used as a loading control and detected a band at 42 kDa. (A) 
CD133 was expressed in both PN and DN populations over the treatment time-course. 
(B) There was a non-significant decrease in CD133 expression over the treatment time-
course in PN populations (P=0.712). There was a non-significant increase in CD133 
expression over the treatment time-course in DN populations (P=0.074). From day 3 of 
treatment, CD133 expression was increased by 84% (P=0.219) in DN populations 
compared to PN populations and by over 4-fold by day 7 (P=0.117) ). N≥1. 
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6.3. Changes in SOCE activity occur from the first day of 9cRA treatment 
As previously described (Chapter 4), there was an uncoupling of Ca2+ store release and 
SOCE in day 7 9cRA-differentiated N-type and S-type populations with the extent of 
SOCE down-regulation greater in S-type than N-type populations. In this section, Ca2+ 
signals associated differentiation responses were observed over the 7 day time-course 
of 9cRA treatment. 
 
In DN populations compared to PN populations, from the first day of 9cRA treatment, 
total SOCE was down-regulated by 39% (P<0.0001, Figure 6.3.1A and B). Total Ca2+ 
store release was reduced at day 2 by 15% (P=0.007) and day 3 by 26% (P<0.0001) 
whilst the extent of total SOCE down-regulation remained at ~30% (Figure 6.3.1A and 
B). The extent of total SOCE down-regulation peaked to 61% at day 4 (P<0.0001) of 
treatment and remained down-regulated by ~60% until day 6 of treatment and by day 
7, total SOCE was down-regulated by 39% (P=0.012, Figure 6.3.1A and B). Following 5 
days of treatment withdrawal, total Ca2+ store release was increased by 38% 
(P<0.0001) and total SOCE remained down-regulated by 40% (Figure 6.3.1A and B). 
These results suggest that 9cRA-induced differentiation of N-type populations induces 
an uncoupling of Ca2+ store release and SOCE in a multi-step manner, causing 
uncoupling from the first day of treatment, the extent of which is exaggerated from 
the fourth day of treatment. This data reveals that the previously observed Ca2+ 
signalling profile seen at day 7 (Chapter 4) is present in DN populations from the fourth 
day of exposure to 9cRA. Following treatment withdrawal, the extent of uncoupling of 
Ca2+ store release and SOCE remains similar to that seen at day 7 of treatment, 
indicating that SOCE uncoupling is at least partially maintained following removal of 
the differentiating stimulus.  
 
In DN populations compared to PN populations, there was some reduction in maximal 
Ca2+ store release but there was no significant difference over the treatment time-
course (P>0.997, Figure 6.3.2A). Maximal SOCE trended towards a down-regulation 
over the treatment time-course (P<0.0001), however this was only significant at day 1 
(P<0.0001) and day 5 (P=0.032) of treatment (Figure 6.3.2A). This implies that maximal 
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Ca2+ entry is not significantly altered over the differentiation response of N-type 
populations of following the withdrawal of the differentiation stimulus. 
 
In DN populations compared to PN populations, rate of Ca
2+ store release was 
significantly reduced at day 1 (P=0.006), day 6 (P=0.05), day 7 and day 12 (P<0.0001, 
Figure 6.3.2B). Rate of SOCE showed an increase over the treatment time-course 
(P<0.0001), however this was only significant at day 7 and 12 (both P<0.0001, Figure 
6.3.2B). This observation suggests that alterations in the speed and/or efficiency of 
Ca2+ entry are confined to the later phase of the differentiation response rather than in 
the initiation of differentiation in N-type populations and are maintained following 
removal of the differentiation stimulus. 
 
In DN populations compared to PN populations, rate of decline of Ca
2+ store release was 
reduced over the treatment time-course (P<0.0001) and from the first day of 
treatment (P=0.009, Figure 6.3.2C). Rate of decline was reduced up to day 5 and 
increased from day 6, however this was only significant at day 12 (P<0.0001, Figure 
6.3.2C). Rate of initial SOCE decline was increased throughout the treatment time-
course (P<0.0001) except at day 6 (P=0.630) whilst rate of late SOCE decline was 
reduced throughout the treatment time-course (P<0.0001) except and day 12 
(P=0.448) and an increase at day 6 (P=0.018, Figure 6.3.2C). These results indicate that 
alterations in speed and/or efficiency of Ca2+ entry inhibition occur early in the 
differentiation response of N-type populations and are maintained following removal 
of the differentiation stimulus. 
 
In DS populations compared to PS populations, from the first day of 9cRA treatment, 
total Ca2+ store release was reduced by 20% (P<0.0001) and total SOCE was down-
regulated by 21% (Figure 6.3.3A and B). The extent of SOCE down-regulation shows a 
steady increase over the treatment time-course, peaking at 71% SOCE down-regulation 
by day 5 (P<0.0001). SOCE remains down-regulated at day 7 (P<0.0001, Figure 6.3.3A 
and B). This suggests that 9cRA-induced differentiation of S-type populations causes an 
uncoupling of Ca2+ store release and SOCE in a gradually increasing manner from the 
first day of treatment. These data reveal that the previously observed Ca2+ signalling 
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profile seen at day 7 (Chapter 4) is present in DS populations from the fifth day of 
exposure to 9cRA. Interestingly, following treatment withdrawal, Ca2+ store release is 
reduced by 34% (P=0.005) and SOCE is restored to that seen in PS populations (Figure 
6.3.3A and B). This suggests that following treatment withdrawal, there is no longer an 
uncoupling of Ca2+ store release and SOCE, indicating that DS populations may either 
revert back to a coupled SOCE response like that of PS populations or that SOCE 
uncoupling is involved in the initiation of the early differentiation response but not in 
maintaining the differentiated state of S-type populations.  
 
In DS populations compared to PS populations, there is a reduction in maximal Ca
2+ 
store release early in the differentiation response day 1 (P=0.002), day 2 (P=0.0005) 
and day 3 (P<0.0001) which becomes unaltered at day 4 (P>0.999) and 5 (P=0.701) 
then increases at day 6 (P<0.0001, Figure 6.3.4A), suggesting a varied effect on Ca2+ 
store size or TG sensitivity between the early and late differentiation response of S-
type populations. Maximal SOCE is down-regulated throughout the treatment time-
course (P<0.0001) except following treatment withdrawal (P>0.999, Figure 6.3.4A), 
indicating maximal Ca2+ entry to be altered early in the differentiation response of S-
type populations which is either lost following the removal of the differentiation 
stimulus or not needed to maintain the differentiation response.  
 
In DS populations compared to PS populations, rate of Ca
2+ store release was reduced 
from day 2 (P<0.0001) to day 5 (P=0.012) of treatment but was increased from day 6 
(P=0.0001) and following treatment removal (P=0.028, Figure 6.3.4B), again suggesting 
a varied effect on the speed of Ca2+ store release rate or on TG sensitivity between the 
early and late differentiation response of S-type populations. Rate of SOCE was 
reduced at day 1 (P<0.0001) and day 2 (P=0.004) of treatment but was increased from 
day 4 (P<0.0001) of treatment and following treatment withdrawal (P=0.028, Figure 
6.3.4B), indicating that the speed and/or efficiency of Ca2+ entry is altered early in the 
differentiation response of S-type populations but is altered in a different manner 
during the differentiation response. 
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In DS populations compared to PS populations, rate of decline of Ca
2+ store release was 
reduced from day 1 to 4 (P<0.0001) and was increased at day 6 (P<0.0001) of 
treatment whilst rate of total SOCE decline was also reduced early in the 
differentiation response (Figure 6.3.4C). Rate of initial SOCE decline was increased 
throughout the treatment time-course and following treatment withdrawal (P<0.0001) 
but was increased at day 7 (P=0.016) whilst rate of late SOCE decline was reduced up 
to day 5 (P<0.0001) and non-significantly increased at day 6 and 7 (P>0.999). These 
results suggest that rate of deactivation of Ca2+ entry is altered early in the 
differentiation response of S-type populations and in a different manner to that 
observed late in the differentiation response. 
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Figure 6.3.1. 9cRA-induced differentiation of N-type populations induces SOCE 
changes in a multi-step manner 
N-type populations were treated over 7 days (1-7) with 1 µM 9cRA (DN) or an 
equivalent volume of EtOH (PN). After 7 days, treatment was withdrawn from both PN 
and DN cells, which were grown in media alone for a further 5 days (12). Changes in 
fluorescence ratio units (FRUs) are reflective of changes in [Ca2+]i. Following addition of 
thapsigargin (TG) there was increase in FR in PN and DN populations indicating Ca
2+ 
store release. Subsequent Ca2+-addback (CaCl2) caused an increase in FR in PN and DN 
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populations, indicating SOCE to replenish depleted stores.  (A) At day 1, there was no 
significant difference in total Ca2+ store release between DN populations (86.16 ± 2.11 
FRUs) and PN populations (93.66 ± 1.83 FRUs, P=0.349) and total SOCE was down-
regulated by 39.23% in DN populations (264.94 ± 18.51 FRUs) compared to PN 
populations (436.01 ± 21.83 FRUs, P<0.0001****). At day 2, there was a 14.78% 
reduction in total Ca2+ store release in DN populations (77.50 ± 3.10 FRUs) compared to 
PN populations (90.94 ± 2.14 FRUs, P=0.007**) and total SOCE was down-regulated by 
27.87% in DN populations (210.53 ± 12.81 FRUs) compared to PN populations (342.47 ± 
15.52 FRUs). At day 3, there was a 26.42% reduction in total Ca2+ store release in DN 
populations (67.13 ± 2.14 FRUs) compared to PN populations (91.25 ± 2.36 FRUs, 
P<0.0001****) and total SOCE was down-regulated by 25.52% in DN populations 
(152.36 ± 9.10 FRUs) compared to PN populations (278.06 ± 21.49 FRUs). At day 4, 
there was no difference in total Ca2+ store release between PN populations (90.85 ± 
2.10 FRUs) and DN populations (90.19 ± 2.53 FRUs, P>0.999) and total SOCE was down-
regulated by 60.85% in DN populations (138.75 ± 19.11 FRUs) compared to PN 
populations (354.41 ± 23.99 FRUs, P<0.0001****). At day 5, there was an 18.43% 
reduction in total Ca2+ store release in DN populations (73.24 ± 2.17 FRUs) compared to 
PN populations (89.79 ± 3.01 FRUs, P<0.0001****) and total SOCE was down-regulated 
by 59.33% in DN populations (135.59 ± 23.71 FRUs) compared to PN populations 
(408.68 ± 22.62 FRUs). At day 6, there was an 18.28% increase in total Ca2+ store 
release in DN populations (82.24 ± 2.83 FRUs) compared to PN populations (69.53 ± 
2.36 FRUs, P=0.020*) and total SOCE was down-regulated by 57.12% in DN populations 
(152.43 ± 23.15 FRUs) compared to PN populations (300.52 ± 14.59 FRUs). At day 7, 
there was no significant difference in total Ca2+ store release between DN populations 
(83.59 ± 2.08 FRUs) and PN populations (84.66 ± 2.10 FRUs, P>0.999) and total SOCE 
was down-regulated by 38.86% in DN populations (186.22 ± 15.61 FRUs) compared to 
PN populations (3004.57 ± 12.82 FRUs, P=0.011*). Following 5 days of treatment 
withdrawal, Ca2+ store release was increased by 37.72% in DN populations (56.26 ± 
1.53 FRUs) compared to PN populations (40.85 ± 0.98 FRUs, P<0.0001) and SOCE was 
down-regulated by 40.5% in DN populations (127.77 ± 9.75 FRUs) compared to PN 
populations (155.93 ± 10.25 FRUs). (B) The following percentages compare the average 
total SOCE of DN populations with corresponding PN populations from each day taken 
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to be 100%. Total SOCE was down-regulated by 31.88% at day 1 (P=0.081), 26.74% at 
day 2 (P=0.253) and 23.23% at day 3 (P=0.276) of treatment. There was a greater 
extent of down-regulation at 4 by 60.07% (P=0.003**) and further down-regulation at 
day 5 by 83.33% (P=0.0002***). By day 6, there was some recovery with total SOCE 
down-regulated by 56.50% (P=0.005**) and further still at day 7 with total SOCE down-
regulated by 40.06% (P=0.045*). Following treatment withdrawal for 5 days, SOCE 
remained down-regulated by 38.08% (P=0.0506). PN: 1 n=335, 2 n=242, 3 n=254, 4 
n=283, 5 n=228, 6 n=253, 7 n=329, 12=282. DN: 1 n=355, 2 n=236, 3 n=390, 4 n=286, 5 
n=279, 6 n=211, 7 n=253, 12=278. N≥2. 
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Figure 6.3.2. 9cRA-induced differentiation of N-type populations induces changes in 
SOCE dynamics from the first day of treatment 
N-type populations were treated over 7 days (1-7) with 1 µM 9cRA (DN) or an 
equivalent volume of EtOH (PN). After 7 days, treatment was withdrawn from both PN 
and DN cells, which were grown in media alone for a further 5 days (12). All calculations 
are for DN cells compared to PN cells. Changes in fluorescence ratio units (FRUs) are 
reflective of changes in [Ca2+]i. Following addition of thapsigargin (TG) there was 
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increase in FRU in PN and DN populations indicating Ca
2+ store release. Subsequent 
Ca2+-addback (CaCl2) caused an increase in FR in PN and DN populations, indicating 
SOCE to replenish depleted stores. (A) At day 1, there was no significant difference in 
maximal Ca2+ store release (P>0.999) and maximal SOCE was down-regulated by 
57.23% (P=0.0009***). At day 2, there was no significant difference in maximal Ca2+ 
store release (P>0.999) and maximal SOCE was down-regulated by 29.88%, though this 
was non-significant (P=0.895). At day 3, there was no significant difference in maximal 
Ca2+ store release (P>0.999) and maximal SOCE was down-regulated by 30.54%, 
though this was non-significant (P=0.994). At day 4, there was no significant difference 
in maximal Ca2+ store release (P>0.999) and maximal SOCE was down-regulated by 
43.81%, though this was non-significant (P=0.904). At day 5, there was no significant 
difference in maximal Ca2+ store release (P>0.999) and maximal SOCE was down-
regulated by 57.61% (P=0.032*). At day 6, there was no significant difference in 
maximal Ca2+ store release (P>0.999) and maximal SOCE was down-regulated by 
29.68%, though this was non-significant (P=0.961). At day 7, there was no difference in 
maximal Ca2+ store release (P>0.999) or maximal SOCE (P>0.999). Following treatment 
withdrawal for 5 days, there was no significant difference in maximal Ca2+ store release 
(P>0.999) or maximal SOCE (P>0.999). (B) Rate of Ca2+ store release was significantly 
reduced at day 1 (P=0.006), day 6 (P=0.005) and day 7 (P<0.0001). Rate of SOCE was 
significantly increased at day 7 (P<0.0001). All other rates were not significantly 
altered. (C) Rate of decline of Ca2+ store release was decreased at day 1 (P=0.009), day 
3 (P=0.020), day 4 (P=0.0001), day 6 (P=0.003) and day 7 (P=0.029). Rate of total SOCE 
decline was significantly increased at day 12 (P<0.0001). Rate of initial SOCE decline 
was significantly increased at day 1 (P=0.002), day 2, 3, 4, 7 and 12 (all P<0.0001) and 
day 5 (P=0.007). Rate of late SOCE decline rate was decreased at day 1-5 and day 7 (all 
P<0.0001) and was increased at day 6 (P=0.018). All other rates were not significantly 
altered.  PN: 1 n=335, 2 n=242, 3 n=254, 4 n=283, 5 n=228, 6 n=253, 7 n=329, 12=282. 
DN: 1 n=355, 2 n=236, 3 n=390, 4 n=286, 5 n=279, 6 n=211, 7 n=253, 12=278. N≥2. 
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Figure 6.3.3. 9cRA-induced differentiation of S-type populations induces SOCE 
changes in a gradual manner 
S-type populations were treated over 7 days (1-7) with 1 µM 9cRA (DS) or an 
equivalent volume of EtOH (PS). After 7 days, treatment was withdrawn from both PS 
and DS cells, which were grown in media alone for a further 5 days (12). Changes in 
fluorescence ratio units (FRUs) are reflective of changes in [Ca2+]i. Following addition of 
thapsigargin (TG) there was increase in FRU in PN and DN populations indicating Ca
2+ 
store release. Subsequent Ca2+-addback (CaCl2) caused an increase in FR in PS and DS 
populations, indicating SOCE to replenish depleted stores. (A) At day 1, there was a 
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20.33% reduction in total Ca2+ store release in DS populations (66.30 ± 1.27 FRUs) 
compared to PS populations (83.22 ± 1.54 FRUs, P<0.0001****) and total SOCE was 
down-regulated by 20.25% in DS populations (198.42 ± 14.12 FRUs) compared to PS 
populations (312.29 ± 12.20 FRUs). At day 2, there was a 16.88% reduction in total Ca2+ 
store release in DS populations (73.03 ± 1.96 FRUs) compared to PS populations (87.85 
± 1.87 FRUs, P<0.0001****) and total SOCE was down-regulated by 16.41% in DS 
populations (153.48 ± 15.39 FRUs) compared to PS populations (220.9 ± 11.38 FRUs). 
At day 3, there was a 19.22% reduction in total Ca2+ store release in DS populations 
(64.37 ± 1.92 FRUs) compared to PS populations (79.69 ± 1.69 FRUs, P<0.0001****) 
and total SOCE was down-regulated by 43.29% in DS populations (124.21 ± 10.98 FRUs) 
compared to PS populations (271.16 ± 12.94 FRUs). At day 4, there was a 32.37% 
reduction in total Ca2+ store release in DS populations (59.83 ± 1.92 FRUs) compared to 
PS populations (88.47 ± 2.39 FRUs, P<0.0001****) and total SOCE was down-regulated 
by 65.48% in DS populations (75.01 ± 14.35 FRUs) compared to PS populations (321.32 
± 13.48 FRUs). At day 5, there was no significant difference in total Ca2+ store release 
between PS populations (52.08 ± 1.23 FRUs) and DS populations (49.82 ± 1.87 FRUs, 
P=0.9997) and total SOCE was down-regulated by 71.09% in DS populations (86.99 ± 
20.48 FRUs) compared to PS populations (314.49 ± 15.57 FRUs, P<0.0001****). At day 
6, there was a 54.22% increase in total Ca2+ store release in DS populations (73.40 ± 
2.44 FRUs) compared to PS populations (47.59 ± 1.21 FRUs, P<0.0001****) and total 
SOCE was down-regulated by 55.82% in DS populations (151.77 ± 15.56 FRUs) 
compared to PS populations (222.72 ± 9.57 FRUs). At day 7, there was no significant 
difference in total Ca2+ store release between PS populations (59.13 ± 1.27 FRUs) and 
DS populations (57.52 ± 1.96 FRUs, P>0.999) and total SOCE was down-regulated by 
70.36% in DS populations (57.82 ± 15.79 FRUs) compared to PS populations (200.52 ± 
9.11 FRUs, P<0.0001****). Following 5 days of treatment withdrawal, Ca2+ store 
release was reduced by 34.26% in DS populations (25.91 ± 2.20 FRUs) compared to PS 
populations (39.41 ± 0.85 FRUs, P=0.005**) and there was no change in SOCE between 
PS populations (162.88 ± 8.05 FRUs) and DS populations (110.55 ± 16.46 FRUs). (B) The 
following percentages compare the average total SOCE of DS populations with 
corresponding PS populations from each day taken to be 100%. At day 1 and 2 of 
treatment, total SOCE is down-regulated by 20.90% and 22.61% respectively. There is a 
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gradual greater extent of total SOCE down-regulation with subsequent days of 
treatment, with down-regulation by 27.62% at day 3, 44.94% at day 4, 55.02% at day 5, 
56.11% at day 6 and 66.59% at day 7. Following treatment withdrawal for 5 days, there 
was no difference in SOCE. PS: 1 n=453, 2 n=361, 3 n=442, 4 n=334, 5 n=513, 6 n=584, 7 
n=260, 12 n=401. DS: 1 n=487, 2 n=407, 3 n=379, 4 n=280, 5 n=317, 6 n=420, 7 n=263, 
12 n=135. N≥2. 
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Figure 6.3.4. 9cRA-induced differentiation of S-type populations induces changes in 
SOCE dynamics from the first day of treatment 
S-type populations were treated over 7 days (1-7) with 1 µM 9cRA (DS) or an 
equivalent volume of EtOH (PS). After 7 days, treatment was withdrawn from both PS 
and DS cells, which were grown in media alone for a further 5 days (12). All calculations 
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are for DS cells compared to PS cells. Changes in fluorescence ratio units (FRUs) are 
reflective of changes in [Ca2+]i. Following addition of thapsigargin (TG) there was 
increase in FRU in PS and DS populations indicating Ca
2+ store release. Subsequent Ca2+-
addback (CaCl2) caused an increase in FR in PN and DN populations, indicating SOCE to 
replenish depleted stores. (A) At day 1, there was a 14.27% reduction in maximal Ca2+ 
store release (P=0.002**) and maximal SOCE was down-regulated by 13.72%. At day 2, 
there was a 21.72% reduction in maximal Ca2+ store release (P=0.0005***) and 
maximal SOCE was down-regulated by 36.65%. At day 3, there was a 20.30% reduction 
in maximal Ca2+ store release (P<0.0001****) and maximal SOCE was down-regulated 
by 3.51%. At day 4, there was no difference in maximal Ca2+ store release (P>0.999) 
and maximal SOCE was down-regulated by 70.14% (P<0.0001****). At day 5, there 
was no difference in maximal Ca2+ store release (P=0.701) and maximal SOCE was 
down-regulated by 97.92% (P<0.0001****). At day 6, there was a 35.83% increase in 
maximal Ca2+ store release (P<0.0001****) and maximal SOCE was down-regulated by 
29.01%. At day 7, there was no difference in maximal Ca2+ store release (P>0.999) and 
maximal SOCE was down-regulated by 66.95% (P=0.0001***). Following treatment 
withdrawal, there was no significant difference in maximal Ca2+ store release and SOCE 
was up-regulated by 33.54%, though this was non-significant (P>0.999). (B) The rate of 
Ca2+ store release was significantly increased at day 1 (P=0.003), day 6 (P=0.0001) and 
day 12 (P=0.028) and was significantly decreased at day 2 (P<0.0001), day 3 (P=0.028), 
day 4 (P=0.011) and day 5 (P=0.012). The rate of SOCE was significantly reduced at day 
1 (P<0.0001) and day 2 (P=0.004) and significantly increased at day 4 and 6 (both 
P<0.0001) and day 12 (P=0.028). All other rates were not significantly altered. (C) Rate 
of Ca2+ store release was significantly reduced at day 1-4 (all P<0.0001) and was 
significantly increased at day 6 (P<0.0001). Rate of total SOCE decline was significantly 
reduced at day 2 and 5 (both P<0.0001) and was significantly increased at day 6 
(P<0.0001). Rate of initial SOCE decline was significantly increased at day 4-6 and day 
12 (all P<0.0001) and significantly reduced at day 7 (P=0.016). Rate of late SOCE 
decline was significantly reduced at day 2-5 (all P<0.0001). All other rates were not 
significantly altered. PS: 1 n=453, 2 n=361, 3 n=442, 4 n=334, 5 n=513, 6 n=584, 7 
n=260, 12 n=401. DS: 1 n=487, 2 n=407, 3 n=379, 4 n=280, 5 n=317, 6 n=420, 7 n=263, 
12 n=135. N≥2.  
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6.4. Changes in SOCE machinery expression are induced from the first day of 9cRA 
treatment 
SOCE becomes down-regulated in a multi-step manner in N-type populations, being 
down-regulated from the first day of 9cRA treatment, the extent of which is increased 
from day 4 of treatment and is retained following treatment withdrawal. SOCE is also 
down-regulated from the first day of 9cRA treatment in S-type populations, the extent 
of which increases in a gradual manner over the treatment time-course and is lost 
following treatment withdrawal. This suggests that there may be underlying difference 
in the expression of SOCE proteins between N-type and S-type populations over the 
time-course of the differentiation response. Therefore expression of the SOCE proteins 
STIM1 and Orai1 were investigated over the time-course of 9cRA treatment and 
following treatment withdrawal in N-type and S-type populations to determine any 
changes in expression that may be associated with the observed changes in SOCE. 
 
STIM1 was expressed in PN and DN populations over the treatment time-course (Figure 
6.4.1A). The total level of STIM1 expression was unchanged over the treatment time-
course in both PN populations (P=0.741) and DN populations (P=0.387, Figure 6.4.1B). 
Also, total STIM1 was expressed to a slightly less extent in DN populations compared to 
PN populations over the treatment time-course (P=0.078), although this was not 
significant. STIM1 was down-regulated by 40% from the first day of treatment 
(P=0.088). However, expression of total STIM1 levels masks the observation that a 
band of less intensity or a slight increase in molecular weight was often observed in DN 
populations. This became particularly clear from the third day of treatment (Figure 
6.4.1A). Following treatment withdrawal, there was a 16% down-regulation in the level 
of STIM1 expression in DN populations compared to PN populations (Figure 6.4.1B) and, 
importantly, the increased molecular weight form of STIM1 normally associated with 
DN cells was no longer observed (Figure 6.4.1A). 
 
Orai1 was expressed in PN populations and to much a lesser extent or was absent in DN 
populations over the treatment time-course (Figure 6.4.1A). There was no significant 
change in the level of Orai1 expression over the treatment time-course by PN 
populations (P=0.127) or DN populations (P=0.116). Orai1 was expressed to a lesser 
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extent in DN populations compared to PN populations over the treatment time-course 
(P=0.0007). There was down-regulation of Orai1 expression in DN populations 
compared to PN populations by 80% at day 1 (P=0.008) and Orai1 remained down-
regulated by 75% at day 5 (P=0.095, Figure 6.4.1C). However, the extent of Orai down-
regulation recovered somewhat by day 6 (31%, P=0.602) and remained down-
regulated by 40% at day 7 (P=0.046, Figure 6.4.1C). Following treatment withdrawal, 
Orai1 expression remained 41% lower in DN populations compared to PN populations 
(Figure 6.4.1A and C). 
 
Taken together, these results are consistent with a down-regulation of both STIM1 and 
Orai1 underlying the initial down-regulation of SOCE observed from the first day of 
9cRA treatment in N-type populations. It may be that an initial down-regulation of 
STIM1 and Orai1 coupled with a potential modification of STIM1, such as 
phosphorylation, drives the initial down-regulation of SOCE. The later ‘step’ of SOCE 
down-regulation could potentially be due to a further drop in expression of STIM1. 
Following treatment withdrawal, the change in STIM1 molecular weight is lost and 
total levels of STIM1 remain slightly dampened whilst Orai1 down-regulation is 
maintained. The observed reduction in SOCE activity could therefore result from a 
combination of dampened Orai1 expression plus dampened STIM1 expression, even 
though the form of STIM1 present may be functional. 
 
STIM1 was expressed in PS and DS populations over the treatment time-course, 
generally with less band intensity in DS populations (Figure 6.4.2A). However, there 
was no significant difference in the level of STIM1 expression in PS populations 
compared to DS populations over the treatment time-course (P=0.948, Figure 6.4.2B). 
Also, the level of STIM1 expression was not significantly altered over the treatment 
time-course in PS populations (P=0.900) or DS populations (P=0.714, Figure 6.4.2A and 
B). Following treatment withdrawal, STIM1 expression was up-regulated over 3-fold in 
DN populations compared to PN populations (Figure 6.4.2B) and a clear increase in 
STIM1 molecular weight could be observed in DS populations (Figure 6.4.2A).  
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Orai1 was expressed in PS populations and to a lesser extent in DS populations, with 
expression diminishing from day 3 of treatment in DS populations (Figure 6.4.2A). Over 
the treatment time-course, there was no significant change in the level of Orai1 
expression in PS populations (P=0.460) and a slight but non-significant decline in the 
level of Orai1 expression in DS populations (P=0.816, Figure 6.4.2A and C). Orai1 was 
generally expressed to a lesser extent in DS populations compared to PN populations 
throughout the treatment time-course, though this was non-significant (P=0.684, 
Figure 6.4.2A and C). Orai1 expression was down-regulated by ~20% from day 2 
(P=0.271) of treatment, increasing to a down-regulation of ~30% by day 6 (P=0.402) 
and by ~40% by day 7 (P=0.073, Figure 6.4.2C). Following treatment withdrawal, Orai1 
expression was reduced by 95% in DS populations compared to PS populations (Figure 
6.4.2A and C).  
 
Taken together, these results suggest that the reduction in SOCE activity during the 
differentiation response of S-type populations could be driven predominantly by Orai1 
down-regulation as the expression of STIM1 is only slightly altered. By day 6 and 7 of 
treatment dampened Orai1 expression coincides with the observed peak in dampened 
SOCE activity. Following treatment withdrawal, there is an increase in the level of 
STIM1 expression however an increase in STIM1 molecular weight can be observed. 
This is accompanied by a further increase in the extent of Orai1 down-regulation. 
Given that SOCE activity is seen to recover after treatment withdrawal, this implies 
that perhaps another SOC channel (e.g.TRPC1) by which SOCE can occur may either be 
up-regulated or undergo a modification in its function in order to compensate for the 
lack of Orai1 following removal of the differentiation stimulus from S-type populations. 
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Figure 6.4.1. STIM1 and Orai1 expression are altered early in differentiating N-type 
populations 
Western blots were performed on protein samples from N-type populations that were 
treated over 7 days (1-7) with 1 µM 9cRA (DN) or an equivalent volume of EtOH (PN). 
After 7 days, treatment was withdrawn from both PN and DN cells, which were grown 
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in standard culture media alone for a further 5 days (12). Blots were probed with anti-
STIM1 antibody which detected a band at 84 kDa, anti-Orai1 antibody which detected 
a band at 50 kDa or β-actin antibody which was used as a loading control and detected 
a band at 42 kDa. (A) STIM1 was expressed in both PN and DN populations over the 
treatment time-course, sometimes with lesser band intensity or a slight increase in 
molecular weight in DN populations, which becomes clear from day 3 of treatment. 
Following treatment withdrawal, this increase in STIM1 molecular weight was also 
observed. Orai1 was expressed in PN populations and to much a lesser extent or was 
absent in DN populations over the treatment time-course and following treatment 
withdrawal. (B) There was no significant change in the level of STIM1 expression over 
the treatment time-course by PN populations (P=0.741) or DN populations (P=0.387). 
DN populations expressed STIM1 to a slightly lesser extent, though non-significantly, 
compared to PN populations over the treatment time-course (P=0.078). In DN 
populations compared to PN populations, STIM1 was down-regulated by 40% at day 1 
(P=0.088) and day 2 (P=0.253). The extent of down-regulation was reduced at day 3 (by 
14%, P=0.612) and day 4 (7%, P=0.870). However, by day 5, the extent of STIM1 down-
regulation had increased to 35% (P=0.275) then was significantly down-regulated by 
74% at day 6 (P=0.017*) and by 34% at day 7 (P=0.134). Following treatment 
withdrawal, there was a 16% reduction in level of STIM1 expression of DN populations 
compared to PN populations. N≥3 except 12 N=1. (C) There was no significant change in 
the level of Orai1 expression over the treatment time-course by PN populations 
(P=0.127) or DN populations (P=0.116). Orai1 was expressed to a lesser extent in DN 
populations compared to PN populations over the treatment time-course (P=0.0007). 
There was a down-regulation of Orai1 expression in DN populations compared to PN 
populations by 80% at day 1 (P=0.008**), 66% at day 2 (P=0.086), 89% at day 3 
(P=0.147), 69% at day 4 (P=0.198), 75% at day 5 (P=0.095), 31% at day 6 (0.602) and 
40% at day 7 (P=0.046*). Following treatment withdrawal, Orai1 expression was 41% 
lower in PN populations compared to DN populations. N≥3 except 12 N=1. 
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Figure 6.4.2. STIM1 and Orai1 expression are altered gradually in differentiating S-
type populations 
Western blots were performed on protein samples from S-type populations that were 
treated over 7 days (1-7) with 1 µM 9cRA (DS) or an equivalent volume of EtOH (PS). 
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After 7 days, treatment was withdrawn from both PS and DS cells, which were grown in 
standard culture media alone for a further 5 days (12). Blots were probed with anti-
STIM1 antibody which detected a band at 84 kDa, anti-Orai1 antibody which detected 
a band at 50 kDa or β-actin antibody which was used as a loading control and detected 
a band at 42 kDa. (A) STIM1 was expressed in both PS and DS populations over the 
treatment time-course, sometimes with less band intensity as can be observed at day 
2, or a slight increase in molecular weight. Following treatment withdrawal, a clear 
increase in STIM1 molecular weight could be observed in DS populations. Orai1 was 
expressed in PS populations and to a lesser extent in DS populations, with expression 
diminishing from day 3 of treatment in DS populations and being absent at day 6 and 7 
and following treatment withdrawal. (B) The level of STIM1 expression was not 
significantly altered over the treatment time-course in PS populations (P=0.900) or DS 
populations (P=0.714). There was no significant difference in the level of STIM1 
expression in PS populations compared to DS populations over the treatment time-
course (P=0.948). In DS compared to PS populations, STIM1 expression was down-
regulated by 13% at day 1 (P=0.716), by 21% at day 6 (P=0.775) and by 20% at day 7 
(P=0.422) and was up-regulated by 27% at day 2 (P=0.670), 31% at day 3 (P=0.549), 
20% at day 4 (P=0.826) and 16% at day 5 (P=0.824). Following treatment withdrawal, 
STIM1 expression was up-regulated over 3-fold in DN populations compared to PN 
populations. N≥3 except 12 N=1. (C) There was no significant change in the level of 
Orai1 expression in PS populations (P=0.460) and a slight but non-significant decline in 
the level of Orai1 expression in DS populations (P=0.816) over the treatment time-
course. Orai1 was generally expressed to a lesser extent in DS populations compared to 
PN populations over the treatment time-course, but this was non-significant (P=0.684). 
Orai1 expression was down-regulated by 23% at day 2 (P=0.271), by 16% at day 3 
(P=0.660), by 32% at day 6 (P=0.402) and by 39% at day 7 (P=0.073) and was up-
regulated by 27% at day 4 (P=0.730). Following treatment withdrawal, Orai1 
expression was down-regulated by 95% in DS populations compared to PS populations. 
N≥2 except 12 N=1. 
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Chapter 6 – Discussion 
As previously explored (Chapter 3-5), treatment of N-type and S-type neuroblastoma 
populations with 1 µM 9cRA for 7 days induces morphological and biochemical 
differentiation. For N-type cells, this includes elongation of neurite-like processes, up-
regulation of Bcl-2, uncoupling of Ca2+ store release and SOCE and a down-regulation 
of the SOCE proteins STIM1 and Orai1. For S-type cells, differentiation involves cell 
margin spreading with increased cell dimensions, a slight down-regulation of Bcl-2, 
uncoupling of Ca2+ store release and SOCE and a down-regulation of the SOCE proteins 
STIM1 and Orai1. The aim of this chapter was to investigate the relationship between 
these characteristic biochemical changes and their association with the time-course of 
morphological the differentiation response.  
 
Morphological differentiation progressed in a multi-step manner in N-type cells and 
was initiated within the first day of 9cRA treatment in N-type populations, as has 
previously been shown (Cheung 2009; N. Bell 2013). There was further increase and a 
peak in differentiation at the fifth day of treatment, suggesting that there may a 
differentiation ‘step’ for N-type cells mid-way through the treatment time-course that 
defines their progression towards a neuronal phenotype. For S-type cells, however, 
morphological differentiation was induced gradually from the third day of treatment, 
peaking at day 5 for SO and SA cells but at day 7 for SE cells, highlighting a subtle 
variability between the sub-populations response to 9cRA-induced differentiation. 
These results also indicate that morphological 9cRA–induced differentiation is initiated 
earlier in N-type populations than S-type populations. RA can induce changes in gene 
expression just hours after exposure (LaRosa 1988) which is consistent with the 
changes observed at day 1 of treatment in N-type populations. Over the treatment 
time-course, the extent of differentiation does not exceed 30% in N-type cells, 
indicating that either cells respond to varying degrees in the given time or that not all 
cells respond to RA treatment, which could have implications for neuroblastoma 
treatment using RA in patients (Discussion 7.1). 
 
Following 5 days of treatment withdrawal, DN populations seem to revert back to a PN 
phenotype indicating that N-type cells may lose their differentiating characteristics 
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following removal of the differentiation stimulus. However, for S-type cells, DS SE cells 
show a potential reversion to a PS phenotype whilst DS SO and DS SA cells retain a DS 
morphology. PS SE cells seem to become more morphologically differentiated over time 
in culture, based on the increase in length between day 7 and 12, therefore it may be 
possible that 9cRA withdrawal does not cause DS SE cells to completely lose their 
differentiating characteristics, suggesting that, overall, S-type morphological 
differentiation may be mostly retained following removal of the differentiation 
stimulus. It is possible that N-type cells need longer exposure to 9cRA than S-type cells 
to reach an irreversible differentiating cell fate. Alternatively, given that N-type cells 
are known to be more tumourigenic than S-type cells in culture and in vivo (Ciccarone 
1989; Picacentini 1996; Walton 2004), N-type cells may be more capable of phenotypic 
interconversion and, in this case, favour a proliferating phenotype and this could 
potentially explain the poor retinoic acid response seen in patients. 
 
Over the differentiation time-course, as expected, the neuronal marker β-tubulin III 
was expressed to a greater extent in N-type populations than S-type populations. Since 
β-tubulin III expression was not altered over the differentiation time-course of DN or DS 
populations, this suggests that the level of β-tubulin III expression was unaffected by 
the differentiation response of N-type and S-type populations. It was expected that β-
tubulin III expression would increase over the differentiation time-course in N-type 
populations as they progress towards a neuronal phenotype, similar to other neuron 
specific proteins such as NeuN (Cheung 2009; Agholme 2010) and neurofilament-68 
(Messi 2008), and decrease over the differentiation time-course in S-type populations 
as they move towards a non-neuronal phenotype. However, as observed here, it has 
previously been shown that expression of other neuronal markers, such as 
neurofilaments and dopamine transporters, do not change with RA-induced 
differentiation (Encinas 2000; Cheung 2009) and that S-type cells can express other 
neuronal markers, such as NF-68 (Messi 2008; Acosta 2009). Following treatment 
withdrawal, β-tubulin III expression was reduced in DN compared to PN populations, 
and there was no difference in expression between PS and DS populations. This 
suggests that there may be some reversion away from a neuronal phenotype with 
removal of the differentiation stimulus in N-type populations that does not occur in S-
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type populations, which corresponds to the morphological response observed, 
perhaps due to the non-neuronal nature of S-type cells. 
 
The non-neuronal marker vimentin was expressed to a greater extent in S-type 
populations than N-type populations throughout the treatment time-course. A slight 
increase in vimentin expression in PS populations early in the treatment time-course 
implies that these cells may move towards a more non-neuronal phenotype over time 
in culture. Vimentin expression also increased in DS populations over the treatment 
time-course and was slightly higher than PS populations at day 6 and 7, indicative of S-
type populations becoming more non-neuronal-like with differentiation. Following 
treatment withdrawal, vimentin expression remained higher in DS compared to PS 
populations, suggesting that S-type cells remain committed to a non-neuronal lineage 
despite removal of the differentiation stimulus, corresponding with the previously 
discussed morphological response and β-tubulin III expression. Vimentin was 
expressed very weakly in PN populations and expression was slightly higher in DN 
populations early in the treatment time-course, which corresponds with the previous 
finding that vimentin is temporarily up-regulated with neurite outgrowth (Shea 1993; 
Whitworth 2012; N. Bell 2013). Vimentin is known to have a role in initial 
neuritogenesis then becomes down-regulated through phosphorylation by Rho-kinase 
(Y. Nakamura 2000) and replaced by neurofilaments, coinciding with dampened 
neurite outgrowth or retraction (Shea 1993; Boyne 1996; Yabe 2003; Dubey 2004).  
 
Bcl-2 expression increased over the differentiation response of N-type populations but 
is slightly reduced with differentiation of S-type populations. This suggests that Bcl-2 is 
an effective marker for differentiation in N-type populations as an increase of 
expression coincides with the differentiation response of N-type populations but not S-
type populations, as previously shown (Bell 2011). Bcl-2 expression was up-regulated 
early in the differentiation process and in DN populations progressively increased from 
the first day of treatment. Bcl-2 expression is associated with neural differentiation 
(Zhang 1996; Middleton 1998; Suzuki 1998) and given that the up-regulation observed 
in this study begins shortly after initial neurite elongation occurs, Bcl-2 may be 
involved in enhancing neurite outgrowth and establishing a differentiating phenotype 
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rather than initiating the neurite elongation seen on the first day of 9cRA treatment. 
Following treatment withdrawal, this up-regulation of Bcl-2 expression in DN 
populations is lost, indicating that N-type cells may revert away from a differentiating 
phenotype following the removal of the differentiation stimulus, correlating with the 
previous morphological and β-tubulin III findings and consistent with the role of Bcl-2 
in neural differentiation (Zhang 1996; Middleton 1998; Suzuki 1998). Bcl-2 expression 
is slightly reduced in DS populations compared to PS populations following treatment 
withdrawal, indicating that S-type cells may retain their non-neuronal-like 
differentiating phenotype, correlating with the previous morphological, β-tubulin III 
and vimentin results. 
 
Expression of the stem cell marker CD133 was slightly up-regulated in DN populations 
compared to PN populations, implying that with differentiation, N-type populations 
may retain stem-cell like properties throughout the differentiation response. These 
findings are in contrast to those which have shown CD133 expression to repress cell 
differentiation and promote proliferation in neuroblastoma (Takenobu 2011) and brain 
tumours (Singh 2003). One possible explanation for this difference is that the increase 
in CD133 expression observed in differentiating cells here actually promotes the N-
type reversion from a differentiating to a proliferating phenotype following removal of 
9cRA, as seen in the morphological response and change in β-tubulin III and Bcl-2 
expression. However, this possibility requires further investigation. 
 
9cRA-induced differentiation of N-type populations was found to induce an uncoupling 
of Ca2+ store release and SOCE in a multi-step manner, with down-regulation of SOCE 
occurring from the first day of treatment and the extent of which is exaggerated from 
the fourth day of treatment. These data extend the previous findings by revealing that 
the previously observed Ca2+ signalling profile seen at day 7 (Chapter 4) was present in 
DN populations from the fourth day of exposure to 9cRA. Furthermore, down-
regulation of SOCE was confined to the total SOCE response since maximal SOCE was 
not significantly altered over the differentiation response. This suggests that the SOCE 
response was of a shortened duration either through accelerated or more efficient 
Ca2+ entry and store replenishment or an increased efficiency of inactivation. Changes 
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in the rate or efficiency of Ca2+ entry were confined to the later phase of the 
differentiation response rather than during the initial differentiation of N-type 
populations whilst alterations in speed and/or efficiency of Ca2+ entry deactivation 
occurred early in the differentiation response of N-type populations, indicating that 
the various phases of the differentiation response may induce changes in the dynamics 
of SOCE activity in a different manner.  
 
These overall changes in SOCE activity can be explained by the expression patterns of 
the Ca2+ sensing protein STIM1 and the SOC channel Orai1. Down-regulation of both 
STIM1 and Orai1 occurred early in the differentiation response of N-type populations, 
thereby potentially driving the initial down-regulation of SOCE observed from the first 
day of 9cRA treatment. By day 3 and 4 of treatment, down-regulated SOCE activity 
seemed to be predominantly driven by a down-regulation of Orai1 given that STIM1 
expression recovered. However, there was an increase in the molecular weight of 
STIM1 suggesting that there may be a modification, such as phosphorylation, taking 
place that could affect STIM1 function thereby contributing to dampened SOCE 
activity, or presence of an alternative isoform of STIM1 that serves a slightly altered 
function. Indeed, as previously discussed (Discussion 5). STIM1 phosphorylation at 
multiple serine residues has been identified (Manji 2000; Smyth 2009; Sundivakkam 
2012; Pozo-Guisado 2013; Sundivakkam 2013) and was found to have multiple roles in 
STIM1 function (Smyth 2009; Pozo-Guisado 2013; Sundivakkam 2013) and the 
existence of the STIM1L isoform has also been identified (Darbellay 2011; Sauc 2015). 
STIM1L has been shown to induce SOCE quicker than STIM1S, attributable to its 
association with Orai1 at rest rather than needing to migrate to bind Orai1 following 
store depletion like that of STIM1S (Darbellay 2011; Horinouchi 2012). The observed 
changes in rate of Ca2+ entry over the differentiation response may therefore be 
associated with shifts in the contribution of these STIM1 isoforms to SOCE activity and 
the presence of STIM1L may also explain the observed changes in STIM1 molecular 
weight as STIM1L has a higher molecular weight than STIM1S (Darbellay 2011). 
 
By day 5 of treatment, STIM1 down-regulation was reinstated, perhaps triggered by a 
potential modification as discussed that was observed in the previous days, whilst 
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Orai1 remained extensively down-regulated and perhaps drives the second ‘step’ in 
dampened SOCE activity in the N-type differentiation response. There was a peak in 
STIM1 down-regulation at day 6 of treatment alongside some recovery of Orai1 
expression that perhaps indicates that Orai1 is contributing less to the maintenance of 
the differentiation response at this stage. These findings correspond with that of the 
previously discussed markers of differentiation and provide further evidence to 
support a multi-step differentiation response in N-type populations.  
 
Following treatment withdrawal from N-type populations, the extent of uncoupling of 
Ca2+ store release and SOCE remained similar to that seen at day 7 of treatment, both 
in total and maximal Ca2+ entry as well as the rates of Ca2+ entry and deactivation, 
indicating that SOCE uncoupling is maintained following removal of the differentiating 
stimulus. This result is in contrast to the previously discussed data that has indicated 
that N-type cells revert back to a proliferating phenotype but can be explained by the 
expression of the underlying SOCE proteins. There was minimal down-regulation of 
STIM1 and the change in STIM1 molecular weight seen with differentiation was lost 
but Orai1 down-regulation was maintained, indicating that the observed reduction in 
SOCE activity is driven solely by dampened Orai1 expression following removal of the 
differentiation stimulus. The restoration of STIM1 expression correlates with the 
previously discussed morphological and β-tubulin III, Bcl-2 and CD133 expression 
findings that N-type cells revert from a differentiating to a proliferating phenotype 
following removal of the differentiation stimulus. Therefore all of the differentiation 
markers used in this study point to N-type cells moving away from a neuronal 
phenotype and losing the characteristics of a differentiating phenotype when exposure 
to 9cRA is stopped, except that of Orai1 expression and SOCE activity. Orai1 expression 
may take longer to recover, leaving SOCE activity dampened. Alternatively, loss of 
Orai1 may represent an irreversible change, perhaps because its place has been taken 
by up-regulation of an alternative SOC such as TRPC1 (Bell et al. 2013). It is important 
to emphasise that, given time restrictions, the protein expression results are made up 
just one time point, therefore the conclusions drawn are speculative and must not be 
over-extrapolated. It will be interesting to determine whether the current hypotheses 
hold true when the analysis is concluded (Discussion 7.2). 
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The ratio of STIM1:Orai1 is known to play an important role in the extent of SOCE 
activity (Hoover 2011; Hodeify 2015). SOCE activation occurs via a diffusion-trap 
mechanism by which ER Ca2+ store depletion induces STIM1 accumulation at plasma 
membrane junctions, where STIM1 is able to bind and trap Orai1 dimers and trigger 
the formation of tetrameric Orai1 channels that cause SOCE (Mignen 2008; Penna 
2008; Hoover 2011; Hodeify 2015). This process has been shown to induce peak SOCE 
activity with a ratio of 2 STIM1:Orai1 and therefore binding of 8 STIM1 per Orai1 
channel (Hoover 2011). In the observed scenario whereby STIM1 expressed and 
functional, there is enough STIM1 to gate all available channels, but since Orai1 
remains depleted, SOCE activity cannot be increased with more STIM1 as the capacity 
for SOCE to occur has been reached. 
 
9cRA-induced differentiation of S-type populations caused an uncoupling of Ca2+ store 
release and SOCE in a gradually increasing manner from the first day of treatment and 
the previously observed Ca2+ signalling profile seen at day 7 (Chapter 4) is present in DS 
populations from the fifth day of exposure to 9cRA, both in total and maximal Ca2+ 
entry. These findings correspond with the previously discussed markers of 
differentiation and provide further evidence to support a gradual differentiation 
response in S-type populations. Similar to N-type populations, there was a varied 
effect on Ca2+ store size or TG sensitivity, as well as changes in the speed and/or 
efficiency of Ca2+ entry and deactivation, between the early and late differentiation 
response of S-type populations, indicating that the various phases of the 
differentiation response may induce changes in Ca2+ entry  in a different manner. 
During the differentiation response of S-type populations, the observed reduction in 
SOCE activity appears to be driven predominantly by Orai1 down-regulation as the 
expression of STIM1 was only slightly altered. By day 6 and 7 of treatment, a slight 
down-regulation of STIM1 and dampened Orai1 expression coincides with, and is likely 
to cause, the observed peak in dampened SOCE activity. 
 
Following treatment withdrawal, the Ca2+ store release and SOCE uncoupling seen in 
differentiating S-type populations was lost and both total and maximal SOCE activity 
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was restored, indicating that differentiating S-type populations may either revert back 
to a coupled SOCE response like that of proliferating S-type populations or that SOCE 
uncoupling is involved in the initiation of the early differentiation response but is not 
needed to maintain the differentiated state of S-type populations. Alongside this 
restoration of SOCE activity, there was an increase in the level of STIM1 expression, 
however, an increase in STIM1 molecular weight could be observed alongside a further 
increase in the extent of Orai1 down-regulation. Given that SOCE activity recovered 
following treatment withdrawal, this implies that potentially there is a SOC channel 
other than Orai1, such as TRPC1, by which SOCE can occur in S-type cells. Indeed, it has 
been shown that STIM1 is able to bind TRPC1 and induce SOC channel functionality 
(Yuan 2007) and induce SOC rather than ROC function through insertion of TRPC1 into 
lipid raft domains (Alicia 2008). This channel may be up-regulated or undergo a 
functional modification to compensate for the lack of Orai1 following removal of the 
differentiation stimulus, thereby inferring that SOCE down-regulation may play a role 
in driving differentiation but is not required to maintain the differentiation response in 
S-type populations, since all other differentiation markers are retained. Again, it must 
be noted that the protein expression results observed are made up just one time 
point, therefore further analysis will test our current hypotheses (Discussion 7.2). 
 
In summary, these results imply that the differentiation response of N-type 
populations occurs in a multi-step manner whilst the S-type cell differentiation 
response occurs gradually. Following the removal of the differentiating stimulus, N-
type populations seem able to revert away from a differentiating neuronal-like 
phenotype whilst S-type populations seem to maintain a differentiating non-neuronal-
like phenotype. This demonstrates that, potentially, N-type cells have a greater 
capacity for therapy evasion, are less sensitive to the differentiating effects of RA or 
that it takes longer exposure to RA to induce irreversible commitment to a neuronal 
fate. 
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Chapter 7: Final Discussion 
 
7.1. Summary of findings 
The aim of this study was to investigate the morphological, biochemical 
(immunofluorescence) and functional (Ca2+ signalling) markers in proliferating and 
9cRA-induced differentiating N-type and S-type neuroblastoma populations at the 
single cell level to establish a phenotype-specific profile of the differentiation process. 
 
The results presented in this thesis provide clear evidence for a multi-step N-type 
morphological and biochemical differentiation response towards a neuronal 
phenotype that coincided with multi-step SOCE down-regulation and a gradual S-type 
morphological and biochemical differentiation towards a non-neuronal phenotype that 
coincided with gradual SOCE down-regulation (summarised in Table 7.1.1).  
 
An uncoupling of Ca2+ store release and SOCE in 9cRA-differentiated N-type 
populations correlates with previous findings (Brown 2005; N. Bell 2013). The 
predominant mechanisms by which Ca2+ entry occurs is dependent on cell type 
(Berridge 2000; Bootman 2001). Whilst SOCE is a ubiquitous Ca2+ entry pathway, 
excitable cells are more reliant on VOC-mediated Ca2+ entry (Berridge 1998) and, since 
N-type cells differentiate towards a neuronal phenotype, this may explain the 
observed dampened SOCE response with N-type differentiation. Indeed, our 
laboratory has previously found that voltage-operated Ca2+ entry remains active in 
9cRA differentiated SH-SY5Y cells (Brown 2005).  
 
An uncoupling of Ca2+ store release and SOCE also occurred with differentiation of S-
type populations which is in contrast to that shown previously (N. Bell 2013). Given the 
differences in S-type sub-population responses (Table 4.4), this may be due to 
variability in the S-type responses. It is important to note that Ca2+ store size was 
slightly reduced in N-type populations over the differentiation response and was 
reduced early but increased late in the differentiation response of S-type populations. 
This change in Ca2+ store size was not previously observed (N. Bell 2013) and may 
contribute to this disparity since SOCE is governed by the extent of store depletion. 
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Another noteworthy point is that the changes in SOCE activity with differentiation 
were consistent with the expression of the SOCE proteins STIM1 and Orai1 in both 
studies (Table 7.1.1). 
 
Dampened SOCE in differentiating S-type populations was unexpected since non-
excitable cells tend to rely on SOCE as a predominant Ca2+ entry pathway. The identity 
of the S-type population phenotype has yet to be discerned, a feat that becomes more 
complex when considering the variability within this cell compartment both in the 
morphology (i.e. SO, SA and SE cells) and the Ca
2+ signal profiles attributed to them 
(Table 4.4). This non-neuronal lineage is thought to consist of glial cells, Schwann cells 
and melanocytes, since markers of these cell types have been observed in S-type cells 
(Ross 1985; Ciccarone 1989; Whitworth 2012; N. Bell 2013). Uncovering the identity of 
S-type cells may therefore explain the reduced reliance on SOCE as a Ca2+ entry 
pathway with 9cRA-induced differentiation. For example, as well as SOCE, voltage-
operated Ca2+ entry has been observed in melanocytes (Wiesner 2002; Bogeski 2012) 
and VOCs are expressed in astrocytes (Carmignoto 1998). Therefore it is also plausible 
that S-type differentiation towards a non-neuronal phenotype brings about changes in 
the predominant Ca2+ entry pathway and this may contribute to the observed 
dampened SOCE response. 
 
N-type and S-type populations exhibit phenotype-specific Ca2+ signals in their 
differentiation response (Table 4.3). Differentiation of N-type populations caused a 
slight reduction in Ca2+ store release and drastically smaller, shortened SOCE 
responses. This Ca2+ signal profile differed from that of differentiating S-type 
populations which had increased Ca2+ store release and rate of store depletion, 
indicating a potential increase in the size of the ER Ca2+ store capacity and/or an 
increased sensitivity to TG and the SOCE was dampened but maintained for longer. 
These differences highlight the possibility of targeting the differentiated SOCE pathway 
as a means of neuroblastoma treatment to be specific to cell phenotype. For example, 
S-type cells are less tumourigenic than N-type cells in culture and in vivo therefore 
manipulation of N-type differentiation-associated Ca2+ signals to induce a more S-type 
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response may pose an interesting route for the development of more effective 
treatment. 
 
This potential for altering phenotype-specific Ca2+ signals has applicability in the 
process of phenotypic transdifferentiation. Within N-type and S-type predominant 
populations, N-type, S-type and I-type cells are always present, regardless of extent of 
enrichment (Introduction 1.3 and Methods 2.3). This may be explained by the fact that 
these cells are known to transdifferentiate in culture (Ciccarone 1989). Both of these 
points are important to consider when investigating cell population responses.  A 
major benefit of adopting the single cell approach to Ca2+ signal studies is that specific 
Ca2+ responses can by identified and attributed to each cell phenotype within a 
population thereby allowing  the Ca2+ responses of the cell phenotypes underlying the 
population responses to be studied. An uncoupling of Ca2+ store release and SOCE 
occurred in all cell types grown in either an N-type or an S-type population yet there 
were distinct differences in the Ca2+ signalling responses and extent of SOCE down-
regulation between the two environments (Table 4.3 and 4.4). 
 
N-type cells within an N-type population exhibited Ca2+ signals that reflected those 
observed at the N-type population level however N-type cells within an S-type 
population showed an increase in Ca2+ store release reflective of either an increase in 
store size or sensitivity to TG and SOCE was down-regulated to a greater extent. This 
indicates that N-type cells may display plasticity in Ca2+ signals that are influenced by 
the surrounding predominant phenotype. S-type cells in an N-type or an S-type 
population exhibited similar Ca2+ signals however the observed response was made up 
of variable responses at the sub-population level. Indeed, the Ca2+ signals in SO, SA and 
SE cells were altered dependent on the predominant phenotype of the population in 
which they were grown but were consistently down-regulated SOCE with 
differentiation (Table 4.4). This sub-population analysis has revealed that S-type cells 
may in fact exhibit plasticity in Ca2+ signals that are influenced by the surrounding 
predominant phenotype which were previously masked by observing Ca2+ signals at 
the population level. I-type cells in an N-type population showed an increase in Ca2+ 
store release reflective of either an increase in store size or sensitivity to TG but in an 
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S-type population Ca2+ store release was not altered. SOCE was down-regulated in I-
type cells to a similar extent in each population but SOCE was shorted in N-type 
populations and of longer duration in S-type populations. This indicates that I-type 
cells may also display plasticity in Ca2+ signals that are influenced by the surrounding 
predominant phenotype.  
 
Additionally, conditioned media from proliferating and differentiating N-type and S-
type populations affected phenotypic characteristics of morphology, protein 
expression and SOCE activity (summarised in Table 7.1.2). This provides evidence for 
an effect of the surrounding phenotypic environment due to the release of factors by 
the predominant population affecting the minority phenotypes characteristics. These 
findings also seemed to indicate that S-type population characteristics were influenced 
by N-type conditioned media, more so than N-type populations characteristics were by 
S-type conditioned media. This could suggest that S-type cells may be more likely to 
transdifferentiate than N-type cells due to the influence of the surrounding 
predominant phenotypic environment. It would be very interesting to determine if this 
influence contributes phenotypic transdifferentiation (Discussion 7.2) as this process is 
currently poorly understood and may play an important in the context of disease 
progression in neuroblastoma patients. 
 
Taken together, these results have revealed the variability Ca2+ signals with 
differentiation, between cell phenotypes and as influenced by the predominant 
surrounding cell population, thus highlighting the advantage of using single cell 
analysis to uncover these differences that may be masked in responses at the 
population level. This heterogeneity within the SH-SY5Y neuroblastoma cell line may 
be reflective of tumour heterogeneity in patients, which could have implications in 
disease progression and/or treatment failure. For example, response to RA treatment 
in neuroblastoma patients is often poor (Matthay 2009; Navalkele 2011). This may be 
attributed to just one compartment of the tumour population, for sake of example, the 
highly tumourigenic putative I-type cells. These I-type cells, which are actually the 
minority cell phenotype, may be less responsive to RA treatment than other 
phenotypes within the population and perhaps actually come into existence through 
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transdifferentiation from another phenotype, to which phenotype-specific Ca2+ signals 
may contribute. The characteristics that I-type cells fundamentally possess or acquire 
through transdifferentiation therefore gives them the ability to continue to proliferate 
and evade treatment. Perhaps they even transdifferentiate back into other 
phenotypes along the way due to influence from other cells, giving rise to a perpetual 
supply of mixed phenotypes and, ultimately, leading to aggressive and unresponsive 
tumour growth. However, if the phenotypic characteristics of these highly 
tumourigenic I-type cells could be identified and remodelled, perhaps through 
manipulation of underlying SOCE-specific components, they could potentially be 
pushed towards a less tumourigenic phenotype or forced to transdifferentiate to 
another phenotype and become responsive to RA treatment. Identification of these 
phenotype-specific responses is the first step to this process and this thesis has 
addressed this problem directly. 
 
On a similar note, withdrawal of 9cRA treatment appeared to induce partial reversion 
of N-type populations from a differentiating phenotype to a phenotype similar to that 
of proliferating N-type cells whilst S-type populations seemed to retain a 
differentiating phenotype (summarised in Table 7.1.3). This suggests that 9cRA-
induced differentiation of S-type cells induces commitment to a non-neuronal lineage 
despite removal of the differentiation stimulus. Moreover, given the low tumourigenic 
characteristics of S-type cells in culture and in vivo (Ciccarone 1989; Picacentini 1996; 
Walton 2004), it seems that S-type cells may be less likely than N-type cells to 
contribute to RA resistance. Despite the apparent maintenance of the differentiating S-
type state, and prevailing Orai1 down-regulation, SOCE activity was restored upon 
removal of the differentiating stimulus. This suggests that in S-type cells, Orai1 may 
drive the differentiation response and another channel, such as TRPC1, may 
compensate to restore SOCE activity and maintain the differentiated state of S-type 
cells. This notion would be consistent with the predominance of SOCE as a Ca2+ entry 
pathway in non-neuronal cells. 
 
These findings also suggest that 9cRA-induced differentiation of N-type cells 
potentially induces a transient shift towards a neuronal phenotype that is reversible, 
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with maintenance of the differentiating phenotype dependent on the presence of the 
differentiating stimulus. It may instead be that N-type cells are less sensitive to 9cRA or 
that they require prolonged exposure to 9cRA compared to S-type cells to reach an 
irreversible differentiating cell fate. On the other hand, N-type cells may acquire some 
form of resistance to 9cRA treatment that could enable them to be more adept at 
evading a fully differentiated phenotype. Alternatively, since N-type cells are more 
tumourigenic than S-type cells in culture and in vivo (Ciccarone 1989; Picacentini 1996; 
Walton 2004), N-type cells may be intrinsically more capable of phenotypic 
interconversion and, in this case, favour a proliferating phenotype. Clearly any of these 
scenarios could have dramatic impact on tumour progression and, the ability of just 
one compartment of the neuroblastoma population to outsmart the differentiation-
inducing effects of RA treatment could potentially explain the poor response to RA that 
is observed in neuroblastoma patients (Matthay 2009; Navalkele 2011). 
 
Overall, this thesis has revealed the extent of variability in the differentiation 
responses attributed to heterogeneity within the SH-SY5Y neuroblastoma cell line. The 
SOCE pathway in the different cell types and, in the case of S-type cells, sub-
populations, may represent potential targets for novel therapeutics of neuroblastoma 
disease.  
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Table 7.1.1. Summary of findings over the 9cRA-induced differentiation response in 
N-type and S-type populations 
Each population response is defined by the early differentiation response (Days 1-4) 
and late differentiation response (Days 5-7). For N-type populations (PN and DN) 
morphology represents a change in neurite length whilst for S-type populations (PS and 
DS) this represents a change in cell dimensions (sub-type diameter or length). – 
represents general expression. X represents no expression. ↑ represents an increase. 
↑↑ represents a large increase. ↓ represents a decrease. ↓↓ represents a large 
decrease. U represents an unknown that was not investigated. MW represents a 
change in the molecular weight of STIM1. 
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Table 7.1.2. Summary of findings with the application of conditioned media to N-
type and S-type populations 
Each population response is defined by the addition of PS, DS, PN or DN conditioned 
media. For N-type populations (PN and DN) morphology represents a change in neurite 
length whilst for S-type populations (PS and DS) this represents a change in cell 
dimensions (sub-type diameter or length). – represents general expression. X 
represents no expression. ↑ represents an increase. ↑↑ represents a large increase. 
↓ represents a decrease. ↓↓ represents a large decrease. MW represents a change 
in the molecular weight of STIM1. 
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Table 7.1.3. Summary of findings following 9cRA treatment withdrawal for 5 days 
For N-type populations (DN) morphology represents a change in neurite length whilst 
for S-type populations (DS) this represents a change in cell dimensions (sub-type 
diameter or length). – represents general expression. X represents no expression. ↑ 
represents an increase. ↑↑ represents a large increase. ↓ represents a decrease. 
↓↓ represents a large decrease. U represents an unknown that was not investigated. 
MW represents a change in the molecular weight of STIM1. 
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7.2. Future investigations 
This study investigated the sequence of changes in expression of STIM1 and Orai1 over 
the differentiation response however, since the reliability of TRPC1 antibody was poor, 
further investigation is needed to determine whether TRPC1 plays a role in SOCE in N-
type and S-type populations. Determining whether any changes in TRPC1 expression 
occur with differentiation and the relationship with changes in expression of STIM1 
and Orai1 over the 9cRA-induced differentiation response is crucial for understanding 
the proliferation-differentiation switch. Similarly, manipulating TRPC1 expression may 
affect the STIM1-Orai1 relationship with SOCE activity in the differentiation response. 
 
A potential STIM1 modification was found to precede down-regulation in N-type 
populations and was present in differentiating S-type populations. This modification 
could represent phosphorylation or glycosylation events or perhaps an increase in 
expression of an alternative isoform, all of which have been previously established in 
STIM1 characterisation (Discussion 5). It would be interesting to investigate this further 
since protein modification may affect function and contribute to dampened SOCE.  
 
This thesis has suggested that following withdrawal of 9cRA treatment, N-type cells 
potentially revert back to a proliferating morphology whilst S-type cells may retain 
characteristics of non-neuronal differentiation. Since these conclusions are speculative 
due to one time-point being assessed, this may be confirmed through experimental 
repeats and raises the question as to how N-type cells are able to revert whilst S-type 
cells do not. N-type cells are known to be more tumourigenic than S-type cells in 
culture and in vivo and therefore may be less sensitive to 9cRA-induced differentiation. 
The heterogeneity in the responses observed has implications for the interpretation of 
this data. At present, we assume that the DN cells that exhibit SOCE down-regulation 
and the DS cells that fully recover the SOCE response following treatment withdrawal 
are the same cells that have SOCE down-regulation in the presence of 9cRA, however 
this is not known for certain. This has the potential to be investigated by mapping the 
morphological changes in specific cells over the differentiation time-course and 
attributing Ca2+ signals to each specific cell. Determining the relationship between the 
morphological and Ca2+ signalling differentiation responses over time may provide 
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clues as to the nature of the changes associated with removal of the differentiating 
stimulus.  
 
Around half of neuroblastoma patients relapse despite RA therapy (Armstrong 2012) 
which may be due to variable cellular RA responses associated with heterogeneity. As 
shown in this study, not all cells were morphologically differentiated following 9cRA 
treatment (Results 3.1). This may be due to some cells exhibiting slower responses to 
9cRA, complete insensitivity to RA or perhaps differential expression of the RARs and 
RXRs through which 9cRA exerts its effects. Whether all cells within N-type and S-type 
populations down-regulate SOCE activity with 9cRA-induced differentiation or whether 
SOCE is completely is abolished in some cells and fully intact in other has yet to be 
determined. The single cell technique and data collected in this thesis have given 
indication that the former is more likely and this is currently being quantified. Not all 
N-type cells were morphologically differentiated in response to 9cRA therefore the 
extent of differentiation may correlate with the extent of SOCE activity, which can now 
be examined through determination of the relationship between morphology and the 
Ca2+ response of individual cells. Some cells may have a delayed respond to RA or may 
be completely RA insensitive. RA acts via binding of RARs and RXRs, which may be 
differentially expressed between cells and therefore bring about variability in the RA 
response (Schug 2007). It is important that the mechanism of action of RA is further 
investigated at the single cell level to understand therapeutic resistance. 
 
This thesis suggests that the predominant phenotype in a population may influence 
the responses of minority cell populations, perhaps as an effect of release of factors 
that affect the local signalling environment. It will be interesting to assess these 
findings further through experimental repeats to reach more solid conclusions. 
Unfortunately, given time constraints, Orai1 expression was not determined but it 
seems likely that it could be down-regulated given the observed changes in SOCE 
activity observed and will be useful to investigate. Also tracking specific cellular 
changes in individual cells, for example determining the incidence of 
transdifferentiation may provide clues as to the phenotypic influence on the 
differentiation response.  
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7.3. Conclusions 
Understanding the mechanistic changes that underlie the differentiation response of 
neuroblastoma cells is a valuable strategy to elucidate novel drug targets and improve 
disease treatment. This strategy has applications in tumour cell differentiation towards 
a benign phenotype, which may improve understanding of retinoid resistance in 
neuroblastoma disease, as well as in neurobiology, since the ability to control neuronal 
precursor differentiation to a fully neuronal phenotype has implications for treatment 
of neurodegenerative disorders. 
 
This study has utilised a system for detection and analysis of Ca2+ signals at the single 
cell level to identify phenotype-specific alterations in the differentiation response or 
neuroblastoma cells. Whilst uncoupling of a SOCE was a universal feature of 
differentiation there were extensive differences in Ca2+ signal profiles and underlying 
protein expression. There was also plasticity in Ca2+ signalling that was influenced by 
the predominant phenotype in the population and cell phenotypes could also be 
altered. 
 
The results presented in this thesis have revealed variability in the differentiation 
responses attributed to heterogeneity within the SHSY5Y neuroblastoma cell line. 
These findings contribute to the understanding of the changes in SOCE responses with 
differentiation, which may be a valuable tool for manipulation in the context of 
treatment for neuroblastoma disease. 
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Appendix 
I: BTP2 
Introduction 
Dampened SOCE activity was associated with differentiation of N-type and S-type 
populations in this study (Chapter 4) indicating that there may be changes occurring in 
SOCE associated proteins with differentiation. Ca2+ entry via the PM can occur via ROC 
or SOC channels (Introduction) and, since there is crosstalk between these pathways 
and association of the proteins involved (Yuan 2007; Jardin 2008; Hong 2011), it is 
important to distinguish that the apparent SOCE changes observed are attributable to 
only SOCE and no other Ca2+ entry pathways. Therefore this chapter investigated the 
effects of BTP2; a cell permeable 3,5-bis(trifluoromethyl)pyrazole derivative that 
inhibits CRAC channels, on N-type populations.  
 
Results 
BTP2 inhibits SOCE in N-type populations in a dose-dependent manner 
Treatment of N-type populations with 100 nM - 5 µM BTP2 for 24 hours did not alter 
N-type cell morphology, which possessed small, rounded cell bodies with short 
neurite-like processes and grew to form cell aggregates (Figure Ai.A-D). Treatment 
with ≥10 µM BTP2 reduced cell viability and induced cell death (Figure Ai.E and F). 
 
BTP2 caused a significant increase in Ca2+ store release (P<0.0001) and a substantial 
down-regulation of SOCE (P<0.0001) in N-type populations, even at low concentrations 
(Figure Aii). Changes in relative cytosolic Ca2+ entry are expressed as fluorescence ratio 
units (FRUs) and compared to DMSO treated cells unless stated otherwise. Treating 
cells for 24 hours with 100 nM BTP caused a 37% increase in total Ca2+ store release 
(85.86 ± 1.82 FRUs) compared to DMSO treated cells (62.87 ± 1.77 FRUs, P<0.0001) 
and total SOCE was reduced by 69% (143.41 ± 9.82 and 337.57 ± 14.60 FRUs, 
respectively, Figure Aii). SOCE was down-regulated by BTP2 in a dose-dependent 
manner and the maximum uncoupling of Ca2+ store release and SOCE was achieved at 
1 µM BTP2, where SOCE was almost completely abolished (10.11 ± 10.36 FRUs, 
P<0.0001 Figure Aii). There was a second phase of SOCE down-regulation and BTP2 
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dose dependency from 2 µM BTP2 whereby SOCE (78.34 ± 13.87 FRUs) was almost 9-
fold higher compared to cells treated with 1 µM BTP2, when taking the change in Ca2+ 
store size into account (Figure Aii). Ca2+ store release and SOCE uncoupling was then 
heightened with greater concentrations of BTP2 (Figure Aii) but was deemed toxic to 
cells treated with 10 µM BTP2 or more (Figure Ai.E and F and Figure Aii). 
 
BTP2 also affected Ca2+ store release and SOCE dynamics. Maximal SOCE was affected 
in a dose dependent manner with an inverse correlation and maximal SOCE was 
significantly reduced with 200 nM – 10 µM BTP2 treatment (all P<0.0001, Figure Aiii.A). 
Maximal SOCE was almost completely abolished with 1 µM BTP2 treatment and was 
restored at 2 µM BTP2 before a second phase of inverse correlation (Figure Aiii A). 
Maximal Ca2+ store release was only marginally affected by BTP2 concentration (Figure 
Aiii.A). Rate of Ca2+ store release was significantly reduced with all concentrations of 
BTP2 below 1 µM (P<0.0001) and non-significantly reduced with 2 µM and 5 µM BTP2 
(Figure Aiii.B) whilst rate of Ca2+ store release deactivation was reduced with all 
concentrations of BTP2 (Figure Aiii.C). Rate of SOCE and rate of SOCE deactivation 
were reduced with 200 nM - 10 µM BTP2 (Figure Aiii.B and C). Rate of initial SOCE 
deactivation was increased with all concentrations of BTP2 except 1 and 5 µM BTP2 
which exhibited a decrease (Figure Aiii.C). Rate of late SOCE deactivation was also 
significantly reduced with all concentrations of BTP2 (all P<0.0001 except 20 µM 
P=0.0003, Figure Aiii.C). 
 
Taken together, these results demonstrate a dose-dependent uncoupling of Ca2+ store 
release and SOCE with an inverse correlation between BTP2 concentration and extent 
of SOCE down-regulation made up of two phases; increasing concentrations from 100 
nM BTP2 and increasing concentrations from 2 µM BTP2. Maximal SOCE inhibition was 
achieved at 1 µM BTP2 treatment. BTP2 caused an increase in total Ca2+ store release 
that was driven by a slight increase in maximal Ca2+ store release and reduced rates of 
activation and deactivation, increasing the duration of Ca2+ store release. Substantial 
down-regulation of total SOCE that was driven by large decreases in maximal SOCE and 
rate of activation with increases in initial rate of deactivation and decreases in late rate 
of deactivation, indicating a dampened SOCE response that was of shortened duration. 
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Figure A.i. BTP2 does not affect N-type population morphology at low concentrations 
but induces cell death at higher concentrations 
N-type populations were treated for 24 hours with various concentrations of BTP2 
(0.1-20µM) or DMSO as a loading control. (A) DMSO treated N-type cells possess short 
neurite-like processes (arrows), and can grow to form aggregates (dashed circle). (B-D) 
N-type cells treated with 0.1 - 5 µM BTP2 grow in a similar manner to DMSO treated 
cells. (E) At a concentration of 10 µM BTP2, N-type cells show reduced cellular integrity 
and increased cell death as observed by an increase in floating cell debris (black 
arrows ). (F) At a concentration of 20 µM BTP2, all cells are dead (arrows) or dying. 
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Figure A.ii. BTP2 drastically inhibits SOCE at low concentrations 
N-type populations were treated for 24 hours with a range of concentrations of BTP 
(0.1 µM to 20 µM) or DMSO as a control. Changes in fluorescence ratio units (FRUs) are 
reflective of changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ 
store release and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish 
depleted stores. (A) DMSO (TG control) measurements were deducted from the 
experimental data. Compared to DMSO treatment, there was a significant effect of 
BTP2 treatment on total Ca2+ store release (P<0.0001) and total SOCE (P<0.00001). 
Cells treated with 0.1 µM BTP2 had a significant increase in total Ca2+ store release by 
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36.58% compared to DMSO treated cells (85.86 ± 1.82 and 62.87 ± 1.77 FRUs, 
respectively, P<0.0001****). Taking this change in store release into account, total 
SOCE (CaCl2) was reduced by 68.90% in cells treated with 0.1 µM BTP2 compared to 
DMSO treated cells (143.41 ± 9.82 and 337.57 ± 14.60 FRUs, respectively). There was 
no significant difference in total Ca2+ store release between cells treated with 0.2 µM 
BTP2 (68.90 ± 2.52 FRUs) and DMSO treated cells (P=0.515) and total SOCE (78.76 ± 
10.11 FRUs) was reduced by 78.71% (P<0.0001****). Cells treated with 0.5 µM BTP2 
had a significant increase in total Ca2+ store release (73.36 ± 2.12 FRUs) by 16.70% 
compared to DMSO treated cells (P=0.005**) and total SOCE (53.06 ± 11.84 FRUs) was 
reduced by 86.53%. Cells treated with 1 µM BTP2 had a significant increase in total 
Ca2+ store release (88.25 ± 1.71 FRUs) by 40.38% compared to DMSO treated cells 
(P<0.0001****) and total SOCE (10.11 ± 10.36 FRUs) was reduced by 97.87%. Cells 
treated with 2 µM BTP2 had a significant increase in total Ca2+ store release (77.93 ± 
1.82 FRUs) by 23.97% compared to DMSO treated cells (P<0.0001****) and total SOCE 
(78.34 ± 13.87 FRUs) was reduced by 81.28%. Cells treated with 5 µM BTP2 had a 
significant increase in total Ca2+ store release (82.38 ± 2.02 FRUs) by 31.04% compared 
to DMSO treated cells (P<0.0001****) and total SOCE (47.15 ± 7.25 FRUs) was reduced 
by 89.34%. Cells treated with 10 µM BTP2 had a significant increase in total Ca2+ store 
release (79.71 ± 2.56 FRUs) by 26.79% compared to DMSO treated cells 
(P<0.0001****) and total SOCE (34.43 ± 10.58 FRUs) was reduced by 91.96%. There 
was no significant difference in total Ca2+ store release between cells treated with 20 
µM BTP2 (56.49 ± 4.72 FRUs) and DMSO treated cells (P=0.994) and total SOCE (19.74 
± 39.58 FRUs) was reduced by 93.49% (P<0.0001****). (B) The following percentages 
compare the average total SOCE of each BTP2 treated population with the average of 
DMSO populations taken to be 100%. Total SOCE was down-regulated by 68.24% at 0.1 
µM BTP2, 77.96% at 0.2 µM BTP2, 88.19% at 0.5 µM BTP2, 93.19% at 1 µM BTP2, 
81.70% at 2 µM BTP2, 89.95% at 5 µM BTP2, 91.47% at 10 µM BTP2 and 91.78% at 20 
µM BTP2.  
For DMSO n=539, 0.1 µM BTP2 n=339, 0.2 µM BTP2 n=191, 0.5 µM BTP2 n=234, 1 µM 
BTP2 n=336, 2 µM BTP2 n=270, 5 µM BTP2 n=295, 10 µM BTP2 n=221 and 20 µM BTP2 
n=24. N≥3 except 20 µM BTP2 N=1. 
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Figure A.iii. BTP2 drastically alters SOCE dynamics at low concentrations 
N-type populations were treated for 24 hours with a range of concentrations of BTP 
(0.1 µM to 20 µM) or DMSO as a control. Changes in fluorescence ratio units (FRUs) are 
reflective of changes in [Ca2+]i following addition of thapsigargin (TG) indicating Ca
2+ 
store release and subsequent Ca2+-addback (CaCl2) indicating SOCE to replenish 
depleted stores. (A) DMSO (TG control) measurements were deducted from the 
experimental data. Compared to DMSO treatment, there was a significant effect of 
BTP2 treatment on maximal Ca2+ store release (P<0.0001) and maximal SOCE 
(P<0.00001).  Cells treated with 0.1 µM BTP2 had a significant 13.7% increase in 
maximal Ca2+ store release (TG) compared to DMSO treated cells (0.20 ± 0.004 and 
0.18 ± 0.003 FRUs, respectively, P<0.0001****). Taking this change in store release 
into account, maximal SOCE (CaCl2) was reduced by 22.06% in cells treated with 0.1 
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µM BTP2 compared to DMSO treated cells (0.36 ± 0.03 and 0.41 ± 0.03 FRUs, 
respectively). There was no significant difference in maximal Ca2+ store release 
between cells treated with 0.2 µM BTP2 (0.16 ± 0.005 FRUs) and DMSO treated cells 
(P=0.187) and maximal SOCE (0.13 ± 0.04 FRUs) was reduced by 66.01% 
(P<0.0001****). There was no significant difference in maximal Ca2+ store release 
between cells treated with 0.5 µM BTP2 (0.17 ± 0.005 FRUs) and DMSO treated cells 
(P=0.997) and maximal SOCE (0.02 ± 0.04 FRUs) was reduced by 94.57% 
(P<0.0001****). Maximal Ca2+ store release was increased by 11.93% in cells treated 
with 1 µM BTP2 (0.20 ± 0.004 FRUs) compared to DMSO treated cells (P=0.0003***) 
and maximal SOCE was completely abolished (P<0.0001****). There was no significant 
difference in maximal Ca2+ store release between cells treated with 2 µM BTP2 (0.19 ± 
0.004 FRUs) and DMSO treated cells (P=0.449) and maximal SOCE (0.14 ± 0.04 FRUs) 
was reduced by 68.12% (P<0.0001****). Maximal Ca2+ store release was increased by 
9.96% in cells treated with 5 µM BTP2 (0.19 ± 0.004 FRUs) compared to DMSO treated 
cells (P=0.011*) and maximal SOCE (0.04 ± 0.03 FRUs) was reduced by 91.04%. There 
was no significant difference in maximal Ca2+ store release between cells treated with 
10 µM BTP2 (0.19 ± 0.005 FRUs) and DMSO treated cells (P=0.338) and maximal SOCE 
was completely abolished (P<0.0001****). There was no significant difference in 
maximal Ca2+ store release between cells treated with 20 µM BTP2 (0.13 ± 0.01 FRUs) 
and DMSO treated cells (P=0.088) and maximal SOCE was completely abolished 
(P=0.067). (B) Compared to DMSO treatment, there was a significant effect of BTP2 
treatment on rate of Ca2+ store release (P<0.0001) and rate of SOCE (P<0.00001). The 
following are comparisons to DMSO treated cells. There was a significant decrease in 
rate of Ca2+ store release in cells treated with 0.1, 0.2, 0.5, 1 and 20 µM BTP2 (all 
P<0.0001) and no significant difference in cells treated with 2, 5 and 10 µM BTP2 
(P=0.951, P>0.999 and P=0.972, respectively). There was a significant decrease in rate 
of SOCE in cells treated with 0.2, 1 and 5 µM BTP2 (all P<0.0001) and 2 and 10 µM 
BTP2 (P=0.002 and P=0.026, respectively). There was a non-significant decrease in rate 
of SOCE in cells treated with 0.5 M BTP2 (P=0.549) and a non-significant increase in 
rate of SOCE in cells treated with 0.1 and 20 µM BTP2 (P=0.838 and P=0.672, 
respectively). (C) Compared to DMSO treatment, there was a significant effect of BTP2 
treatment on rate of decline of Ca2+ store release (P<0.0001), total SOCE (P<0.00001), 
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initial SOCE (P<0.00001) and late SOCE (P<0.00001). The following are comparisons to 
DMSO treated cells. There was a significant reduction in rate of decline of Ca2+ store 
release in cells treated with 0.2, 0.5, 5, and 20 µM BTP2 (all P<0.0001) and 2 µM BTP2 
(P=0.002) and all other rates were non-significantly decreased. There was a significant 
reduction in rate of decline of SOCE in cells treated with 0.2, 0.5, 1, 5, and 10 µM BTP2 
(all P<0.0001) and 2 µM BTP2 (P=0.009) and all other rates were not significantly 
altered. There was a significant increase in rate of decline of initial SOCE in cells 
treated with 0.1 and 2 µM BTP2 (both P<0.0001) whilst 0.2, 0.5, 10 and 20 µM BTP2 
were non-significantly decreased and 1 and 5 µM BTP2 were non-significantly 
increased. There was a significant reduction in rate of decline of late SOCE in cells 
treated with all concentrations of BTP2 (all P<0.0001).  
For DMSO n=539, 0.1 µM BTP2 n=339, 0.2 µM BTP2 n=191, 0.5 µM BTP2 n=234, 1 µM 
BTP2 n=336, 2 µM BTP2 n=270, 5 µM BTP2 n=295, 10 µM BTP2 n=221 and 20 µM BTP2 
n=24. N≥3 except 20 µM BTP2 N=1. 
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Discussion 
BTP2 (N-[4-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]-4-methyl-1,2,3-thiadiazole-5-
carboxamide) has been extensively utilised to investigate Ca2+ entry and inhibition (Zitt 
2004; He 2005; Takezawa 2006; Ohga 2008; Law 2011; Schleifer 2012; Liu 2015). BTP2 
has been shown to inhibit SOCE in sinoatrial node cells (Liu 2015), HEK293 cells (He 
2005; Schleifer 2012), T cells (Zitt 2004; Takezawa 2006; Ohga 2008), DT40 B cells and 
A7r5 smooth muscle cells (He 2005). In this study, exposure to BTP2 for 24 hours 
induced a dose-dependent uncoupling of Ca2+ store release and SOCE in N-type 
populations that was evident in concentrations as low as 100 nM with a maximal 
inhibitory effect at 1 µM. BTP2 did not affect N-type cell morphology but did reduce 
cell viability and induce extensive cell death at concentrations above 10 µM.  
 
Inhibition of Ca2+ entry by BTP2 is not solely SOCE specific and, whilst there are many 
agents that offer non-selective inhibition of SOCE (Putney 2001), there are currently no 
means for exclusive SOCE inhibition as other Ca2+ entry pathways may also be affected. 
However, whilst there is an inhibitory effect of BTP2 on ROCE, potency for SOCE 
inhibition has been found to be 7-fold greater than that of ROCE inhibition and direct 
inhibition of STIM1-Orai1-mediated CRAC currents was confirmed in HEK293 cells 
(Schleifer 2012). BTP2 specifically inhibited SOCE at low nanomolar concentrations 
(IC50 ~10 nM) in T cells with no effect on other SOCE-related pathways including ER 
Ca2+ store release, Ca2+ pumps, mitochondrial Ca2+ or K+ channels (Zitt 2004). BTP2 was 
also found to reduce ICRAC in Jurkat T cells and did not significantly affect K
+ or Cl- 
channel activity (Takezawa 2006). Similarly, the imidazole compound SKF-96395 has 
been shown to inhibit SOCE through STIM1-Orai1 interactions (Putney 2001) and it was 
found that STIM1 overexpression in sinoatrial node cells caused an increase in SOCE 
that was almost completely inhibited by SKF-96395 (Liou 2005). Likewise, BTP2 
inhibited SOCE in sinoatrial node cells in a similar manner to SKF-96395 (Liu 2015), 
suggesting that BTP2 may function through STIM1-Orai1 inhibition however, the 
mechanisms by which BTP2 exerts inhibition on the SOCE pathway is unclear. The 
trifluoromethyl group at the C3 position was found to be critical for BTP2 activity (Law 
2011). It has also been suggested that the underlying mechanism by which BTP2 acts in 
lymphocytes is via TRPM4 interaction whereby Ca2+ acts on TRPM4 which regulates 
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Ca2+ signals through depolarisation of lymphocytes thereby reducing Ca2+ influx which 
is promoted by BTP2 (Takezawa 2006). BTP2 treatment of lymphocytes enhanced 
TRPM4 activity in a dose-dependent manner, however, this only occurred at low 
nanomolar concentrations and ICRAC was blocked only at concentrations over 100-fold 
higher and it was concluded that BTP2 seemed to be the most potent and selective 
ICRAC inhibitor of those investigated (Takezawa 2006). 
 
Overall, the results from the discussed investigations and the effect of BTP2 on SOCE 
found here potentially demonstrate that the results from this study involving a down-
regulation of SOCE observed with 9cRA-induced differentiation are likely due to 
changes in the SOCE-associated proteins STIM1 and Orai1. 
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II: RNA sequencing 
STIM1 and Orai1 protein expression was down-regulated with differentiation of N-type 
populations, which may be caused by a change in gene expression. RNA from 
proliferating and differentiating N-type populations was sequenced under a 
collaboration with Professor Caroline Austin and Lauren Harkin. Preliminary RNAseq 
data is presented. 
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Figure A.iv. Overall gene expression is significantly altered with 9cRA-induced 
differentiation of N-type populations 
PCA plot of normalised read counts for mapped to all genes expressed between 
proliferating N-type populations (blue, Undiff) and differentiating N-type populations 
(red, Diff). N=4 for each dataset. 
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Figure A.v. Calcium signalling genes have significantly altered expression with 9cRA-
induced differentiation of N-type populations 
Log2 2 fold change in expression of genes of interest using DESeq analysis. All genes 
shown were significantly up- or down-regulated with adjusted P≤0.001. However, FDR 
was >0.05. 
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Figure A.vi. Differential gene expression in the calcium signalling pathway with 
differentiation of N-type populations 
Ingenuity Pathway Analysis (IPA) of changes in gene expression with differentiation of 
N-type populations. Red spectrum colouring represents an up-regulation in expression. 
Blue spectrum colouring represents a down-regulation in expression. Darker colours 
represent greater expression changes. White represents no significant change. 
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